WO2003006610A2 - Thermostable phosphatases and methods of making and using them - Google Patents

Thermostable phosphatases and methods of making and using them Download PDF

Info

Publication number
WO2003006610A2
WO2003006610A2 PCT/US2002/021693 US0221693W WO03006610A2 WO 2003006610 A2 WO2003006610 A2 WO 2003006610A2 US 0221693 W US0221693 W US 0221693W WO 03006610 A2 WO03006610 A2 WO 03006610A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
nucleic acid
residues
region
Prior art date
Application number
PCT/US2002/021693
Other languages
French (fr)
Other versions
WO2003006610A3 (en
Inventor
Jay M. Short
Eric J. Mathur
Edd Lee
Edward J. Bylina
Original Assignee
Diversa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diversa Corporation filed Critical Diversa Corporation
Priority to AU2002324477A priority Critical patent/AU2002324477A1/en
Publication of WO2003006610A2 publication Critical patent/WO2003006610A2/en
Publication of WO2003006610A3 publication Critical patent/WO2003006610A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Definitions

  • This invention relates generally to molecular and cellular biology.
  • the invention is directed to enzymes having phosphatase activity, particularly, thermostable phosphatase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
  • the phosphatase activity of the enzymes of the invention include the enzymatic removal of phosphate groups from organophosphate ester compounds and hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA.
  • Phosphatases are a group of enzymes that remove phosphate groups from organophosphate ester compounds. There are numerous phosphatases, including alkaline phosphatases, phosphodiesterases and phytases. Alkaline phosphatases are widely distributed enzymes and are composed of a group of enzymes that hydrolyze organic phosphate ester bonds at alkaline pH.
  • Phosphodiesterases are capable of hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA.
  • the classification of phosphodiesterases depends upon which side of the phosphodiester bridge is attacked.
  • the 3' enzymes specifically hydrolyze the ester linkage between the 3' carbon and the phosphoric group whereas the 5' enzymes hydrolyze the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge.
  • the best known of the class 3' enzymes is a phosphodiesterase from the venom of the rattlesnake or from a rustle's viper, which hydrolyses all the 3' bonds in either RNA or DNA liberating nearly all the nucleotide units as nucleotide 5' phosphates.
  • This enzyme requires a free 3' hydroxyl group on the terminal nucleotide residue and proceeds stepwise from that end of the polynucleotide chain.
  • This enzyme and all other nucleases that attack only at the ends of the polynucleotide chains are called exonucleases.
  • the 5' enzymes are represented by a phosphodiesterase from bovine spleen, also an exonuclease, which hydrolyses all the 5' linkages of both DNA and RNA and thus liberates only nucleoside 3' phosphates. It begins its attack at the end of the chain having a free 3' hydroxyl group.
  • Phytases are enzymes that recently have been introduced to commerce.
  • the phytase enzyme removes phosphate from phytic acid (inositol hexaphosphoric acid), a compound found in plants such as corn, wheat and rice.
  • the enzyme has commercial use for the treatment of animal feed, making the inositol of the phytic acid available for animal nutrition.
  • Aspergillus fwuum and wheat are sources of phytase.
  • Phytase is used to improve the utilization of natural phosphorus in animal feed.
  • Use of phytase as a feed additive enables the animal to metabolize a larger degree of its cereal feed's natural mineral content thereby reducing or altogether eliminating the need for synthetic phosphorus additives.
  • More important than the reduced need for phosphorus additives is the corresponding reduction of phosphorus in pig and chicken waste.
  • Many European countries severely limit the amount of manure that can be spread per acre due to concerns regarding phosphorus contamination of ground water.
  • Alkaline phosphatase hydro lyzes monophosphate esters, releasing an organic phosphate and the cognate alcohol compound. It is non-specific with respect to the alcohol moiety and it is this feature that accounts for the many uses of this enzyme.
  • the enzyme has a pH optimum between 9 and 10, however, it can also function at neutral pH.
  • Alkaline phosphatases are not irreversibly inactivated even when heated to 60°C or more for brief periods of time, as, for example, in the practice of hydrolyzing monophosphate esters.
  • Alkaline phosphatases may be obtained from numerous thermophilic organisms, such as Ammonifex degensii, Aquifex pyrophilus, Archaeoglobus lithotrophicus, Methanococcus igneus, Pyrolobus (a Crenarchaeota), Pyrococcus and Thermococcus, which are mostly Eubacteria and Euryarchaeota. Many of these organisms grow at temperatures up to about 103°C and are unable to grow below 70°C.
  • alkaline phosphatases are isolated from extreme environments.
  • Thermococcus CL-2 was isolated from a worm residing on a "black smoker" sulfite structure.
  • Interest in alkaline phosphatases from thermophilic microbes has increased recently due to their value for commercial applications. [0007] Two sources of alkaline phosphatases dominate and compete commercially:
  • Bacterial alkaline phosphatase is an alternative to calf alkaline phosphatase due to bacterial alkaline phosphatase's extreme thermotolerance at temperatures as high as 95°C (see, e.g., Tomazic- Allen, S.J.; Recombinant Bacterial Phosphatase as an Immunodiagnostic Enzyme, Annals D Biology Clinique, 49(5):287:90 (1991)), however, the enzyme has a very low turnover number.
  • thermostable alkaline phosphatases whose enhanced thermostability is beneficial in enzyme labeling processes and certain recombinant DNA techniques, such as in the dephosphorylation of vector DNA prior to insert DNA ligation.
  • Recombinant phosphatase enzymes provide the proteins in a format amenable to efficient production of pure enzyme, which can be utilized in a variety of applications as described herein. Accordingly, there is a need for the characterization, amino acid sequencing, DNA sequencing, and heterologous expression of thermostable phosphatase enzymes.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO: 19 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, e.g., thermostable phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • a phosphatase activity e.g., thermostable phosphatase activity
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:20 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:21 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:22 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:23 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:24 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:25 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:26 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:27 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:37 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 4000, 4200, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:38 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:39 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 3800, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:37 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3200, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:41 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:43 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:45 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:47 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:49 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:51 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:53 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
  • the invention provides isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleic acid having a sequence as set forth in SEQ ED NO: 19, sequence as set forth in SEQ ID NO:20, sequence as set forth in SEQ ID NO:21, sequence as set forth in SEQ ED NO:22, sequence as set forth in SEQ ID NO:23, sequence as set forth in SEQ ED NO:24, sequence as set forth in SEQ ID NO:25, sequence as set forth in SEQ ID NO:26, sequence as set forth in SEQ ED NO:27, sequence as set forth in SEQ ED NO:37, sequence as set forth in SEQ ED NO:38, sequence as set forth in SEQ ED NO:39, sequence as set forth in SEQ ID NO:40, sequence as set forth in SEQ ID NO:41, sequence as set forth in SEQ ED NO:43, sequence as set forth in SEQ ED NO:45, sequence as set forth in SEQ ID NO:47, sequence as set forth in SEQ ID NO:
  • the invention provides isolated or recombinant nucleic acid, wherein the nucleic acid sequence encodes a polypeptide comprising a sequence as set forth in SEQ ED NO:28, sequence as set forth in SEQ ED NO:29, sequence as set forth in SEQ ID NO:30, sequence as set forth in SEQ ED NO:31, sequence as set forth in SEQ ID NO:32, sequence as set forth in SEQ ID NO:33, sequence as set forth in SEQ ID NO:34, sequence as set forth in SEQ ID NO:35, sequence as set forth in SEQ ID NO:36, sequence as set forth in SEQ ED NO:42, sequence as set forth in SEQ ID NO:44, sequence as set forth in SEQ ID NO:46, sequence as set forth in SEQ ED NO:48, sequence as set forth in SEQ ID NO:50, sequence as set forth in SEQ ID NO:52, or sequence as set forth in SEQ ID NO:54.
  • the sequence comparison algorithm is
  • the phosphatase activity comprises an alkaline phosphatase activity.
  • the phosphatase activity comprises a phosphodiesterase activity.
  • the phosphatase activity comprises a phytase activity.
  • the phosphatase activity comprises removal of phosphate group.
  • the phosphodiesterase activity comprises hydrolysis of the phosphodiester bridges of nucleic acids.
  • the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the 3' carbon and the phosphoric group.
  • the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge.
  • the phytase activity can comprise removal of phosphate from phytic acid (inositol hexaphosphoric acid).
  • the alkaline phosphatase activity can comprise hydrolysis of monophosphate esters.
  • the alkaline phosphatase activity can comprise hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
  • the isolated or recombinant nucleic acid encodes a polypeptide having a phosphatase activity that is thermostable.
  • the polypeptide can retain a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C.
  • the isolated or recombinant nucleic acid encodes a polypeptide having a phosphatase activity that is thermotolerant.
  • the polypeptide can retain a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C.
  • the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 50°C.
  • the isolated or recombinant nucleic acid comprises a sequence that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ED NO:26, a sequence as set forth in SEQ ED NO:27, a sequence as set forth in SEQ ID NO:37, a sequence as set forth in SEQ ED NO:38, a sequence as set forth in SEQ ID NO:39, a sequence as set forth in SEQ ED NO:40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ID NO:
  • the nucleic acid can be at least about 100, 200, 300, 400, 500, 600, 700, 800,
  • the stringent conditions can include a wash step comprising a wash in 0.2X SSC at a temperature of about 65°C for about 15 minutes.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 consecutive bases of a sequence comprising a sequence as set forth in SEQ ED NO: 19, a sequence as set forth in SEQ ID NO:20, a sequence as set forth in SEQ ED NO:21, a sequence as set forth in SEQ ID NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ID NO:25, a sequence
  • the probe can comprise at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence as set forth in SEQ ID NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ID NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ID NO:26, a sequence as set forth in SEQ ID NO:27, a sequence as set forth in SEQ ID NO:37, a sequence as set forth in SEQ ED NO:38, a sequence as set forth in SEQ ID NO:39, a sequence as set forth in SEQ ED NO:40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ID NO:43, a sequence as set forth in
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO: 19, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:20, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:21, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ED NO:22, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:23, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:24, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% > , or more, sequence identity to SEQ ED NO:25, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:26, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:27, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO: 37, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ED NO:38, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%>, or more, sequence identity to SEQ ID NO:39, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%>, or more, sequence identity to SEQ ID NO:40, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:41, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:43, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:45, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:47, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:49, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:51, or a subsequence thereof, over a region of at least about 100 residues.
  • the invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:53, or a subsequence thereof, over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection.
  • the probe can comprise an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence as set forth in SEQ ED NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ED NO:24, a sequence as set forth in SEQ ID NO:25, a sequence as set forth in SEQ ED NO:26, a sequence as set forth in SEQ ID NO:27, a sequence as set forth in SEQ ED NO:37, a sequence as set forth in SEQ ID NO:38, a sequence as set forth in SEQ ED NO:39, a sequence as set forth in SEQ ID NO:40, a sequence as set forth in SEQ ED NO:41, a sequence
  • the invention provides an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subseque
  • One or each member of the amplification primer sequence pair can comprise an oligonucleotide comprising at least about 10 to 50 consecutive bases of the sequence.
  • the invention provides methods of amplifying a nucleic acid encoding a polypeptide with a phosphatase activity comprising amplification of a template nucleic acid with an amplification primer sequence pair capable of amplifying a nucleic acid sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ
  • the invention provides expression cassettes comprising a nucleic acid of the invention, e.g., comprising: (i) a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100
  • the invention provides vectors comprising a nucleic acid of the invention, e.g., (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about at least about
  • the invention provides cloning vehicles comprising a nucleic acid of the invention or a vector of the invention.
  • the cloning vehicle can be a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome.
  • the viral vector can comprise an adenovirus vector, a retroviral vectors or an adeno-associated viral vector.
  • the cloning vehicle can comprise a bacterial artificial chromosome (B AC), a plasmid, a bacteriophage PI -derived vector (PAC), a yeast artificial chromosome (YAC), a mammalian artificial chromosome (MAC).
  • the invention provides transformed cells comprising a nucleic acid of the invention or a vector of the invention or a cloning vehicle of the invention.
  • the vector can comprise a nucleic acid of the invention, for example, a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth
  • the invention provides transformed cells comprising a nucleic acid of the invention, e.g., (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region
  • the invention provides non-human animals comprising a nucleic acid of the invention or a vector of the invention.
  • the transgenic animal is a mouse.
  • the invention provides transgenic plants comprising a nucleic acid of the invention or a vector of the invention.
  • the transgenic plant can be an oilseed plant, a rapeseed plant, a soybean plant, a palm, a canola plant, a sunflower plant, a sesame plant, a peanut plant or a tobacco plant.
  • the invention provides transgenic seeds comprising a nucleic acid of the invention or a vector of the invention.
  • the transgenic seed can be an oilseed, a rapeseed, a soybean seed, a palm kernel, a canola plant seed, a sunflower seed, a sesame seed, a peanut or a tobacco plant seed.
  • the invention provides an antisense oligonucleotide comprising a nucleic acid s -.e-q ⁇ u ⁇ eennccee complementary to or capable of hybridizing under stringent conditions to (i) a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO: 22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least
  • the antisense oligonucleotide can be between about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 bases in length.
  • the invention provides methods of inhibiting the translation of a phosphatase message in a cell comprising administering to the cell or expressing in the cell an antisense oligonucleotide comprising a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to a nucleic acid comprising (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about
  • the invention provides an isolated or recombinant polypeptide comprising an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%), 98%, 99%o, or more, sequence identity to SEQ ID NO:28 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:29 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:30 over a region of
  • the polypeptide can have a phosphatase activity.
  • the phosphatase activity comprises an alkaline phosphatase activity.
  • the phosphatase activity can comprise a phytase activity.
  • the phosphatase activity can comprise a phosphodiesterase activity.
  • the phosphatase activity can comprise removal of phosphate group.
  • the phosphodiesterase activity can comprise hydrolysis of the phosphodiester bridges of nucleic acids.
  • the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the 3' carbon and the phosphoric group.
  • the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge.
  • the phytase activity comprises removal of phosphate from phytic acid (inositol hexaphosphoric acid).
  • the phosphatase activity comprises hydrolysis of monophosphate esters.
  • the phosphatase activity can comprise hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
  • the phosphatase activity is thermostable.
  • the polypeptide can retain a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C.
  • the phosphatase activity is thermotolerant.
  • the polypeptide can retain a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C, or in the range from greater than 37°C to about 50°C.
  • the invention provides the isolated or recombinant polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:28, an amino acid sequence as set forth in SEQ ID NO:29, an amino acid sequence as set forth in SEQ ED NO:30, an amino acid sequence as set forth in SEQ ID NO:31, an amino acid sequence as set forth in SEQ ID NO:32, an amino acid sequence as set forth in SEQ ED NO:33, an amino acid sequence as set forth in SEQ ID NO:34, an amino acid sequence as set forth in SEQ ED NO:35, an amino acid sequence as set forth in SEQ ID NO:36, an amino acid sequence as set forth in SEQ ID NO:42, an amino acid sequence as set forth in SEQ ID NO:44, an amino acid sequence as set forth in SEQ ID NO:46, an amino acid sequence as set forth in SEQ ID NO:48, an amino acid sequence as set forth in SEQ ED NO:50, an amino acid sequence as set forth in SEQ ED NO:52, or
  • the phosphatase activity can be thermostable when heated to a temperature in the range from about 37°C to about 50°C, about 50°C to about 70°C or about 70°C to about 90°C.
  • the phosphatase activity can comprise a specific activity at about 37°C in the range from about 100 to about 1000 units per milligram of protein.
  • the phosphatase activity comprises a specific activity from about 500 to about 750 units per milligram of protein.
  • the phosphatase activity comprises a specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein.
  • the phosphatase activity comprises a specific activity at 37°C in the range from about 750 to about 1000 units per milligram of protein.
  • the phosphatase activity can be thermotolerant after being heated to an elevated temperature in the range from about 37°C to about 90°C.
  • the phosphatase activity can be thermotolerant after being heated to a temperature in the range from about 37°C to about 70°C.
  • the thermotolerance can comprise retention of at least half of the specific activity of the phosphatase at 37°C after being heated to the elevated temperature.
  • the thermotolerance can comprise retention of specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein after being heated to the elevated temperature.
  • the invention provides the isolated or recombinant polypeptide, wherein the phosphatase comprises at least one glycosylation site.
  • glycosylation can be an N-linked glycosylation.
  • the polypeptide can be glycosylated after being expressed in a P. pastoris or a S. pombe.
  • the polypeptide can retain a phosphatase activity under conditions comprising about pH 5. In another aspect, the polypeptide can retain a phosphatase activity under conditions comprising about pH 4.5. Alternatively, the polypeptide of the invention can retain a phosphatase activity under conditions comprising about pH 9.0, pH 9.5, pH 10, 10.5, pH 11, pH 11.5 or pH 12.
  • the invention provides protein preparations comprising a polypeptide of the invention, wherein the protein preparation comprises a liquid, a solid or a gel.
  • the invention provides heterodimers comprising a polypeptide of the invention and a second domain. n one aspect, the second domain can be a polypeptide and the heterodimer is a fusion protein. En one aspect, the second domain can be an epitope or a tag.
  • the invention provides immobilized polypeptides having a phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or is a polypeptide encoded by a nucleic acid of the invention, or a polypeptide comprising a polypeptide of the invention and a second domain.
  • the polypeptide can be immobilized on a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, an array or a capillary tube.
  • the invention provides arrays comprising an immobilized polypeptide, wherein the polypeptide is a polypeptide of the invention, or is a polypeptide encoded by a nucleic acid of the invention, or a polypeptide comprising a polypeptide of the invention and a second domain.
  • the invention provides arrays comprising an immobilized nucleic acid of the invention.
  • the invention provides arrays comprising an antibody of the invention.
  • the invention provides isolated or recombinant antibodies that specifically bind to a polypeptide of the invention or to a polypeptide encoded by a nucleic acid of the invention.
  • the antibody can be a monoclonal or a polyclonal antibody.
  • the invention provides hybridomas comprising an antibody of the invention.
  • the invention provides food supplements for an animal comprising a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention.
  • the polypeptide can be glycosylated.
  • the invention provides edible enzyme delivery matrices comprising a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention, wherein the polypeptide comprises a phosphatase activity.
  • the delivery matrix can comprise a pellet.
  • the polypeptide can be glycosylated.
  • the phosphatase activity can be thermotolerant or thermostable.
  • the invention provides methods of isolating or identifying a polypeptide with phosphatase activity comprising the steps of: (a) providing an antibody of the invention; (b) providing a sample comprising polypeptides; and (c) contacting the sample of step (b) with the antibody of step (a) under conditions wherein the antibody can specifically bind to the polypeptide, thereby isolating or identifying a phosphatase.
  • the invention provides methods of making an anti -phosphatase antibody comprising administering to a non-human animal a nucleic acid of the invention, or a polypeptide of the invention, in an amount sufficient to generate a humoral immune response, thereby making an anti-phosphatase antibody.
  • the invention provides methods of producing a recombinant polypeptide comprising the steps of: (a) providing a nucleic acid of the invention operably linked to a promoter; and (b) expressing the nucleic acid of step (a) under conditions that allow expression of the polypeptide, thereby producing a recombinant polypeptide.
  • the method can further comprise transforming a host cell with the nucleic acid of step (a) followed by expressing the nucleic acid of step (a), thereby producing a recombinant polypeptide in a transformed cell.
  • the invention provides methods for identifying a polypeptide having a phosphatase activity comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention; (b) providing a phosphatase substrate; and (c) contacting the polypeptide or a fragment or variant thereof of step (a) with the substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of a reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product detects a polypeptide having a phosphatase activity.
  • the substrate can be an organophosphate ester compound.
  • the invention provides methods for identifying a phosphatase substrate comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic of the invention; (b) providing a test substrate; and (c) contacting the polypeptide of step (a) with the test substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of a reaction product identifies the test substrate as a phosphatase substrate.
  • the invention provides methods of determining whether a compound specifically binds to a polypeptide comprising the following steps: (a) expressing a nucleic acid of the invention or a vector comprising the nucleic acid of the invention under conditions permissive for translation of the nucleic acid to a polypeptide, or, providing a polypeptide of the invention; (b) contacting the polypeptide with the test compound; and (c) determining whether the test compound specifically binds to the polypeptide, thereby determining that the compound specifically binds to the polypeptide.
  • the invention provides methods for identifying a modulator of a phosphatase activity comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention; (b) providing a test compound; (c) contacting the polypeptide of step (a) with the test compound of step (b) and measuring an activity of the phosphatase, wherein a change in the phosphatase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the phosphatase activity.
  • the phosphatase activity can be measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product, or, an increase in the amount of the substrate or a decrease in the amount of a reaction product.
  • a decrease in the amount of the substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity.
  • an increase in the amount of the substrate or a decrease in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an inhibitor of phosphatase activity.
  • the invention provides computer systems comprising a processor and a data storage device wherein said data storage device has stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises a polypeptide of the invention, or subsequence thereof, and the nucleic acid comprises a nucleic acid of the invention, or subsequence thereof.
  • the computer system can further comprise a sequence comparison algorithm and a data storage device having at least one reference sequence stored thereon.
  • the sequence comparison algorithm comprises a computer program that indicates polymorphisms.
  • the computer system can further comprise an identifier that identifies one or more features in said sequence.
  • the invention provides computer readable mediums having stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention, or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention, or subsequence thereof.
  • the invention provides methods for identifying a feature in a sequence comprising the steps of: (a) reading the sequence using a computer program which identifies one or more features in a sequence, wherein the sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention or subsequence thereof; and (b) identifying one or more features in the sequence with the computer program.
  • the invention provides methods for comparing a first sequence to a second sequence comprising the steps of: (a) reading the first sequence and the second sequence through use of a computer program which compares sequences, wherein the first sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention, or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention or subsequence thereof; and (b) determining differences between the first sequence and the second sequence with the computer program.
  • the step of determining differences between the first sequence and the second sequence can comprise the step of identifying polymorphisms.
  • the step of determining differences between the first sequence and the second sequence further comprises the step of identifying polymo ⁇ hisms.
  • the method comprises an identifier that identifies one or more features in a sequence.
  • the method can comprise reading the first sequence using a computer program and identifying one or more features in the sequence.
  • the invention provides methods for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of: (a) providing an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO:54, or a subseque
  • each member of the amplification primer sequence pair comprises an oligonucleotide comprising at least about 10 to 50 consecutive bases of a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO: 54, or a subsequence thereof.
  • the invention provides methods for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of: (a) providing a polynucleotide probe, wherein the polynucleotide probe comprises a nucleic acid of the invention or a subsequence thereof; (b) isolating a nucleic acid from the environmental sample or treating the environmental sample such that nucleic acid in the sample is accessible for hybridization to a polynucleotide probe of step (a); (c) combining the isolated nucleic acid or the treated environmental sample of step (b) with the polynucleotide probe of step (a); and (d) isolating a nucleic acid that specifically hybridizes with the polynucleotide probe of step (a), thereby isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample.
  • the environmental sample can comprise a water sample, a liquid sample, a soil sample, an air sample or a biological sample.
  • the biological sample can be derived from a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell.
  • the invention provides methods of generating a variant of a nucleic acid encoding a phosphatase comprising the steps of: (a) providing a template nucleic acid of the invention; and (b) modifying, deleting or adding one or more nucleotides in the template sequence, or a combination thereof, to generate a variant of the template nucleic acid.
  • the method can further comprise expressing the variant nucleic acid to generate a variant phosphatase polypeptide.
  • the modifications, additions or deletions can be introduced by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site- specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR) and a combination thereof.
  • the modifications, additions or deletions are introduced by a method comprising recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof.
  • the method is iteratively repeated until a phosphatase having an altered or different activity or an altered or different stability from that of a polypeptide encoded by the template nucleic acid is produced.
  • the variant phosphatase polypeptide can be thermotolerant, and retains some activity after being exposed to an elevated temperature.
  • the variant phosphatase polypeptide has increased glycosylation as compared to the phosphatase encoded by a template nucleic acid.
  • the variant phosphatase polypeptide has a phosphatase activity under a high temperature, wherein the phosphatase encoded by the template nucleic acid is not active under the high temperature.
  • the method can be iteratively repeated until a phosphatase coding sequence having an altered codon usage from that of the template nucleic acid is produced. In another aspect, the method is iteratively repeated until a phosphatase gene having higher or lower level of message expression or stability from that of the template nucleic acid is produced.
  • the invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising: (a) providing a nucleic acid of the invention; and, (b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a preferred or neutrally used codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell.
  • the invention provides methods for modifying codons in a nucleic acid encoding a phosphatase polypeptide, the method comprising (a) providing a nucleic acid of the invention; and, (b) identifying a codon in the nucleic acid of step (a) and replacing it with a different codon encoding the same amino acid as the replaced codon, thereby modifying codons in a nucleic acid encoding a phosphatase.
  • the invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising (a) providing a nucleic acid of the invention; and, (b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a preferred or neutrally used codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell.
  • the invention provides methods for modifying a codon in a nucleic acid encoding a phosphatase to decrease its expression in a host cell, the method comprising (a) providing a nucleic acid of the invention; and (b) identifying at least one preferred codon in the nucleic acid of step (a) and replacing it with a non-preferred or less preferred codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in a host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to decrease its expression in a host cell.
  • the host cell can be a bacterial cell, a fungal cell, an insect cell, a yeast cell, a plant cell or a mammalian cell.
  • the invention provides methods for producing a library of nucleic acids encoding a plurality of modified phosphatase active sites or substrate binding sites, wherein the modified active sites or substrate binding sites are derived from a first nucleic acid comprising a sequence encoding a first active site or a first substrate binding site the method comprising: (a) providing a first nucleic acid encoding a first active site or first substrate binding site, wherein the first nucleic acid sequence comprises a sequence that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ID NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35,
  • the method can comprise mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system, site-saturation mutagenesis (GSSM), synthetic ligation reassembly (SLR).
  • the method can comprise mutagenizing the first nucleic acid of step (a) or variants by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, and a combination thereof.
  • the method can comprise mutagenizing the first nucleic acid of step (a) or variants by a method comprising recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction- purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof.
  • the invention provides methods of making a small molecule comprising the steps of: (a) providing a plurality of biosynthetic enzymes capable of synthesizing or modifying a small molecule, wherein one of the enzymes comprises a phosphatase enzyme encoded by a nucleic acid of the invention; (b) providing a substrate for at least one of the enzymes of step (a); and (c) reacting the substrate of step (b) with the enzymes under conditions that facilitate a plurality of biocatalytic reactions to generate a small molecule by a series of biocatalytic reactions.
  • the invention provides method for modifying a small molecule comprising the steps: (a) providing a polypeptide of the invention, or, a polypeptide which is encoded by a nucleic acid of the invention; (b) providing a small molecule; and (c) reacting the polypeptide of step (a) with the small molecule of step (b) under conditions that facilitate an enzymatic reaction catalyzed by the phosphatase enzyme, thereby modifying a small molecule by a phosphatase enzymatic reaction.
  • the method comprises a plurality of small molecule substrates for the enzyme of step (a), thereby generating a library of modified small molecules produced by at least one enzymatic reaction catalyzed by the phosphatase enzyme.
  • the method can further comprise a plurality of additional enzymes under conditions that facilitate a plurality of biocatalytic reactions by the enzymes to form a library of modified small molecules produced by the plurality of enzymatic reactions.
  • the method can comprise the step of testing the library to determine if a particular modified small molecule that exhibits a desired activity is present within the library.
  • the step of testing the library further comprises the steps of systematically eliminating all but one of the biocatalytic reactions used to produce a portion of the plurality of the modified small molecules within the library by testing the portion of the modified small molecule for the presence or absence of the particular modified small molecule with a desired activity, and identifying at least one specific biocatalytic reaction that produces the particular modified small molecule of desired activity.
  • the invention provides methods for determining a functional fragment of a phosphatase enzyme comprising the steps of: (a) providing a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; and (b) deleting a plurality of amino acid residues from the sequence of step (a) and testing the remaining subsequence for a phosphatase activity, thereby determining a functional fragment of a phosphatase enzyme.
  • the phosphatase activity is measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product.
  • a decrease in the amount of an enzyme substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity.
  • the invention provides methods for whole cell engineering of new or modified phenotypes by using real-time metabolic flux analysis, the method comprising the following steps: (a) making a modified cell by modifying the genetic composition of a cell, wherein the genetic composition is modified by addition to the cell of a nucleic acid of the invention; (b) culturing the modified cell to generate a plurality of modified cells; (c) measuring at least one metabolic parameter of the cell by monitoring the cell culture of step (b) in real time; and, (d) analyzing the data of step (c) to determine if the measured parameter differs from a comparable measurement in an unmodified cell under similar conditions, thereby identifying an engineered phenotype in the cell using real-time metabolic flux analysis.
  • the genetic composition of the cell is modified by a method comprising deletion of a sequence or modification of a sequence in the cell, or, knocking out the expression of a gene.
  • the method can further comprise selecting a cell comprising a newly engineered phenotype.
  • the method can comprise culturing the selected cell, thereby generating a new cell strain comprising a newly engineered phenotype.
  • the invention provides methods for inhibiting degradation of the cyclic nucleotides comprising the following steps: (a) providing a polypeptide liaving a phosphodiesterase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphodiesterase inhibitor; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the composition inhibits phosphodiesterase activity thereby inhibiting degradation of the cyclic nucleotides.
  • the phosphodiesterase is cyclic AMP or cyclic GMP specific.
  • the invention provides methods for removing a phosphate group comprising the following steps: (a) providing a polypeptide having a phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphate group; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphatase group.
  • the invention provides methods for hydrolysis of the phosphodiester bridges comprising the following steps: (a) providing a polypeptide having a phosphodiesterase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphodiester bridge; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the phosphodiester bridge.
  • the composition comprising a phosphodiester bridge can be a nucleic acid.
  • the invention provides methods for removal of phosphate comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphate; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphate group.
  • the composition is phytic acid.
  • the invention provides methods for hydrolysis of monophosphate esters comprising the following steps: (a) providing a polypeptide having an alkaline phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a monophosphate ester; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the monophosphate esters.
  • the invention provides methods of increasing thermotolerance or thermostability of a phosphatase polypeptide, the method comprising glycosylating a phosphatase polypeptide, wherein the polypeptide comprises at least thirty contiguous amino acids of a sequence of a polypeptide of the invention, or a polypeptide encoded by a nucleic acid of the invention, thereby increasing the thermotolerance or thermostability of the phosphatase polypeptide.
  • the phosphatase specific activity can be thermostable or thermotolerant at a temperature in the range from greater than about 37°C to about 90°C.
  • the invention provides methods for overexpressing a recombinant phosphatase polypeptide in a cell comprising expressing a vector comprising a nucleic acid of the invention, e.g., a nucleic acid comprising a sequence having at least 50%> sequence identity to the nucleic acid of the invention over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection, wherein overexpression is effected by use of a high activity promoter, a dicistronic vector or by gene amplification of the vector.
  • a vector comprising a nucleic acid of the invention, e.g., a nucleic acid comprising a sequence having at least 50%> sequence identity to the nucleic acid of the invention over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection, wherein overexpression is effected by use of a high activity promoter, a dicistronic vector
  • the invention provides methods for improving phosphate consumption in animals comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) ingesting the polypeptide of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization.
  • the invention provides methods for improving phosphate consumption in animals comprising the following steps: (a) providing a genetically engineered seed comprising a nucleic acid of the invention, wherein the nucleic acid encodes a polypeptide comprising a phytase activity; (b) ingesting the seeds of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization.
  • the animals can be swine or poultry.
  • the invention provides methods for treating solid or liquid animal waste products comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide comprises a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a solid or a liquid animal waste; and (c) contacting the polypeptide of step (a) and the solid or liquid waste of step (b) under conditions wherein the phytase can treat the waste.
  • the present invention provides nucleic acids (e.g., DNA) and amino acid sequence information and expression and purification protocols for thermostable phosphatases.
  • the invention provides an isolated nucleic acid having a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 and variants thereof having at least 50%> sequence identity to SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 and encoding polypeptides having phosphatase activity.
  • One aspect of the invention is an isolated nucleic acid having a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 (hereinafter referred to as "Group A nucleic acid sequences"), sequences substantially identical thereto, and sequences complementary thereto.
  • Another aspect of the invention is an isolated nucleic acid including at least 10 consecutive bases of a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, and the sequences complementary thereto.
  • the invention provides an isolated nucleic acid encoding a polypeptide having a sequence as set forth in SEQ ID NOs.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 44, 46, 48, 50, 52, 54, and variants thereof encoding a polypeptide having phosphatase activity and having at least 50% sequence identity to such sequences.
  • Another aspect of the invention is an isolated nucleic acid encoding a polypeptide or a functional fragment thereof having a sequence as set forth in SEQ ID Nos.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 43, 44, 46, 47, 48, 50, 52, 54, (hereinafter referred to as "Group B amino acid sequences"), and sequences substantially identical thereto.
  • Group B amino acid sequences Another aspect of the invention is an isolated nucleic acid encoding a polypeptide having at least 10 consecutive amino acids of a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • the invention provides a purified polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is an isolated or purified antibody that specifically binds to a polypeptide of the invention, e.g., a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is an isolated or purified antibody or binding fragment thereof, which specifically binds to a polypeptide having at least 10 consecutive amino acids of one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a method of making a polypeptide of the invention, e.g., having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • the method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid.
  • Another aspect of the invention is a method of making a polypeptide having at least 10 amino acids of a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • the method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid, thereby producing the polypeptide.
  • Another aspect of the invention is a method of generating a variant including obtaining a nucleic acid having a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, sequences complementary to the sequences of Group A nucleic acid sequences, fragments comprising at least 30 consecutive nucleotides of the foregoing sequences, and changing one or more nucleotides in the sequence to another nucleotide, deleting one or more nucleotides in the sequence, or adding one or more nucleotides to the sequence.
  • Another aspect of the invention is a computer readable medium having stored thereon a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a computer system including a processor and a data storage device wherein the data storage device has stored thereon a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a method for comparing a first sequence to a reference sequence wherein the first sequence is a nucleic acid having a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide of the invention, e.g., a code of Group B amino acid sequences, and sequences substantially identical thereto.
  • the method includes reading the first sequence and the reference sequence through use of a computer program that compares sequences; and determining differences between the first sequence and the reference sequence with the computer program.
  • Another aspect of the invention is a method for identifying a feature in a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto, including reading the sequence through the use of a computer program which identifies features in sequences; and identifying features in the sequence with the computer program.
  • Another aspect of the invention is an assay for identifying fragments or variants of polypeptides of the invention, e.g., of Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of the polypeptides of the invention, e.g., of Group B amino acid sequences, and sequences substantially identical thereto.
  • the assay includes contacting the polypeptide of the invention, e.g., of Group B amino acid sequences, sequences substantially identical thereto, or polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate thereby identifying a fragment or variant of such sequences.
  • Figure 1 is a block diagram of a computer system.
  • Figure 2 is a flow diagram illustrating one aspect of a process for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.
  • Figure 3 is a flow diagram illustrating one aspect of a process in a computer for determining whether two sequences are homologous.
  • Figure 4 is a flow diagram illustrating one aspect of an identifier process 300 for detecting the presence of a feature in a sequence.
  • Figure 5 is an illustration of an exemplary sequence of the invention, a full- length DNA and corresponding deduced amino acid sequence of isolated Ammonifex degensii KC4 of the present invention. Sequencing was performed using a 378 automated DNA sequence for all sequences of the present invention (Applied Biosystems, Inc. Foster City, California).
  • Figure 6 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Methanococcus igneus Kol5.
  • Figure 7 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus alcaliphilus AEDII12RA.
  • Figure 8 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus celer.
  • Figures 9A and 9B are an illustration of an exemplary sequence of the invention, the full-length DNA and corresponding deduced amino acid sequence of isolated Thermococcus GU5L5.
  • Figures 10A and 10B are an illustration of an exemplary sequence of the invention, the full-length DNA and corresponding deduced amino acid sequence of isolated OC9a.
  • Figure 11 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Ml 1TL.
  • Figure 12 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus CL- 2.
  • Figure 13 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Aquifex VF-5.
  • the invention provides enzymes having various phosphatase activities, such as thermostable phosphatase activities, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
  • the phosphatase activity of the enzymes of the invention include the enzymatic removal of phosphate groups from organophosphate ester compounds and hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA. Definitions
  • the present invention provides phosphatases, polynucleotides encoding them, antibodies that bind to them and methods for making and using these compositions.
  • phosphatase encompasses all enzymes having any phosphatase activity as described herein, such as the enzymatic removal of phosphate groups from organophosphate ester compounds, or, hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA; including any hydrolase activity, for example, including enzymes capable of hydrolyzing glycosidic linkages present in starch.
  • antibody includes a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope, see, e.g. Fundamental Immunology, Third Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994) J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97.
  • antibody includes antigen-binding portions, i.e., "antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341 : 544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
  • Antigen binding sites e.g., fragments, sub
  • a ⁇ ay or “microarray” or “biochip” or “chip” as used herein is a plurality of target elements, each target element comprising a defined amount of one or more polypeptides (including antibodies) or nucleic acids immobilized onto a defined area of a substrate surface.
  • expression cassette refers to a nucleotide sequence which is capable of affecting expression of a structural gene (i.e., a protein coding sequence, such as a phosphatase of the invention) in a host compatible with such sequences.
  • Expression cassettes include at least a promoter operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used, e.g., enhancers.
  • operably linked refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence.
  • expression cassettes also include plasmids, expression vectors, recombinant viruses, any form of recombinant "naked DNA” vector, and the like.
  • a “vector” comprises a nucleic acid that can infect, transfect, and transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid.
  • the vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.).
  • Vectors include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated.
  • Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Patent No. 5,217,879), and includes both the expression and non-expression plasmids.
  • a recombinant microorganism or cell culture is described as hosting an "expression vector" this includes both extra-chromosomal circular and linear DNA and DNA that has been inco ⁇ orated into the host chromosome(s).
  • the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is inco ⁇ orated within the host's genome.
  • nucleic acid or “nucleic acid sequence” as used herein refer to an oligonucleotide, nucleotide, polynucleotide, or to a fragment of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin, including, e.g., iRNA, ribonucleoproteins (e.g., iRNPs).
  • PNA peptide nucleic acid
  • nucleic acids i.e., oligonucleotides, containing known analogues of natural nucleotides.
  • the term also encompasses nucleic- acid-like structures with synthetic backbones, see e.g., Mata (1997) Toxicol. Appl. Pharmacol. 144:189-197; Strauss-Soukup (1997) Biochemistry 36:8692-8698; Straussense Nucleic Acid Drug Dev 6:153-156.
  • nucleic acid or “nucleic acid sequence” as used herein include oligonucleotides, nucleotides, polynucleotides and to fragments of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin.
  • PNA peptide nucleic acid
  • a "coding sequence of ' or a "nucleotide sequence encoding" a particular polypeptide or protein is a nucleic acid sequence which is transcribed and translated into a polypeptide or protein when placed under the control of appropriate regulatory sequences.
  • gene means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as, where applicable, intervening sequences (introns) between individual coding segments (exons).
  • amino acid or “amino acid sequence” as used herein refer to an oligopeptide, peptide, polypeptide, or protein sequence, or to a fragment, portion, or subunit of any of these, and to naturally occurring or synthetic molecules.
  • polypeptide refers to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids.
  • the polypeptides may be modified by either natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also a given polypeptide may have many types of modifications.
  • Modifications include acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphytidylinositol, cross-linking cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation.
  • the term "isolated” means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • the term “purified” does not require absolute purity; rather, it is intended as a relative definition.
  • nucleic acids obtained from a library have been conventionally purified to electrophoretic homogeneity.
  • the sequences obtained from these clones could not be obtained directly either from the library or from total human DNA.
  • the purified nucleic acids of the invention have been purified from the remainder of the genomic DNA in the organism by at least 104-106 fold.
  • the term "purified” also includes nucleic acids that have been purified from the remainder of the genomic DNA or from other sequences in a library or other environment by at least one order of magnitude, typically two or three orders, and more typically four or five orders of magnitude.
  • the term “recombinant” means that the nucleic acid is adjacent to a "backbone” nucleic acid to which it is not adjacent in its natural environment. Additionally, to be “enriched” the nucleic acids will represent 5%> or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules.
  • Backbone molecules according to the invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest.
  • the enriched nucleic acids represent 15%> or more of the number of nucleic acid inserts in the population of recombinant backbone molecules.
  • the enriched nucleic acids represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In one aspect, the enriched nucleic acids represent 90%> or more of the number of nucleic acid inserts in the population of recombinant backbone molecules.
  • "Recombinant" polypeptides or proteins refer to polypeptides or proteins produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide or protein.
  • synthetic polypeptides or protein are those prepared by chemical synthesis. Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention.
  • assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431 A automated peptide synthesizer.
  • Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.
  • a promoter sequence is "operably linked to" a coding sequence when RNA polymerase which initiates transcription at the promoter will transcribe the coding sequence into mRNA.
  • “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA.
  • the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan.
  • For analytical pu ⁇ oses typically 1 mg of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ml of buffer solution.
  • Oligonucleotide refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.
  • substantially identical in the context of two nucleic acids or polypeptides, refers to two or more sequences that have at least 50%>, 60%, 70%>, 80%, and in some aspects 90-95 %>, or more, nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the known sequence comparison algorithms or by visual inspection.
  • the substantial identity exists over a region of at least about 100 residues, and most commonly the sequences are substantially identical over at least about 150-200 residues.
  • the sequences are substantially identical over the entire length of the coding regions.
  • substantially identical amino acid sequence is a sequence that differs from a reference sequence by one or more conservative or non-conservative amino acid substitutions, deletions, or insertions, particularly when such a substitution occurs at a site that is not the active site of the molecule, and provided that the polypeptide essentially retains its functional properties.
  • a conservative amino acid substitution for example, substitutes one amino acid for another of the same class (e.g., substitution of one hydrophobic amino acid, such as isoleucine, valine, leucine, or methionine, for another, or substitution of one polar amino acid for another, such as substitution of arginine for lysine, glutamic acid for aspartic acid or glutamine for asparagine).
  • One or more amino acids can be deleted, for example, from a phosphatase polypeptide, resulting in modification of the structure of the polypeptide, without significantly altering its biological activity.
  • amino- or carboxyl- terminal amino acids that are not required for phosphatase biological activity can be removed.
  • Modified polypeptide sequences of the invention can be assayed for phosphatase biological activity by any number of methods, including contacting the modified polypeptide sequence with a phosphatase substrate and determining whether the modified polypeptide decreases the amount of specific substrate in the assay or increases the bioproducts of the enzymatic reaction of a functional phosphatase polypeptide with the substrate.
  • Fragments are a portion of a naturally occurring protein which can exist in at least two different conformations. Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. “Substantially the same” means that an amino acid sequence is largely, but not entirely, the same, but retains at least one functional activity of the sequence to which it is related. In general two amino acid sequences are “substantially the same” or “substantially homologous” if they are at least about 85% > identical. Fragments which have different three dimensional structures as the naturally occurring protein are also included. An example of this, is a "pro-form" molecule, such as a low activity proprotein that can be modified by cleavage to produce a mature enzyme with significantly higher activity.
  • Hybridization refers to the process by which a nucleic acid strand joins with a complementary strand through base pairing. Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations.
  • Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.
  • hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C.
  • Hybridization could occur under reduced stringency conditions in about 35%) to 25%) formamide at about 30°C to 35°C.
  • hybridization could occur under high stringency conditions at 42°C in 50%) formamide, 5X SSPE, 0.3%) SDS, and 200 n/ml sheared and denatured salmon sperm DNA.
  • Hybridization could occur under reduced stringency conditions as described above, but in 35%> formamide at a reduced temperature of 35°C.
  • the temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.
  • variant refers to polynucleotides or polypeptides of the invention modified at one or more base pairs, codons, introns, exons, or amino acid residues (respectively) yet still retain the biological activity of a phosphatase of the invention.
  • Variants can be produced by any number of means included methods such as, for example, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof.
  • GSSM saturation mutagenesis
  • optical directed evolution system or “optimized directed evolution” includes a method for reassembling fragments of related nucleic acid sequences, e.g., related genes, and explained in detail, below.
  • SLR synthetic ligation reassembly
  • thermostable and “thermostability” as used herein with reference to an enzyme mean the ability of the enzyme to function at increased temperatures, for example to have comparable specific activity at 70°C and at 85°C at a common pH.
  • a "thermostable” enzyme will maintain much or all of its activity at an increased temperature or may be more active at an increased temperature than at its normal temperature (e.g., room temperature) or its optimum temperature prior to mutagenesis to obtain enhanced thermostability.
  • thermotolerant and “thermotolerance” as used herein with reference to an enzyme mean the ability of the enzyme to function normally after exposure to high temperature, even though the high temperature may temporarily deactivate the enzyme.
  • the invention provides nucleic acids, including expression cassettes such as expression vectors, encoding the polypeptides and phosphatases of the invention.
  • the invention also includes methods for discovering new phosphatase sequences using the nucleic acids of the invention.
  • methods for modifying the nucleic acids of the invention by, e.g., synthetic ligation reassembly, optimized directed evolution system and/or saturation mutagenesis.
  • nucleic acids of the invention can be made, isolated and/or manipulated by, e.g., cloning and expression of cDNA libraries, amplification of message or genomic DNA by PCR, and the like.
  • homologous genes can be modified by manipulating a template nucleic acid, as described herein.
  • the invention can be practiced in conjunction with any method or protocol or device known in the art, which are well described in the scientific and patent literature.
  • nucleic acid sequence as set forth in SEQ ED Nos. : 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51 and 53 encompasses the nucleotide sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, as well as sequences homologous to Group A nucleic acid sequences, and fragments thereof and sequences complementary to all of the preceding sequences.
  • the fragments include portions of SEQ ID Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51 and 53 comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto.
  • Homologous sequences and fragments of Group A nucleic acid sequences, and sequences substantially identical thereto refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%,or 50%) homology to these sequences.
  • Homology may be determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters.
  • Homologous sequences also include RNA sequences in which uridines replace the thymines in the nucleic acid sequences as set forth in the Group A nucleic acid sequences.
  • the homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error. It will be appreciated that the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format (See, e.g., the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which records the identity of the nucleotides in a sequence.
  • the invention provides an isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of the Group B amino acid sequences.
  • the coding sequences of these nucleic acids may be identical to one of the coding sequences of one of the nucleic acids of Group A nucleic acid sequences, or a fragment thereof or may be different coding sequences which encode one of the polypeptides of Group B amino acid sequences, sequences substantially identical thereto, and fragments having at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, as a result of the redundancy or degeneracy of the genetic code.
  • the genetic code is well known to those of skill in the art and can be obtained, for example, on page 214 of B. Lewin, Genes VI, Oxford University Press, 1997.
  • the isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto may include, but is not limited to: only the coding sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, and additional coding sequences, such as leader sequences or proprotein sequences and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence.
  • polynucleotide encoding a polypeptide encompasses a polynucleotide which includes only the coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
  • nucleic acid sequences of Group A nucleic acid sequences, and sequences substantially identical thereto may be mutagenized using conventional techniques, such as site directed mutagenesis, or other techniques familiar to those skilled in the art, to introduce silent changes into the polynucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto.
  • silent changes include, for example, changes which do not alter the amino acid sequence encoded by the polynucleotide. Such changes may be desirable in order to increase the level of the polypeptide produced by host cells containing a vector encoding the polypeptide by introducing codons or codon pairs which occur frequently in the host organism.
  • the invention also relates to polynucleotides which have nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.
  • nucleotide changes may be introduced using techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion, and other recombinant DNA techniques.
  • nucleotide changes may be naturally occurring allelic variants which are isolated by identifying nucleic acids which specifically hybridize to probes comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto (or the sequences complementary thereto) under conditions of high, moderate, or low stringency as provided herein.
  • One aspect of the invention is an isolated nucleic acid comprising one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of a Group A nucleic acid sequence (or the sequences complementary thereto).
  • the isolated, nucleic acids may comprise DNA, including cDNA, genomic DNA, and synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
  • the isolated nucleic acids may comprise RNA.
  • RNA, iRNA, antisense nucleic acid, cDNA, genomic DNA, vectors, viruses or hybrids thereof may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/ generated recombinantly. Recombinant polypeptides generated from these nucleic acids can be individually isolated or cloned and tested for a desired activity. Any recombinant expression system can be used, including bacterial, mammalian, yeast, and insect or plant cell expression systems.
  • these nucleic acids can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Patent No. 4,458,066.
  • nucleic acids such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed.
  • Another useful means of obtaining and manipulating nucleic acids used to practice the methods of the invention is to clone from genomic samples, and, if desired, screen and re-clone inserts isolated or amplified from, e.g., genomic clones or cDNA clones.
  • Sources of nucleic acid used in the methods of the invention include genomic or cDNA libraries contained in, e.g., mammalian artificial chromosomes (MACs), see, e.g., U.S. Patent Nos. 5,721,118; 6,025,155; human artificial chromosomes, see, e.g., Rosenfeld (1997) Nat. Genet.
  • MACs mammalian artificial chromosomes
  • yeast artificial chromosomes YAC
  • bacterial artificial chromosomes BAC
  • PI artificial chromosomes see, e.g., Woon (1998) Genomics 50:306-316
  • Pl-derived vectors see, e.g., Kern (1997) Biotechniques 23:120-124; cosmids, recombinant viruses, phages or plasmids.
  • the nucleic acid sequences of the invention can further comprise transcriptional and translational control elements, e.g., promoters, suitable for expressing the polypeptide or fragment thereof in any cell, e.g., a bacteria, e.g., E. coli.
  • transcriptional and translational control elements e.g., promoters
  • Promoters suitable for expressing the polypeptide or fragment thereof in bacteria include the E.
  • coli lac or t ⁇ promoters the lad promoter, the lacZ promoter, the T3 promoter, the T7 promoter, the gpt promoter, the lambda PR promoter, the lambda PL promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter.
  • Fungal promoters include the " factor promoter.
  • Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses may also be used.
  • the invention provides expression cassettes and vectors, e.g., expression vectors and cloning vehicles comprising the nucleic acids of the invention.
  • exemplary expression vectors include viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g., vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), PI -based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, Aspergillus and yeast).
  • the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide.
  • Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available.
  • Bacterial pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (lambda-ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXTl, pSG5 (Stratagene), pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia).
  • any other plasmid or other vector may be used so long as they are replicable and viable in the host.
  • Low copy number or high copy number vectors may be employed with the present invention.
  • DNA sequences in the expression vector can be operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis.
  • promoter particularly named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda P R , Pi and trp.
  • Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers.
  • the expression vectors can contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
  • Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp in length that act on a promoter to increase its transcription.
  • the expression vectors typically contain one or more selectable marker genes to permit selection of host cells containing the vector.
  • selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in E. coli, and the S. cerevisiae TRP1 gene.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures.
  • the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, blunt ends in both the insert and the vector may be ligated.
  • a variety of cloning techniques are disclosed in Ausubel et al. Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory Press (1989). Such procedures and others are deemed to be within the scope of those skilled in the art.
  • the vector may be, for example, in the form of a plasmid, a viral particle, or a phage.
  • Other vectors include chromosomal, nonchromosomal and synthetic DNA sequences, derivatives of SV40; bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), GEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pDIO, psiX174 pBluescript II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7.
  • Particular eukaryotic vectors include pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia).
  • any other vector may be used as long as it is replicable and viable in the host cell.
  • the vector may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer.
  • Particular m'ethods include, e.g., calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
  • Host cells and transformed cells include, e.g., calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
  • the invention provides cells comprising a polypeptide or a nucleic acid of the invention.
  • the host cell may be any cell, including prokaryotic cells, eukaryotic cells, mammalian cells, insect cells and plant cells. Polynucleotides of the invention can be introduced into a suitable host cell by any means.
  • the host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, mammalian cells, insect cells, or plant cells.
  • prokaryotic cells such as E. coli, Streptomyces, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus
  • fungal cells such as yeast
  • insect cells such as Drosophila S2 and Spodoptera Sf9
  • animal cells such as CHO, COS or Bowes melanoma
  • adenoviruses The selection of an appropriate host is within the abilities of those skilled in the art.
  • the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the invention.
  • the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.
  • Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification.
  • Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art.
  • the expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • mammalian cell culture systems can also be employed to express recombinant protein.
  • mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts (described by Gluzman, Cell, 23:175, 1981), and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines.
  • the constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
  • the polypeptides produced by host cells containing the vector may be glycosylated or may be non-glycosylated.
  • Polypeptides of the mvention may or may not also include an initial methionine amino acid residue.
  • Polynucleotides selected and isolated as hereinabove described are introduced into a suitable host cell.
  • a suitable host cell is any cell which is capable of promoting recombination and/or reductive reassortment.
  • the selected polynucleotides can already be in a vector which includes appropriate control sequences.
  • the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or, the host cell can be a prokaryotic cell, such as a bacterial cell.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis et al, 1986).
  • mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described in "SV40-transformed simian cells support the replication of early SV40 mutants" (Gluzman, 1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.
  • Host cells containing the polynucleotides of interest can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the clones which are identified as having the specified enzyme activity may then be sequenced to identify the polynucleotide sequence encoding an enzyme having the enhanced activity. Amplification of Nucleic Acids
  • nucleic acids encoding the polypeptides of the invention, or modified nucleic acids can be reproduced by, e.g., amplification.
  • the invention provides amplification primer sequence pairs for amplifying nucleic acids encoding polypeptides with a phosphatase activity, where the primer pairs are capable of amplifying nucleic acid sequences including the exemplary nucleic acids of the invention, or a subsequence thereof.
  • One of skill in the art can design amplification primer sequence pairs for any part of or the full length of these sequences.
  • Amplification reactions can also be used to quantify the amount of nucleic acid in a sample (such as the amount of message in a cell sample), label the nucleic acid (e.g., to apply it to an array or a blot), detect the nucleic acid, or quantify the amount of a specific nucleic acid in a sample.
  • message isolated from a cell or a cDNA library are amplified.
  • the skilled artisan can select and design suitable oligonucleotide amplification primers.
  • Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (see, e.g., PCR PROTOCOLS, A GUEDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Lnnis, Academic Press, Inc., N.Y., ligase chain reaction (LCR) (see, e.g., Wu (1989) Genomics 4:560; Landegren (1988) Science 241 :1077; Barringer (1990) Gene 89:117); transcription amplification (see, e.g., Kwoh (1989) Proc. Natl.
  • PCR see, e.g., PCR PROTOCOLS, A GUEDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995),
  • PCR protocols are described in Ausubel and Sambrook.
  • the amplification may comprise a ligase chain reaction, 3SR, or strand displacement reaction.
  • 3SR ligase chain reaction
  • strand displacement reaction See Barany, F., "The Ligase Chain Reaction in a PCR World", PCR Methods and Applications 1:5- 16, 1991; E. Fahy et al, “Self-sustained Sequence Replication (3SR): An Isothermal Transcription-based Amplification System Alternative to PCR", PCR Methods and Applications 1:25-33, 1991; and Walker G.T. et al, "Strand Displacement Amplification-an Isothermal in vitro DNA Amplification Technique", Nucleic Acid Research 20:1691-1696, 1992).
  • the nucleic acids in the sample are contacted with the probes, the amplification reaction is performed, and any resulting amplification product is detected.
  • the amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide.
  • one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product maybe detected by autoradiography after gel electrophoresis. Determining the degree of sequence identity
  • the invention provides an isolated or recombinant nucleic acids comprising a nucleic acid sequence having at least 50%> to about 99%> or more sequence identity to SEQ ID NOs:19 to 27, SEQ ED NOs:37 to 40, SEQ ED NO:41, SEQ ED NO:43, SEQ ED NO:45, SEQ ED NO:47, SEQ ED NO:49, SEQ ED NO:51, and SEQ ED NO:53, over a region of at least about 100 residues to the full length of the coding sequence.
  • the invention provides an isolated or recombinant polypeptides having at least 50%> to about 99% or more sequence identity to SEQ ID NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54, over a region of at least about 100 residues to the full length of the protein.
  • Protein and/or nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-2448, 1988; Altschul et al, J. Mol. Biol. 2_15(3):403-410, 1990; Thompson et al, Nucleic Acids Res. 22(2):4673-4680, 1994; Higgins et al, Methods Enzymol. 266:383-402. 1996; Altschul et al, J. Mol. Biol. 215(3):403-410, 1990; Altschul et al, Nature Genetics 3:266-272, 1993).
  • sequence comparison algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTAL
  • homology or identity is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various deletions, substitutions and other modifications.
  • sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • a “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
  • Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, J. Mol.
  • Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences.
  • a number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (Gibbs, 1995). At least twenty-one other genomes have already been sequenced, including, for example, M. genitalium (Fraser et al, 1995), M. jannaschii (Bult et al, 1996), H. influenzae (Fleischmann et al, 1995), E. coli (Blattner et al, 1997), and yeast (S. cerevisiae) (Mewes et al, 1997), and ).
  • BLAST and BLAST 2.0 algorithms are described in Altschul et al, Nuc. Acids Res. 25:3389-3402, 1977, and Altschul et al, J. Mol. Biol. 215:403-410, 1990, respectively.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is refened to as the neighborhood word score threshold (Altschul et al, supra).
  • initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them.
  • the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • W wordlength
  • E expectation
  • N N—4
  • B BLOSUM62 scoring matrix
  • the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873, 1993).
  • One measure of similarity provided by BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a nucleic acid is considered similar to a references sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, or, less than about 0.01, or, less than about 0.001.
  • protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST")
  • BLAST Basic Local Alignment Search Tool
  • five specific BLAST programs are used to perform the following task: [00219] (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;
  • BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database
  • TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands)
  • TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.
  • the BLAST programs identify homologous sequences by identifying similar segments, which are refened to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which can be obtained from a protein or nucleic acid sequence database.
  • High-scoring segment pairs can be identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art.
  • the scoring matrix used can be the BLOSUM62 matrix (Gonnet et al, Science 256:1443-1445, 1992; Henikoff and Henikoff, Proteins 17:49-61, 1993).
  • the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation). BLAST programs are accessible through the U.S. National Library of Medicine.
  • the parameters used with the above algorithms may be adapted depending on the sequence length and degree of homology studied. In some aspects, the parameters may be the default parameters used by the algorithms in the absence of instructions from the user.
  • sequences of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. Accordingly, the invention provides computers, computer systems, computer readable mediums, computer programs products and the like recorded or stored thereon the nucleic acid and polypeptide sequences of the invention, e.g., the exemplary sequences of the invention. The sequences of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded” and “stored” refer to a process for storing information on a computer medium.
  • a skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a computer readable medium having recorded thereon one or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a computer readable medium having recorded thereon one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 of the sequences as set forth above.
  • Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media.
  • the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.
  • CD-ROM Compact Disc
  • DVD Digital Versatile Disk
  • RAM Random Access Memory
  • ROM Read Only Memory
  • a computer system 100 refers to the hardware components, software components, and data storage components used to analyze a nucleotide sequence of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in the Group B amino acid sequences.
  • the computer system 100 typically includes a processor for processing, accessing and manipulating the sequence data.
  • the processor 105 can be any well-known type of central processing unit, such as, for example, the Pentium III from Intel Co ⁇ oration, or similar processor from Sun, Motorola, Compaq, AMD or International Business Machines.
  • the computer system 100 is a general pu ⁇ ose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components.
  • the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components.
  • a skilled artisan can readily appreciate that any one of the cunently available computer systems are suitable.
  • the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (can be implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon.
  • the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.
  • the data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, or a modem capable of connection to a remote data storage system (e.g. , via the internet) etc.
  • the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon.
  • the computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.
  • the computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.
  • Software for accessing and processing the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, may reside in main memory 115 during execution.
  • the computer system 100 may further comprise a sequence comparison algorithm for comparing a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, stored on a computer readable medium to a reference nucleotide or polypeptide sequence(s) stored on a computer readable medium.
  • a "sequence comparison algorithm” refers to one or more programs which are implemented (locally or remotely) on the computer system 100 to compare a nucleotide sequence with other nucleotide sequences and/or compounds stored within a data storage means.
  • the sequence comparison algorithm may compare the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies or structural motifs.
  • sequence comparison programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.
  • Figure 2 is a flow diagram illustrating one aspect of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.
  • the database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK that is available through the Internet.
  • the process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100.
  • the memory could be any type of memory, including RAM or an internal storage device.
  • the process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison.
  • the process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer.
  • a comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database.
  • Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.
  • the term "same” is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200. If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database.
  • the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database. It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.
  • one aspect of the invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a sequence comparer for conducting the comparison.
  • the sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described nucleic acid code of Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes.
  • the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is a method for determining the level of homology between a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a reference nucleotide sequence.
  • the method including reading the nucleic acid code or the polypeptide code and the reference nucleotide or polypeptide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code or polypeptide code and the reference nucleotide or polypeptide sequence with the computer program.
  • the computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, (e.g., BLAST2N with the default parameters or with any modified parameters).
  • the method may be implemented using the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the above described nucleic acid sequences as set forth in the Group A nucleic acid sequences, or the polypeptide sequences as set forth in the Group B amino acid sequences through use of the computer program and determining homology between the nucleic acid codes or polypeptide codes and reference nucleotide sequences or polypeptide sequences.
  • Figure 3 is a flow diagram illustrating one aspect of a process 250 in a computer for determining whether two sequences are homologous.
  • the process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory.
  • the second sequence to be compared is then stored to a memory at a state 256.
  • the process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read.
  • the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U.
  • the sequence is a protein sequence, then it can be in the single letter amino acid code so that the first and sequence sequences can be easily compared.
  • the level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%>.
  • the computer program may be a computer program which compares the nucleotide sequences of a nucleic acid sequence as set forth in the invention, to one or more reference nucleotide sequences in order to determine whether the nucleic acid code of Group A nucleic acid sequences, and sequences substantially identical thereto, differs from a reference nucleic acid sequence at one or more positions.
  • a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.
  • the computer program may be a program which determines whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, contains a single nucleotide polymo ⁇ hism (SNP) with respect to a reference nucleotide sequence.
  • SNP single nucleotide polymo ⁇ hism
  • Another aspect of the invention is a method for determining whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program.
  • the computer program is a program which identifies single nucleotide polymo ⁇ hisms. The method may be implemented by the computer systems described above and the method illustrated in Figure 3.
  • the method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.
  • the computer based system may further comprise an identifier for identifying features within a nucleic acid sequence as set forth in the Group A nucleic acid sequences or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • An "identifier" refers to one or more programs which identifies certain features within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • the identifier may comprise a program which identifies an open reading frame in a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.
  • Figure 5 is a flow diagram illustrating one aspect of an identifier process 300 for detecting the presence of a feature in a sequence.
  • the process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100.
  • the process 300 then moves to a state 306 wherein a database of sequence features is opened.
  • a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG”. Another example would be the feature name "TAATAA Box" and the feature attribute would be "TAATAA”.
  • the features may be structural polypeptide motifs such as alpha helices, beta sheets, or functional polypeptide motifs such as enzymatic active sites, helix-turn-helix motifs or other motifs known to those skilled in the art.
  • the process 300 moves to a state 308 wherein the first feature is read from the database.
  • a comparison of the attribute of the first feature with the first sequence is then made at a state 310.
  • a determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence.
  • the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.
  • the process 300 then moves to a decision state 320 wherein a determination is made whether move features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence. It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.
  • Another aspect of the invention is a method of identifying a feature within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, comprising reading the nucleic acid code(s) or polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) with the computer program.
  • computer program comprises a computer program which identifies open reading frames.
  • the method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 40 of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto, through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.
  • a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, may be stored and manipulated in a variety of data processor programs in a variety of formats.
  • nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE.
  • nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • sequence comparison algorithms identifiers, or sources of reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
  • the programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, J. Mol. Biol. 2L5: 403, 1990), FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444, 1988), FASTDB (Brutlag et al Comp. App. Biosci.
  • Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.
  • the invention provides isolated or recombinant nucleic acids that hybridize under stringent conditions to an exemplary sequence of the invention, e.g., a sequence as set forth in SEQ ID NOs:19 to 27, SEQ ED NOs:37 to 40, SEQ ED NO:41, SEQ ED NO:43, SEQ ED NO:45, SEQ ED NO:47, SEQ ED NO:49, SEQ ED NO:51, and SEQ ED NO:53, or a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ED NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54.
  • the stringent conditions can be highly stringent conditions, medium stringent conditions, low stringent conditions, including the high and reduced stringency conditions described herein.
  • nucleic acid hybridization reactions the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.
  • Hybridization may be carried out under conditions of low stringency, moderate stringency or high stringency.
  • nucleic acid hybridization a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45 DC in a solution consisting of 0.9 M NaCl, 50 mM NaH 2 PO 4 , pH 7.0, 5.0 mM Na 2 EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid. Approximately 2 X 10 7 cpm (specific activity 4-9 X 10 8 cpm/ug) of 32 P end-labeled oligonucleotide probe are then added to the solution.
  • the membrane is washed for 30 minutes at room temperature in IX SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na 2 EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh IX SET at T m -10DC for the oligonucleotide probe.
  • IX SET 150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na 2 EDTA
  • the membrane is then exposed to auto-radiographic film for detection of hybridization signals.
  • T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly complementary probe. Very stringent conditions are selected to be equal to or about 5°C lower than the T m for a particular probe.
  • Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% > SDS, lOODg denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5%) SDS, lOODg denatured fragmented salmon sperm DNA, 50% formamide.
  • Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25 DC below the T m . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 5-10DC below the T m . Typically, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68 DC. Usually, for hybridizations in 50%) formamide containing solutions, the hybridization is conducted at approximately 42 DC.
  • the filter is washed to remove any non-specifically bound detectable probe.
  • the stringency used to wash the filters can also be varied depending on the nature of the nucleic acids being hybridized, the length of the nucleic acids being hybridized, the degree of complementarity, the nucleotide sequence composition (e.g., GC v. AT content), and the nucleic acid type (e.g., RNA v. DNA).
  • Examples of progressively higher stringency condition washes are as follows: 2X SSC, 0.1% SDS at room temperature for 15 minutes (low stringency); 0.1X SSC, 0.5%> SDS at room temperature for 30 minutes to 1 hour (moderate stringency); 0.1X SSC, 0.5%> SDS for 15 to 30 minutes at between the hybridization temperature and 68°C (high stringency); and 0.15M NaCl for 15 minutes at 72°C (very high stringency).
  • a final low stringency wash can be conducted in 0. IX SSC at room temperature.
  • the examples above are merely illustrative of one set of conditions that can be used to wash filters.
  • One of skill in the art would know that there are numerous recipes for different stringency washes. Some other examples are given below.
  • Nucleic acids which have hybridized to the probe are identified by autoradiography or other conventional techniques.
  • the above procedure may be modified to identify nucleic acids having decreasing levels of homology to the probe sequence.
  • less stringent conditions may be used.
  • the hybridization temperature may be decreased in increments of 5DC from 68 DC to 42 DC in a hybridization buffer having a Na+ concentration of approximately 1M.
  • the filter maybe washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be “moderate” conditions above 50DC and "low” conditions below 50DC.
  • a specific example of “moderate” hybridization conditions is when the above hybridization is conducted at 55 DC.
  • a specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 45 DC.
  • the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C.
  • concentration of formamide in the hybridization buffer may be reduced in 5%> increments from 50%> to 0%> to identify clones having decreasing levels of homology to the probe.
  • the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be “moderate” conditions above 25% formamide and "low” conditions below 25% formamide.
  • a specific example of “moderate” hybridization conditions is when the above hybridization is conducted at 30% formamide.
  • a specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 10% formamide.
  • the preceding methods may be used to isolate nucleic acids having a sequence with at least about 97%>, at least 95%>, at least 90%, at least 85%, at least 80%), at least 75%, at least 70%, at least 65%>, at least 60%, at least 55%, or at least 50% homology to a nucleic acid sequence selected from the group consisting of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. Homology may be measured using the alignment algorithm.
  • the homologous polynucleotides may have a coding sequence which is a naturally occurring allelic variant of one of the coding sequences described herein.
  • allelic variants may have a substitution, deletion or addition of one or more nucleotides when compared to the nucleic acids of Group A nucleic acid sequences or the sequences complementary thereto.
  • nucleic acids which encode polypeptides having at least about 99%, 95%, at least 90%>, at least 85%, at least 80%), at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, or at least 50%> homology to a polypeptide having the sequence of one of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using a sequence alignment algorithm (e.g., such as the FASTA version 3.0t78 algorithm with the default parameters).
  • a sequence alignment algorithm e.g., such as the FASTA version 3.0t78 algorithm with the default parameters.
  • wash conditions used to identify nucleic acids within the scope of the invention include, e.g.: a salt concentration of about 0.02 molar at pH 7 and a temperature of at least about 50°C or about 55°C to about 60°C; or, a salt concentration of about 0.15 M NaCl at 72°C for about 15 minutes; or, a salt concentration of about 0.2X SSC at a temperature of at least about 50°C or about 55°C to about 60°C for about 15 to about 20 minutes; or, the hybridization complex is washed twice with a solution with a salt concentration of about 2X SSC containing 0.1 %> SDS at room temperature for 15 minutes and then washed twice by 0.1X SSC containing 0.1%> SDS at 68oC for 15 minutes; or, equivalent conditions.
  • Stringent conditions for washing can also be 0.2 X SSC/0.1%> SDS at 420C.
  • stringent conditions can include washing in 6X SSC/0.05% sodium pyrophosphate at 37EC (for 14_base oligos), 48EC (for 17-base oligos), 55EC (for 20-base oligos), and 60EC (for 23-base oligos).
  • 6X SSC/0.05% sodium pyrophosphate at 37EC (for 14_base oligos), 48EC (for 17-base oligos), 55EC (for 20-base oligos), and 60EC (for 23-base oligos).
  • the invention also provides nucleic acid probes for identifying and isolating nucleic acids of the invention and nucleic acids encoding a polypeptide of the invention.
  • the nucleic acid sequences of the invention can be used as probes to determine whether a biological sample, such as a soil sample, contains an organism having a nucleic acid sequence of the invention or an organism from which the nucleic acid was obtained. In such procedures, a biological sample potentially harboring the organism from which the nucleic acid was isolated is obtained and nucleic acids are obtained from the sample.
  • the nucleic acids are contacted with the probe under conditions which permit the probe to specifically hybridize to any complementary sequences from which are present therein.
  • conditions which permit the probe to specifically hybridize to complementary sequences may be determined by placing the probe in contact with complementary sequences from samples known to contain the complementary sequence as well as control sequences which do not contain the complementary sequence.
  • Hybridization conditions such as the salt concentration of the hybridization buffer, the formamide concentration of the hybridization buffer, or the hybridization temperature, may be varied to identify conditions which allow the probe to hybridize specifically to complementary nucleic acids.
  • Hybridization may be detected by labeling the probe with a detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.
  • detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.
  • Many methods for using the labeled probes to detect the presence of complementary nucleic acids in a sample are familiar to those skilled in the art. These include Southern Blots, Northern Blots, colony hybridization procedures, and dot blots. Protocols for each of these procedures are provided in Ausubel et al. Cunent Protocols in Molecular Biology, John Wiley 503 Sons, Enc.
  • more than one probe may be used in an amplification reaction to determine whether the sample contains an organism containing a nucleic acid sequence of the invention (e.g., an organism from which the nucleic acid was isolated).
  • the probes comprise oligonucleotides.
  • the amplification reaction may comprise a PCR reaction. PCR protocols are described in Ausubel and Sambrook.
  • the amplification may comprise a ligase chain reaction, 3SR, or strand displacement reaction.
  • the amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide.
  • an intercalator such as ethidium bromide.
  • one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product may be detected by autoradiography after gel electrophoresis.
  • Probes derived from sequences near the ends of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, may also be used in chromosome walking procedures to identify clones containing genomic sequences located adjacent to the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto. Such methods allow the isolation of genes which encode additional proteins from the host organism.
  • the isolated nucleic acids of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or the sequences complementary thereto may be used as probes to identify and isolate related nucleic acids.
  • the related nucleic acids may be cDNAs or genomic DNAs from organisms other than the one from which the nucleic acid was isolated.
  • the other organisms may be related organisms.
  • Antisense Oligonucleotides [00270] The invention provides antisense oligonucleotides capable of binding phosphatase message which can inhibit phosphatase activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such phosphatase oligonucleotides using the novel reagents of the invention.
  • RNA mapping protocols to screen for effective antisense oligonucleotides are well known in the art, see, e.g., Ho (2000) Methods Enzymol. 314:168-183, describing an RNA mapping assay, which is based on standard molecular techniques to provide an easy and reliable method for potent antisense sequence selection. See also Smith (2000) Euro. J. Pharm. Sci. 11:191-198. [00271] Naturally occurring nucleic acids are used as antisense oligonucleotides.
  • the antisense oligonucleotides can be of any length; for example, in alternative aspects, the antisense oligonucleotides are between about 5 to 100, about 10 to 80, about 15 to 60, about 18 to 40. The optimal length can be determined by routine screening.
  • the antisense oligonucleotides can be present at any concentration. The optimal concentration can be determined by routine screening.
  • a wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2- aminoethyl) glycine units can be used.
  • PNAs peptide nucleic acids
  • Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) Toxicol Appl Pharmacol 144:189-197; Antisense Therapeutics, ed. Agarwal (Humana Press, Totowa, N.J., 1996).
  • Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and mo ⁇ holino carbamate nucleic acids, as described above.
  • Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense phosphatase sequences of the invention (see, e.g., Gold (1995) J. of Biol. Chem. 270:13581-13584).
  • Target such as the sense and antisense phosphatase sequences of the invention.
  • the invention provides for with ribozymes capable of binding phosphatase message which can inhibit phosphatase enzyme activity by targeting mRNA.
  • ribozymes capable of binding phosphatase message which can inhibit phosphatase enzyme activity by targeting mRNA.
  • Strategies for designing ribozymes and selecting the phosphatase-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such ribozymes using the novel reagents of the invention.
  • Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA.
  • the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the conect site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.
  • a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide.
  • antisense technology where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule
  • This potential advantage reflects the ability of the ribozyme to act enzymatically.
  • a single ribozyme molecule is able to cleave many molecules of target RNA.
  • a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non- targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.
  • the enzymatic ribozyme RNA molecule can be formed in a hammerhead motif, but may also be formed in the motif of a hai ⁇ in, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence).
  • hammerhead motifs are described by Rossi (1992) Aids Research and Human Retroviruses 8:183; hai ⁇ in motifs by Hampel (1989) Biochemistry 28:4929, and Hampel (1990) Nuc. Acids Res.
  • RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate binding site which imparts an RNA cleaving activity to the molecule.
  • the invention provides methods of generating variants of the nucleic acids of the invention, e.g., those encoding phosphatase enzymes of the invention. These methods can be repeated or used in various combinations to generate phosphatase enzymes having an altered or different activity or an altered or different stability from that of a phosphatase encoded by the template nucleic acid. These methods also can be repeated or used in various combinations, e.g., to generate variations in gene/ message expression, message translation or message stability.
  • the genetic composition of a cell is altered by, e.g., modification of a homologous gene ex vivo, followed by its reinsertion into the cell.
  • a nucleic acid of the invention can be altered by any means. For example, random or stochastic methods, or, non-stochastic, or "directed evolution," methods.
  • Methods for random mutation of genes are well known in the art, see, e.g., U.S. Patent No. 5,830,696.
  • mutagens can be used to randomly mutate a gene. Mutagens include, e.g., ultraviolet light or gamma inadiation, or a chemical mutagen, e.g., mitomycin, nitrous acid, photoactivated psoralens, alone or in combination, to induce DNA breaks amenable to repair by recombination.
  • Other chemical mutagens include, for example, sodium bisulfite, nitrous acid, hydroxylamine, hydrazine or formic acid.
  • Other mutagens are analogues of nucleotide precursors, e.g., nitrosoguanidine, 5-bromouracil, 2-aminopurine, or acridine. These agents can be added to a PCR reaction in place of the nucleotide precursor thereby mutating the sequence.
  • Intercalating agents such as proflavine, acriflavine, quinacrine and the like can also be used. Any technique in molecular biology can be used, e.g., random PCR mutagenesis, see, e.g., Rice (1992) Proc. Natl.
  • nucleic acids e.g., genes
  • can be reassembled after random, or "stochastic," fragmentation see, e.g., U.S. Patent Nos. 6,291,242; 6,287,862; 6,287,861; 5,955,358; 5,830,721; 5,824,514; 5,811,238; 5,605,793.
  • modifications, additions or deletions are introduced by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR), recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair- deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation
  • Mutational methods of generating diversity include, for example, site-directed mutagenesis (Ling et al. (1997) "Approaches to DNA mutagenesis: an overview" Anal Biochem. 254(2): 157-178; Dale et al. (1996) “Oligonucleotide-directed random mutagenesis using the phosphorothioate method” Methods Mol. Biol. 57:369-374; Smith (1985) "In vitro mutagenesis” Ann. Rev. Genet. 19:423-462; Botstein & Shortle (1985) "Strategies and applications of in vitro mutagenesis” Science 229:1193-1201; Carter (1986) "Site-directed mutagenesis” Biochem.
  • Additional protocols used in the methods of the invention include point mismatch repair (Kramer (1984) "Point Mismatch Repair” Cell 38:879-887), mutagenesis using repair-deficient host strains (Carter et al. (1985) "Improved oligonucleotide site- directed mutagenesis using Ml 3 vectors” Nucl. Acids Res. 13: 4431-4443; and Carter (1987) "Improved oligonucleotide-directed mutagenesis using Ml 3 vectors” Methods in Enzymol.
  • deletion mutagenesis (Eghtedarzadeh (1986) "Use of oligonucleotides to generate large deletions” Nucl. Acids Res. 14: 5115), restriction-selection and restriction- selection and restriction-purification (Wells et al. (1986) "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin” Phil. Trans. R. Soc. Lond. A 317: 415-423), mutagenesis by total gene synthesis (Nambiar et al.
  • Non-stochastic, or "directed evolution,” methods include, e.g., saturation mutagenesis (GSSM), synthetic ligation reassembly (SLR), or a combination thereof are used to modify the nucleic acids of the invention to generate phosphatases with new or altered properties (e.g., activity under highly acidic or alkaline conditions, high temperatures, and the like).
  • Polypeptides encoded by the modified nucleic acids can be screened for an activity before testing for a phosphatase or other activity. Any testing modality or protocol can be used, e.g., using a capillary anay platform. See, e.g., U.S. Patent Nos. 6,280,926; 5,939,250. Saturation mutagenesis, or, GSSM
  • non- stochastic gene modification a "directed evolution process” is used to generate phosphatases with new or altered properties. Variations of this method have been termed “gene site-saturation mutagenesis,” “site- saturation mutagenesis,” “saturation mutagenesis” or simply “GSSM.” It can be used in combination with other mutagenization processes. See, e.g., U.S. Patent Nos. 6,171,820; 6,238,884.
  • GSSM comprises providing a template polynucleotide and a plurality of oligonucleotides, wherein each oligonucleotide comprises a sequence homologous to the template polynucleotide, thereby targeting a specific sequence of the template polynucleotide, and a sequence that is a variant of the homologous gene; generating progeny polynucleotides comprising non-stochastic sequence variations by replicating the template polynucleotide with the oligonucleotides, thereby generating polynucleotides comprising homologous gene sequence variations.
  • the invention also provides for the use of proprietary codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)).
  • GSSM gene site saturated mutagenesis
  • the oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, but not necessarily a second homologous sequence.
  • the downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
  • one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions.
  • at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions.
  • more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site.
  • This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s).
  • oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
  • the present invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence.
  • degenerate cassettes having less degeneracy than the N,N,N sequence.
  • this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide.
  • the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
  • This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to conesponding amino acid changes, and point mutations that cause the generation of stop codons and the conesponding expression of polypeptide fragments.
  • each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position conesponding to the codon position mutagenized in the parental polynucleotide.
  • the 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g., cloned into a suitable E. coli host using an expression vector) and subjected to expression screening.
  • clonal amplification e.g., cloned into a suitable E. coli host using an expression vector
  • an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the correspondingly favorable amino acid substitution contained therein.
  • favorable amino acid changes may be identified at more than one amino acid position.
  • One ' or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position.
  • site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening.
  • This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. En one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening.
  • this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
  • mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • a separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence.
  • a group of 3 positions to be mutagenized may be a codon.
  • the mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette.
  • Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo).
  • saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length).
  • a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized.
  • a grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis.
  • sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group.
  • a "defined sequences" for this pu ⁇ ose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
  • this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby.
  • the invention also provides for the use of proprietary codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)).
  • GSSM gene site saturated mutagenesis
  • the oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, and can be a second homologous sequence.
  • the downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
  • one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions.
  • at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions.
  • more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site.
  • This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s).
  • oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
  • the present invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence.
  • degenerate cassettes having less degeneracy than the N,N,N sequence.
  • this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide.
  • the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
  • This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to conesponding amino acid changes, and point mutations that cause the generation of stop codons and the conesponding expression of polypeptide fragments.
  • each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position conesponding to the codon position mutagenized in the parental polynucleotide.
  • the 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g., cloned into a suitable E. coli host using an expression vector) and subjected to expression screening.
  • clonal amplification e.g., cloned into a suitable E. coli host using an expression vector
  • an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the conespondingly favorable amino acid substitution contained therein.
  • favorable amino acid changes may be identified at more than one amino acid position.
  • One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position.
  • site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening.
  • This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. In one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening.
  • this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
  • mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • a separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence.
  • a group of 3 positions to be mutagenized may be a codon.
  • the mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette.
  • Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo).
  • saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length).
  • a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized.
  • a grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis.
  • sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group.
  • a "defined sequences" for this pu ⁇ ose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
  • this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby.
  • the invention also provides for the use of codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)).
  • GSSM gene site saturated mutagenesis
  • the oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, and can be a second homologous sequence.
  • the downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
  • one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions.
  • at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions.
  • more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site.
  • This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s).
  • oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
  • the invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence.
  • this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide.
  • the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions).
  • an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence 32 individual sequences that code for 20 possible amino acids.
  • a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides.
  • the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
  • This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to corresponding amino acid changes, and point mutations that cause the generation of stop codons and the corresponding expression of polypeptide fragments.
  • each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position corresponding to the codon position mutagenized in the parental polynucleotide.
  • the 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g. , cloned into a suitable E. coli host using an expression vector) and subjected to expression screening.
  • an individual progeny polypeptide When an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the conespondingly favorable amino acid substitution contained therein. [00309] It is appreciated that upon mutagenizing each and every amino acid position in a parental polypeptide using saturation mutagenesis as disclosed herein, favorable amino acid changes may be identified at more than one amino acid position. One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position.
  • site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening.
  • This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. In one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening.
  • this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
  • mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • the number of bases to be mutagenized can be every integer from 15 to 100,000.
  • a separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence.
  • a group of 3 positions to be mutagenized may be a codon.
  • the mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette.
  • Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A G, A T, C/G, C/T, G/T, C/G/T, A G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo).
  • saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length).
  • a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized.
  • a grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis.
  • sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group.
  • a "defined sequences" for this pu ⁇ ose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
  • this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby.
  • Synthetic Ligation Reassembly SLR
  • the invention provides a non-stochastic gene modification system termed "synthetic ligation reassembly,” or simply “SLR,” a “directed evolution process,” to generate phosphatases with new or altered properties.
  • SLR is a method of ligating oligonucleotide fragments together non-stochastically. This method differs from stochastic oligonucleotide shuffling in that the nucleic acid building blocks are not shuffled, concatenated or chimerized randomly, but rather are assembled non-stochastically. See, e.g., U.S. Patent Application Serial No.
  • SLR comprises the following steps: (a) providing a template polynucleotide, wherein the template polynucleotide comprises sequence encoding a homologous gene; (b) providing a plurality of building block polynucleotides, wherein the building block polynucleotides are designed to cross-over reassemble with the template polynucleotide at a predetermined sequence, and a building block polynucleotide comprises a sequence that is a variant of the homologous gene and a sequence homologous to the template polynucleotide flanking the variant sequence; (c) combining a building block polynucleotide with a template polynucleotide such that the building block polynucleotide cross-over reassembles with the
  • the present invention provides a non-stochastic method termed synthetic gene reassembly, that is somewhat related to stochastic shuffling, save that the nucleic acid building blocks are not shuffled or concatenated or chimerized randomly, but rather are assembled non-stochastically.
  • the synthetic gene reassembly method does not depend on the presence of a high level of homology between polynucleotides to be shuffled.
  • the invention can be used to non-stochastically generate libraries (or sets) of progeny molecules comprised of over 10 100 different chimeras.
  • synthetic gene reassembly can even be used to generate libraries comprised of over 10 1000 different progeny chimeras.
  • the invention provides a non- stochastic method of producing a set of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design, which method is comprised of the steps of generating by design a plurality of specific nucleic acid building blocks having serviceable mutually compatible ligatable ends, and assembling these nucleic acid building blocks, such that a designed overall assembly order is achieved.
  • the mutually compatible ligatable ends of the nucleic acid building blocks to be assembled are considered to be "serviceable" for this type of ordered assembly if they enable the building blocks to be coupled in predetermined orders.
  • the overall assembly order in which the nucleic acid building blocks can be coupled is specified by the design of the ligatable ends and, if more than one assembly step is to be used, then the overall assembly order in which the nucleic acid building blocks can be coupled is also specified by the sequential order of the assembly step(s).
  • the annealed building pieces are treated with an enzyme, such as a ligase (e.g., T4 DNA ligase) to achieve covalent bonding of the building pieces.
  • a ligase e.g., T4 DNA ligase
  • the design of nucleic acid building blocks is obtained upon analysis of the sequences of a set of progenitor nucleic acid templates that serve as a basis for producing a progeny set of finalized chimeric nucleic acid molecules.
  • These progenitor nucleic acid templates thus serve as a source of sequence information that aids in the design of the nucleic acid building blocks that are to be mutagenized, i.e. chimerized or shuffled.
  • the invention provides for the chimerization of a family of related genes and their encoded family of related products.
  • the encoded products are enzymes.
  • the phosphatases of the present invention can be mutagenized in accordance with the methods described herein.
  • the sequences of a plurality of progenitor nucleic acid templates e.g., polynucleotides of Group A nucleic acid sequences
  • the demarcation points can be used to delineate the boundaries of nucleic acid building blocks to be generated.
  • the demarcation points identified and selected in the progenitor molecules serve as potential chimerization points in the assembly of the progeny molecules.
  • a serviceable demarcation point is an area of homology (comprised of at least one homologous nucleotide base) shared by at least two progenitor templates, but the demarcation point can be an area of homology that is shared by at least half of the progenitor templates, at least two thirds of the progenitor templates, at least three fourths of the progenitor templates, or, at almost all of the progenitor templates.
  • a serviceable demarcation point is an area of homology that is shared by all of the progenitor templates.
  • the gene reassembly process is performed exhaustively in order to generate an exhaustive library.
  • all possible ordered combinations of the nucleic acid building blocks are represented in the set of finalized chimeric nucleic acid molecules.
  • the assembly order i.e. the order of assembly of each building block in the 5' to 3 sequence of each finalized chimeric nucleic acid
  • the assembly order is by design (or non-stochastic). Because of the non-stochastic nature of the method, the possibility of unwanted side products is greatly reduced.
  • the method provides that the gene reassembly process is performed systematically, for example to generate a systematically compartmentalized library, with compartments that can be screened systematically, e.g., one by one.
  • the invention provides that, through the selective and judicious use of specific nucleic acid building blocks, coupled with the selective and judicious use of sequentially stepped assembly reactions, an experimental design can be achieved where specific sets of progeny products are made in each of several reaction vessels. This allows a systematic examination and screening procedure to be performed. Thus, it allows a potentially very large number of progeny molecules to be examined systematically in smaller groups.
  • the instant invention provides for the generation of a library (or set) comprised of a large number of progeny molecules.
  • the progeny molecules generated can comprise a library of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design.
  • such a generated library is comprised of greater than 10 3 to greater than l ⁇ 1000 different progeny molecular species.
  • a set of finalized chimeric nucleic acid molecules, produced as described is comprised of a polynucleotide encoding a polypeptide.
  • this polynucleotide is a gene, which may be a man-made gene.
  • this polynucleotide is a gene pathway, which may be a man-made gene pathway.
  • the invention provides that one or more man-made genes generated by the invention may be inco ⁇ orated into a man-made gene pathway, such as pathway operable in a eukaryotic organism (including a plant).
  • the synthetic nature of the step in which the building blocks are generated allows the design and introduction of nucleotides (e.g., one or more nucleotides, which may be, for example, codons or introns or regulatory sequences) that can later be optionally removed in an in vitro process (e.g., by mutagenesis) or in an in vivo process (e.g., by utilizing the gene splicing ability of a host organism). It is appreciated that in many instances the introduction of these nucleotides may also be desirable for many other reasons in addition to the potential benefit of creating a serviceable demarcation point.
  • nucleotides e.g., one or more nucleotides, which may be, for example, codons or introns or regulatory sequences
  • the invention provides that a nucleic acid building block can be used to introduce an intron.
  • the invention provides that functional introns may be introduced into a man-made gene of the invention.
  • the invention also provides that functional introns may be introduced into a man-made gene pathway of the invention.
  • the invention provides for the generation of a chimeric polynucleotide that is a man-made gene containing one (or more) artificially introduced intron(s).
  • the invention also provides for the generation of a chimeric polynucleotide that is a man-made gene pathway containing one (or more) artificially introduced intron(s).
  • the artificially introduced intron(s) can be functional in one or more host cells for gene splicing much in the way that naturally-occurring introns serve functionally in gene splicing.
  • the invention provides a process of producing man-made intron-containing polynucleotides to be introduced into host organisms for recombination and/or splicing.
  • a man-made gene produced using the invention can also serve as a substrate for recombination with another nucleic acid.
  • a man-made gene pathway produced using the invention can also serve as a substrate for recombination with another nucleic acid.
  • the recombination can be facilitated by, or occurs at, areas of homology between the man- made, intron-containing gene and a nucleic acid, which serves as a recombination partner.
  • the recombination partner may also be a nucleic acid generated by the invention, including a man-made gene or a man-made gene pathway. Recombination may be facilitated by or may occur at areas of homology that exist at the one (or more) artificially introduced intron(s) in the man-made gene.
  • the synthetic gene reassembly method of the invention utilizes a plurality of nucleic acid building blocks, each of which can have two ligatable ends.
  • the two ligatable ends on each nucleic acid building block may be two blunt ends (i.e. each having an overhang of zero nucleotides), or, one blunt end and one overhang, or, two overhangs.
  • a useful overhang for this pu ⁇ ose may be a 3 ' overhang or a 5 ' overhang.
  • a nucleic acid building block may have a 3 ' overhang or alternatively a 5 ' overhang or alternatively two 3' overhangs or alternatively two 5' overhangs.
  • the overall order in which the nucleic acid building blocks are assembled to form a finalized chimeric nucleic acid molecule is determined by pu ⁇ oseful experimental design and is not random.
  • a nucleic acid building block is generated by chemical synthesis of two single-stranded nucleic acids (also referred to as single-stranded oligos) and contacting them so as to allow them to anneal to form a double-stranded nucleic acid building block.
  • a double-stranded nucleic acid building block can be of variable size. The sizes of these building blocks can be small or large. Sizes for building blocks can range from 1 base pair (not including any overhangs) to 100,000 base pairs (not including any overhangs).
  • a double-stranded nucleic acid building block is generated by first generating two single stranded nucleic acids and allowing them to anneal to form a double-stranded nucleic acid building block.
  • the two strands of a double-stranded nucleic acid building block may be complementary at every nucleotide apart from any that form an overhang; thus containing no mismatches, apart from any overhang(s).
  • the two strands of a double-stranded nucleic acid building block are complementary at fewer than every nucleotide apart from any that form an overhang.
  • a double-stranded nucleic acid building block can be used to introduce codon degeneracy.
  • the codon degeneracy can be introduced using the site- saturation mutagenesis described herein, using one or more N,N,G/T cassettes or alternatively using one or more N,N,N cassettes. In vivo recombination methods
  • the in vivo recombination method of the invention can be performed blindly on a pool of unknown hybrids or alleles of a specific polynucleotide or sequence. However, it is not necessary to know the actual DNA or RNA sequence of the specific polynucleotide.
  • the approach of using recombination within a mixed population of genes can be useful for the generation of any useful proteins, for example, interleukin I, antibodies, tPA and growth hormone. This approach may be used to generate proteins having altered specificity or activity.
  • the approach may also be useful for the generation of hybrid nucleic acid sequences, for example, promoter regions, introns, exons, enhancer sequences, 31 untranslated regions or 51 untranslated regions of genes. Thus this approach may be used to generate genes having increased rates of expression. This approach may also be useful in the study of repetitive DNA sequences. Finally, this approach may be useful to mutate ribozymes or aptamers.
  • the invention described herein is directed to the use of repeated cycles of reductive reassortment, recombination and selection which allow for the directed molecular evolution of highly complex linear sequences, such as DNA, RNA or proteins thorough recombination.
  • the invention includes a method for producing a hybrid polynucleotide from at least a first polynucleotide and a second polynucleotide.
  • the invention can be used to produce a hybrid polynucleotide by introducing at least a first polynucleotide and a second polynucleotide which share at least one region of partial sequence homology into a suitable host cell.
  • the regions of partial sequence homology promote processes which result in sequence reorganization producing a hybrid polynucleotide.
  • hybrid polynucleotide is any nucleotide sequence which results from the method of the present invention and contains sequence from at least two original polynucleotide sequences. Such hybrid polynucleotides can result from intermolecular recombination events which promote sequence integration between DNA molecules. In addition, such hybrid polynucleotides can result from intramolecular reductive reassortment processes which utilize repeated sequences to alter a nucleotide sequence within a DNA molecule. [00342] The invention provides a means for generating hybrid polynucleotides which may encode biologically active hybrid polypeptides (e.g., hybrid phosphatases).
  • biologically active hybrid polypeptides e.g., hybrid phosphatases
  • the original polynucleotides encode biologically active polypeptides.
  • the method of the invention produces new hybrid polypeptides by utilizing cellular processes which integrate the sequence of the original polynucleotides such that the resulting hybrid polynucleotide encodes a polypeptide demonstrating activities derived from the original biologically active polypeptides.
  • the original polynucleotides may encode a particular enzyme from different microorganisms.
  • An enzyme encoded by a first polynucleotide from one organism or variant may, for example, function effectively under a particular environmental condition, e.g. high salinity.
  • An enzyme encoded by a second polynucleotide from a different organism or variant may function effectively under a different environmental condition, such as extremely high temperatures.
  • a hybrid polynucleotide containing sequences from the first and second original polynucleotides may encode an enzyme which exhibits characteristics of both enzymes encoded by the original polynucleotides.
  • the enzyme encoded by the hybrid polynucleotide may function effectively under environmental conditions shared by each of the enzymes encoded by the first and second polynucleotides, e.g., high salinity and extreme temperatures.
  • novel polynucleotides can be generated by the process of reductive reassortment.
  • the method involves the generation of constructs containing consecutive sequences (original encoding sequences), their insertion into an appropriate vector, and their subsequent introduction into an appropriate host cell.
  • the reassortment of the individual molecular identities occurs by combinatorial processes between the consecutive sequences in the construct possessing regions of homology, or between quasi-repeated units.
  • the reassortment process recombines and/or reduces the complexity and extent of the repeated sequences, and results in the production of novel molecular species.
  • Various treatments may be applied to enhance the rate of reassortment.
  • the reassortment process may involve homologous recombination or the natural property of quasi-repeated sequences to direct their own evolution.
  • Quadsi-repeated sequences play a role in genetic instability.
  • “quasi-repeats” are repeats that are not restricted to their original unit structure. Quasi-repeated units can be presented as an array of sequences in a construct; consecutive units of similar sequences. Once ligated, the junctions between the consecutive sequences become essentially invisible and the quasi-repetitive nature of the resulting construct is now continuous at the molecular level. The deletion process the cell performs to reduce the complexity of the resulting construct operates between the quasi-repeated sequences.
  • the quasi-repeated units provide a practically limitless repertoire of templates upon which slippage events can occur.
  • the constructs containing the quasi-repeats thus effectively provide sufficient molecular elasticity that deletion (and potentially insertion) events can occur virtually anywhere within the quasi-repetitive units.
  • the quasi-repeated sequences are all ligated in the same orientation, for instance head to tail or vice versa, the cell cannot distinguish individual units. Consequently, the reductive process can occur throughout the sequences.
  • the inversion delineates the endpoints of the adjacent unit so that deletion formation will favor the loss of discrete units.
  • the sequences can be in the same orientation.
  • Sequences can be assembled in a head to tail orientation using any of a variety of methods, including the following: [00348] a) Primers that include a poly-A head and poly-T tail which when made single-stranded would provide orientation can be utilized. This is accomplished by having the first few bases of the primers made from RNA and hence easily removed RNAseH.
  • the recovery of the re-assorted sequences relies on the identification of cloning vectors with a reduced repetitive index (RI).
  • the re-assorted encoding sequences can then be recovered by amplification.
  • the products are re-cloned and expressed.
  • the recovery of cloning vectors with reduced RI can be affected by:
  • Encoding sequences for example, genes
  • genes may demonstrate a high degree of homology and encode quite diverse protein products.
  • These types of sequences are particularly useful in the present invention as quasi-repeats.
  • the examples illustrated below demonstrate the reassortment of nearly identical original encoding sequences (quasi-repeats), this process is not limited to such nearly identical repeats.
  • the following example demonstrates a method of the invention.
  • Encoding nucleic acid sequences (quasi-repeats) derived from three (3) unique species are described. Each sequence encodes a protein with a distinct set of properties. Each of the sequences differs by a single or a few base pairs at a unique position in the sequence.
  • the quasi- repeated sequences are separately or collectively amplified and ligated into random assemblies such that all possible permutations and combinations are available in the population of ligated molecules.
  • the number of quasi-repeat units can be controlled by the assembly conditions.
  • the average number of quasi-repeated units in a construct is defined as the repetitive index (RI).
  • the constructs may, or may not be size fractionated on an agarose gel according to published protocols, inserted into a cloning vector, and transfected into an appropriate host cell.
  • the cells are then propagated and "reductive reassortment" is effected.
  • the rate of the reductive reassortment process may be stimulated by the introduction of DNA damage if desired.
  • the reduction in RI is mediated by deletion formation between repeated sequences by an "intra-molecular” mechanism, or mediated by recombination-like events through "inter-molecular” mechanisms is immaterial. The end result is a reassortment of the molecules into all possible combinations.
  • the method comprises the additional step of screening the library members of the shuffled pool to identify individual shuffled library members having the ability to bind or otherwise interact, or catalyze a particular reaction (e.g., such as catalytic domain of an enzyme) with a predetermined macromolecule, such as for example a proteinaceous receptor, an oligosaccharide, virion, or other predetermined compound or structure.
  • a particular reaction e.g., such as catalytic domain of an enzyme
  • a predetermined macromolecule such as for example a proteinaceous receptor, an oligosaccharide, virion, or other predetermined compound or structure.
  • polypeptides that are identified from such libraries can be used for therapeutic, diagnostic, research and related pu ⁇ oses (e.g. , catalysts, solutes for increasing osmolarity of an aqueous solution, and the like), and/or can be subjected to one or more additional cycles of shuffling and/or selection.
  • pu ⁇ oses e.g. , catalysts, solutes for increasing osmolarity of an aqueous solution, and the like
  • polynucleotides generated by the method of the invention can be subjected to agents or processes which promote the introduction of mutations into the original polynucleotides.
  • the introduction of such mutations would increase the diversity of resulting hybrid polynucleotides and polypeptides encoded therefrom.
  • the agents or processes which promote mutagenesis can include, but are not limited to: (+)-CC-1065, or a synthetic analog such as (+)-CC-1065-(N3-Adenine (See Sun and Hurley, (1992); an N-acetylated or deacetylated 4'-fluro-4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See , for example, van de Poll et al. (1992)); or a N-acetylated or deacetylated 4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See also, van de Poll et al. (1992), pp.
  • trivalent chromium a trivalent chromium salt, a polycyclic aromatic hydrocarbon (PAH) DNA adduct capable of inhibiting DNA replication, such as 7-bromomethyl- benz[ ⁇ ]anthracene ("BMA”), tris(2,3-dibromopropyl)phosphate (“Tris-BP”), l,2-dibromo-3- chloropropane (“DBCP”), 2-bromoacrolein (2BA), benzo[ ⁇ ]pyrene-7,8-dihydrodiol-9-10- epoxide (“BPDE”), a platinum(II) halogen salt, N-hydroxy-2-amino-3-methylimidazo[4,5-
  • BMA 7-bromomethyl- benz[ ⁇ ]anthrac
  • One means for slowing or halting PCR amplification consist of UV light (+)-CC-1065 and (+)-CC-1065-(N3-Adenine).
  • Particularly encompassed means are DNA adducts or polynucleotides comprising the DNA adducts from the polynucleotides or polynucleotides pool, which can be released or removed by a process including heating the solution comprising the polynucleotides prior to further processing.
  • the invention is directed to a method of producing recombinant proteins having biological activity by treating a sample comprising double- stranded template polynucleotides encoding a wild-type protein under conditions according to the invention which provide for the production of hybrid or re-assorted polynucleotides.
  • Optimizing codons to achieve high levels of protein expression in host cells [00363]
  • the invention provides methods for modifying phosphatase-encoding nucleic acids to modify codon usage.
  • the invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase or decrease its expression in a host cell.
  • the invention also provides nucleic acids encoding a phosphatase modified to increase its expression in a host cell, phosphatase enzymes so modified, and methods of making the modified phosphatase enzymes.
  • the method comprises identifying a "non- prefened” or a “less prefened” codon in phosphatase-encoding nucleic acid and replacing one or more of these non-prefened or less prefened codons with a "prefened codon” encoding the same amino acid as the replaced codon and at least one non-prefened or less preferred codon in the nucleic acid has been replaced by a preferred codon encoding the same amino acid.
  • a prefened codon is a codon over-represented in coding sequences in genes in the host cell and a non-prefened or less preferred codon is a codon under- represented in coding sequences in genes in the host cell.
  • Host cells for expressing the nucleic acids, expression cassettes and vectors of the invention include bacteria, yeast, fungi, plant cells, insect cells and mammalian cells. Thus, the invention provides methods for optimizing codon usage in all of these cells, codon- altered nucleic acids and polypeptides made by the codon-altered nucleic acids.
  • Exemplary host cells include gram negative bacteria, such as Escherichia coli and Pseudomonas fluorescens; gram positive bacteria, such as Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris, Bacillus subtilis.
  • Exemplary host cells also include eukaryotic organisms, e.g., various yeast, such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger, and mammalian cells and cell lines and insect cells and cell lines.
  • yeast such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger, and mammalian cells and cell lines and insect cells and cell lines.
  • the codons of a nucleic acid encoding a phosphatase isolated from a bacterial cell are modified such that the nucleic acid is optimally expressed in a bacterial cell different from the bacteria from which the phosphatase was derived, a yeast, a fungi, a plant cell, an insect cell or a mammalian cell.
  • Methods for optimizing codons are well known in the art, see, e.g., U.S. Patent No. 5,795,737; Baca (2000) Int. J. Parasitol. 30:113-118; Hale (1998) Protein Expr. Purif. 12:185-188; Narum (2001) Infect. Immun. 69:7250-7253.
  • the invention provides transgenic non-human animals comprising a nucleic acid, a polypeptide, an expression cassette or vector or a transfected or transformed cell of the invention.
  • the transgenic non-human animals can be, e.g., goats, rabbits, sheep, pigs, cows, rats and mice, comprising the nucleic acids of the invention. These animals can be used, e.g., as in vivo models to study phosphatase activity, or, as models to screen for modulators of phosphatase activity in vivo.
  • the coding sequences for the polypeptides to be expressed in the transgenic non-human animals can be designed to be constitutive, or, under the control of tissue-specific, developmental-specific or inducible transcriptional regulatory factors.
  • Transgenic non-human animals can be designed and generated using any method known in the art; see, e.g., U.S. Patent Nos.
  • U.S. Patent No. 6,211,4208 describes making and using transgenic non-human mammals which express in their brains a nucleic acid construct comprising a DNA sequence.
  • U.S. Patent No. 5,387,742 describes injecting cloned recombinant or synthetic DNA sequences into fertilized mouse eggs, implanting the injected eggs in pseudo-pregnant females, and growing to term transgenic mice whose cells express proteins related to the pathology of Alzheimer's disease.
  • U.S. Patent No. 6,187,992 describes making and using a transgenic mouse whose genome comprises a disruption of the gene encoding amyloid precursor protein (APP).
  • APP amyloid precursor protein
  • Knockout animals can also be used to practice the methods of the invention.
  • the transgenic or modified animals of the invention comprise a "knockout animal,” e.g., a “knockout mouse,” engineered not to express or to be unable to express a phosphatase.
  • the phosphatase enzymes, fragments thereof and nucleic acids that encode the enzymes and fragments can be affixed to a solid support. This is often economical and efficient in the use of the phosphatases in industrial processes. For example, a consortium or cocktail of phosphatase enzymes (or active fragments thereof), which are used in a specific chemical reaction, can be attached to a solid support and dunked into a process vat. The enzymatic reaction can occur. Then, the solid support can be taken out of the vat, along with the enzymes affixed thereto, for repeated use.
  • an isolated nucleic acid of the invention is affixed to a solid support.
  • the solid support is selected from the group of a gel, a resin, a polymer, a ceramic, a glass, a microelectrode and any combination thereof.
  • solid supports useful in this invention include gels.
  • Some examples of gels include Sepharose, gelatin, glutaraldehyde, chitosan-treated glutaraldehyde, albumin-glutaraldehyde, chitosan-Xanthan, toyopearl gel (polymer gel), alginate, alginate- polylysine, canageenan, agarose, glyoxyl agarose, magnetic agarose, dextran-agarose, poly(Carbamoyl Sulfonate) hydrogel, BSA-PEG hydrogel, phosphorylated polyvinyl alcohol (PVA), monoaminoethyl-N- ⁇ aminoethyl (MANA), amino, or any combination thereof.
  • PVA phosphorylated polyvinyl alcohol
  • Another solid support useful in the present invention are resins or polymers.
  • resins or polymers include cellulose, acrylamide, nylon, rayon, polyester, anion-exchange resin, AMBERLITETM XAD-7, AMBERLITETM XAD-8, AMBERLITETM ERA-94, AMBERLITETM IRC-50, polyvinyl, polyacrylic, polymethacrylate, or any combination thereof
  • another type of solid support useful in the present invention is ceramic.
  • Some examples include non-porous ceramic, porous ceramic, SiO 2 , A1 2 0 3 .
  • Another type of solid support useful in the present invention is glass. Some examples include non-porous glass, porous glass, aminopropyl glass or any combination thereof.
  • solid support Another type of solid support that can be used is a microelectrode.
  • An example is a polyethyleneimine-coated magnetite.
  • Graphitic particles can be used as a solid support.
  • Another example of a solid support is a cell, such as a red blood cell.
  • Capillary arrays such as the GIGAMATRIXTM, Diversa Co ⁇ oration, San Diego, CA, can be used to in the methods of the invention.
  • Nucleic acids or polypeptides of the invention can be immobilized to or applied to an anay, including capillary arrays.
  • Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention.
  • Capillary anays provide another system for holding and screening samples.
  • a sample screening apparatus can include a plurality of capillaries formed into an anay of adjacent capillaries, wherein each capillary comprises at least one wall defining a lumen for retaining a sample.
  • the apparatus can further include interstitial material disposed between adjacent capillaries in the anay, and one or more reference indicia formed within of the interstitial material.
  • a capillary for screening a sample wherein the capillary is adapted for being bound in an array of capillaries, can include a first wall defining a lumen for retaining the sample, and a second wall formed of a filtering material, for filtering excitation energy provided to the lumen to excite the sample.
  • a polypeptide or nucleic acid e.g., a ligand
  • a first component into at least a portion of a capillary of a capillary array.
  • Each capillary of the capillary anay can comprise at least one wall defining a lumen for retaining the first component.
  • An air bubble can be introduced into the capillary behind the first component.
  • a second component can be introduced into the capillary, wherein the second component is separated from the first component by the air bubble.
  • a sample of interest can be introduced as a first liquid labeled with a detectable particle into a capillary of a capillary anay, wherein each capillary of the capillary anay comprises at least one wall defining a lumen for retaining the first liquid and the detectable particle, and wherein the at least one wall is coated with a binding material for binding the detectable particle to the at least one wall.
  • the method can further include removing the first liquid from the capillary tube, wherein the bound detectable particle is maintained within the capillary, and introducing a second liquid into the capillary tube.
  • the capillary array can include a plurality of individual capillaries comprising at least one outer wall defining a lumen.
  • the outer wall of the capillary can be one or more walls fused together.
  • the wall can define a lumen that is cylindrical, square, hexagonal or any other geometric shape so long as the walls form a lumen for retention of a liquid or sample.
  • the capillaries of the capillary array can be held together in close proximity to form a planar structure.
  • the capillaries can be bound together, by being fused (e.g., where the capillaries are made of glass), glued, bonded, or clamped side-by-side.
  • the capillary anay can be formed of any number of individual capillaries, for example, a range from 100 to 4,000,000 capillaries.
  • a capillary array can form a microtiter plate having about 100,000 or more individual capillaries bound together. Arrays, or "BioChips"
  • Nucleic acids or polypeptides of the invention can be immobilized to or applied to an array.
  • Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention.
  • a monitored parameter is transcript expression of a phosphatase gene.
  • One or more, or, all the transcripts of a cell can be measured by hybridization of a sample comprising transcripts of the cell, or, nucleic acids representative of or complementary to transcripts of a cell, by hybridization to immobilized nucleic acids on an anay, or "biochip.”
  • an “array” of nucleic acids on a microchip some or all of the transcripts of a cell can be simultaneously quantified.
  • arrays comprising genomic nucleic acid can also be used to determine the genotype of a newly engineered strain made by the methods of the invention.
  • Polypeptide anays can also be used to simultaneously quantify a plurality of proteins.
  • the present invention can be practiced with any known “anay,” also refened to as a “microa ⁇ ay” or “nucleic acid anay” or “polypeptide anay” or “antibody anay” or “biochip,” or variation thereof.
  • Arrays are generically a plurality of “spots” or “target elements,” each target element comprising a defined amount of one or more biological molecules, e.g., oligonucleotides, immobilized onto a defined area of a substrate surface for specific binding to a sample molecule, e.g., mRNA transcripts.
  • any known array and/or method of making and using anays can be inco ⁇ orated in whole or in part, or variations thereof, as described, for example, in U.S. Patent Nos. 6,277,628; 6,277,489; 6,261,776; 6,258,606; 6,054,270; 6,048,695; 6,045,996; 6,022,963; 6,013,440; 5,965,452; 5,959,098; 5,856,174; 5,830,645; 5,770,456; 5,632,957; 5,556,752; 5,143,854; 5,807,522; 5,800,992; 5,744,305; 5,700,637; 5,556,752; 5,434,049; see also, e.g., WO 99/51773; WO 99/09217; WO 97/46313; WO 96/17958; see also, e.g., Johnston (1998) Cun
  • the invention provides an isolated or recombinant polypeptides having at least 50%o to about 99%> or more sequence identity to SEQ ED NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54, over a region of at least about 100 residues to the full length of the protein.
  • the isolated nucleic acids of one of the Group A nucleic acid sequences, and sequences substantially identical thereto may be used to prepare one of the polypeptides of a Group B amino acid sequence, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, .75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.
  • Another aspect of the invention is an isolated or purified polypeptide comprising the sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • polypeptides may be obtained by inserting a nucleic acid encoding the polypeptide into a vector such that the coding sequence is operably linked to a sequence capable of driving the expression of the encoded polypeptide in a suitable host cell.
  • the expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • nucleic acid encoding one of the polypeptides of Group B ' amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof.
  • the nucleic acid can encode a fusion polypeptide in which one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is fused to heterologous peptides or polypeptides, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification.
  • polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be synthetically produced by conventional peptide synthesizers.
  • fragments or portions of the polypeptides may be employed for producing the conesponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides.
  • Cell-free translation systems can also be employed to produce one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof using mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof.
  • the DNA construct may be linearized prior to conducting an in vitro transcription reaction. The transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.
  • the invention also relates to variants of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • variant includes derivatives or analogs of these polypeptides.
  • the variants may differ in amino acid sequence from the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.
  • the variants may be naturally occurring or created in vitro.
  • variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, Exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures. [00386] Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids which encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the sequence obtained from the natural isolate are generated and characterized. Typically, these nucleotide differences result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates.
  • variants may be created using enor prone PCR.
  • En error prone PCR PCR is performed under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product.
  • Enor prone PCR is described in Leung, D.W., et al, Technique, 1:11-15, 1989) and Caldwell, R. C. & Joyce G.F., PCR Methods Applic, 2:28-33, 1992.
  • nucleic acids to be mutagenized are mixed with PCR primers, reaction buffer, MgCl 2 , MnCl 2 , Taq polymerase and an appropriate concentration of dNTPs for achieving a high rate of point mutation along the entire length of the PCR product.
  • the reaction may be performed using 20 fmoles of nucleic acid to be mutagenized, 30pmole of each PCR primer, a reaction buffer comprising 50mM KC1, lOmM Tris HCl (pH 8.3) and 0.01% gelatin, 7mM MgCl 2 , 0.5mM MnCl 2 , 5 units of Taq polymerase, 0.2mM dGTP, 0.2mM dATP, ImM dCTP, and ImM dTTP.
  • PCR may be performed for 30 cycles of 94° C for 1 min, 45° C for 1 min, and 72° C for 1 min. However, it will be appreciated that these parameters may be varied as appropriate.
  • the mutagenized nucleic acids are cloned into an appropriate vector and the activities of the polypeptides encoded by the mutagenized nucleic acids is evaluated.
  • Variants may also be created using oligonucleotide directed mutagenesis to generate site-specific mutations in any cloned DNA of interest.
  • Oligonucleotide mutagenesis is described in Reidhaar-Olson, J.F. & Sauer, R.T., et al, Science, 241:53-57, 1988. Briefly, in such procedures a plurality of double stranded oligonucleotides bearing one or more mutations to be introduced into the cloned DNA are synthesized and inserted into the cloned DNA to be mutagenized. Clones containing the mutagenized DNA are recovered and the activities of the polypeptides they encode are assessed.
  • Assembly PCR involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction. Assembly PCR is described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, "Method of DNA Reassembly by Interrupting Synthesis".
  • Still another method of generating variants is sexual PCR mutagenesis.
  • sexual PCR mutagenesis forced homologous recombination occurs between DNA molecules of different but highly related DNA sequence in vitro, as a result of random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction.
  • Sexual PCR mutagenesis is described in Stemmer, W.P., PNAS, USA, 91:10747-10751, 1994. Briefly, in such procedures a plurality of nucleic acids to be recombined are digested with DNase to generate fragments having an average size of 50-200 nucleotides.
  • Fragments of the desired average size are purified and resuspended in a PCR mixture.
  • PCR is conducted under conditions which facilitate recombination between the nucleic acid fragments.
  • PCR may be performed by resuspending the purified fragments at a concentration of 10-30ng/ ⁇ l in a solution of 0.2mM of each dNTP, 2.2mM MgC12, 50mM KCL, lOmM Tris HCl, pH 9.0, and 0.1% Triton X- 100.
  • PCR 2.5 units of Taq polymerase per lOO ⁇ l of reaction mixture is added and PCR is performed using the following regime: 94° C for 60 seconds, 94° C for 30 seconds, 50-55° C for 30 seconds, 72° C for 30 seconds (30-45 times) and 72° C for 5 minutes.
  • oligonucleotides may be included in the PCR reactions.
  • the Klenow fragment of DNA polymerase I may be used in a first set of PCR reactions and Taq polymerase may be used in a subsequent set of PCR reactions. Recombinant sequences are isolated and the activities of the polypeptides they encode are assessed.
  • Variants may also be created by in vivo mutagenesis.
  • random mutations in a sequence of interest are generated by propagating the sequence of interest in a bacterial strain, such as an E. coli strain, which carries mutations in one or more of the DNA repair pathways.
  • a bacterial strain such as an E. coli strain
  • Such "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA.
  • Mutator strains suitable for use for in vivo mutagenesis are described in PCT Publication No. WO 91/16427, published October 31, 1991, entitled "Methods for Phenotype Creation from Multiple Gene Populations”.
  • Variants may also be generated using cassette mutagenesis.
  • cassette mutagenesis a small region of a double stranded DNA molecule is replaced with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.
  • Recursive ensemble mutagenesis may also be used to generate variants. Recursive ensemble mutagenesis is an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis.
  • Recursive ensemble mutagenesis is described, e.g., in Arid (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815. [00394] In some aspects, variants are created using exponential ensemble mutagenesis. Exponential ensemble mutagenesis is a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. Exponential ensemble mutagenesis is described in Delegrave (1993) Biotechnology Research 11 :1548-1552. Random and site-directed mutagenesis are described in Arnold (1993) Cunent Opinion in Biotechnology 4:450-455.
  • the variants are created using shuffling procedures wherein portions of a plurality of nucleic acids which encode distinct polypeptides are fused together to create chimeric nucleic acid sequences which encode chimeric polypeptides as described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, “Method of DNA Reassembly by Interrupting Synthesis", and U.S. Patent No. 5,939,250, filed May 22, 1996, entitled, "Production of Enzymes Having Desired Activities by Mutagenesis”.
  • the variants of the polypeptides of Group B amino acid sequences may be variants in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences are substituted with a conserved or non-conserved amino acid residue (can be a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.
  • Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Alanine, Valine, Leucine and Isoleucine with another aliphatic amino acid; replacement of a Serine with a Threonine or vice versa; replacement of an acidic residue such as Aspartic acid and Glutamic acid with another acidic residue; replacement of a residue bearing an amide group, such as Asparagine and Glutamine, with another residue bearing an amide group; exchange of a basic residue such as Lysine and Arginine with another basic residue; and replacement of an aromatic residue such as Phenylalanine, Tyrosine with another aromatic residue.
  • conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Alanine, Valine, Leucine and Isoleucine with another aliphatic amino acid; replacement of a Serine with a Threonine or vice versa
  • variants are those in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences includes a substituent group. Still other variants are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol). Additional variants are those in which additional amino acids are fused to the polypeptide, such as a leader sequence, a secretory sequence, a proprotein sequence or a sequence which facilitates purification, enrichment, or stabilization of the polypeptide.
  • the fragments, derivatives and analogs retain the same biological function or activity as a polypeptide of the invention, e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.
  • the fragment, derivative, or analog includes a proprotein, such that the fragment, derivative, or analog can be activated by cleavage of the proprotein portion to produce an active polypeptide.
  • polypeptides or fragments thereof which have at least about 50%, at least about 55%, at least about 60%, at least about 65%>, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more than about 95%> homology to a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • polypeptides or fragments having homology to a polypeptide of the invention e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be obtained by isolating the nucleic acids encoding them using the techniques described above.
  • the homologous polypeptides or fragments may be obtained through biochemical enrichment or purification procedures.
  • the sequence of potentially homologous polypeptides or fragments may be determined by proteolytic digestion, gel electrophoresis and/or microsequencing.
  • the sequence of the prospective homologous polypeptide or fragment can be compared to a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof using any of the programs described above.
  • Another aspect of the invention is an assay for identifying fragments or variants of a polypeptide of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of a polypeptide of the invention, e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.
  • the fragments or variants of said polypeptides may be used to catalyze biochemical reactions, which indicate that the fragment or variant retains the enzymatic activity of a polypeptide of the invention, e.g., the polypeptides in the Group B amino acid sequences.
  • the assay for determining if fragments of variants retain the enzymatic activity of the polypeptides of a polypeptide of the invention includes the steps of: contacting the polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate.
  • polypeptides of the invention e.g., Group B amino acid sequences, and sequences substantially identical thereto or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in a variety of applications.
  • the polypeptides or fragments thereof may be used to catalyze biochemical reactions.
  • a process for utilizing a polypeptide of the invention e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto or polynucleotides encoding such polypeptides for hydrolyzing glycosidic linkages.
  • a substance containing a glycosidic linkage e.g., a starch
  • a polypeptide of the invention e.g., one of the polypeptides of Group B amino acid sequences, or sequences substantially identical thereto under conditions which facilitate the hydrolysis of the glycosidic linkage.
  • Enzymes are highly selective catalysts. Their hallmark is the ability to catalyze reactions with extraordinar stereo-, regio-, and chemo- selectivities that are unparalleled in conventional synthetic chemistry. Moreover, enzymes are remarkably versatile. They can be tailored to function in organic solvents, operate at extreme pHs (for example, high pHs and low pHs) extreme temperatures (for example, high temperatures and low temperatures), extreme salinity levels (for example, high salinity and low salinity), and catalyze reactions with compounds that are structurally unrelated to their natural, physiological substrates. [00406] Enzymes are reactive toward a wide range of natural and unnatural substrates, thus enabling the modification of virtually any organic lead compound.
  • enzymes are highly enantio- and regio-selective.
  • the high degree of functional group specificity exhibited by enzymes enables one to keep track of each reaction in a synthetic sequence leading to a new active compound.
  • Enzymes are also capable of catalyzing many diverse reactions unrelated to their physiological function in nature.
  • the present invention exploits the unique catalytic properties of enzymes.
  • biocatalysts i.e., purified or crude enzymes, non-living or living cells
  • the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds.
  • Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.
  • the biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds.
  • biocatalytic derivatization Thousands of variations of the original compound can be produced with each iteration of biocatalytic derivatization.
  • Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods.
  • This high degree of biocatalytic specificity provides the means to identify a single active compound within the library.
  • the library is characterized by the series of biocatalytic reactions used to produce it, a so-called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined.
  • This mode of identification unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.
  • Enzymes encoded by the polynucleotides of the invention include, but are not limited to, hydrolases, such as phosphatases.
  • a hybrid polypeptide resulting from the method of the invention may exhibit specialized enzyme activity not displayed in the original enzymes. For example, following recombination and/or reductive reassortment of polynucleotides encoding hydrolase activities, the resulting hybrid polypeptide encoded by a hybrid polynucleotide can be screened for specialized hydrolase activities obtained from each of the original enzymes, i.e. the type of bond on which the hydrolase acts and the temperature at which the hydrolase functions.
  • the hydrolase may be screened to ascertain those chemical functionalities which distinguish the hybrid hydrolase from the original hydrolases, such as: (a) amide (peptide bonds), i.e., proteases; (b) ester bonds, i.e., esterases and Upases; (c) acetals, i.e., glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.
  • amide (peptide bonds), i.e., proteases i.e., proteases
  • ester bonds i.e., esterases and Upases
  • acetals i.e., glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.
  • Sources of the original polynucleotides may be isolated from individual organisms ("isolates”), collections of organisms that have been grown in defined media (“enrichment cultures”), or, uncultivated organisms ("environmental samples”).
  • isolated cultures collections of organisms that have been grown in defined media
  • uncultivated organisms uncultivated organisms
  • the use of a culture-independent approach to derive polynucleotides encoding novel bioactivities from environmental samples can be used since it allows one to access untapped resources of biodiversity.
  • Environmental libraries are generated from environmental samples and represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. Because the cloned DNA is initially extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species.
  • gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest.
  • Potential pathways encoding bioactive molecules of interest are first captured in prokaryotic cells in the form of gene expression libraries.
  • Polynucleotides encoding activities of interest are isolated from such libraries and introduced into a host cell. The host cell is grown under conditions which promote recombination and/or reductive reassortment creating potentially active biomolecules with novel or enhanced activities.
  • the microorganisms from which the polynucleotide may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
  • Polynucleotides may be isolated from environmental samples in which case the nucleic acid may be recovered without culturing of an organism or recovered from one or more cultured organisms.
  • such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, barophiles and acidophiles.
  • Polynucleotides encoding enzymes isolated from extremophilic microorganisms can be used. Such enzymes may function at temperatures above 100°C in tenestrial hot springs and deep sea thermal vents, at temperatures below 0°C in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge.
  • enzymes may function at temperatures above 100°C in tenestrial hot springs and deep sea thermal vents, at temperatures below 0°C in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge.
  • esterases and lipases cloned and expressed from extremophilic organisms show high activity throughout a wide range of temperatures and pHs.
  • a polypeptide sequence as set forth in SEQ ID Nos.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 43, 44, 46, 47, 48, 50, 52, and 54 encompasses the polypeptide sequence of Group B amino acid sequences, and sequences substantially identical thereto, which are encoded by a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53, polypeptide sequences homologous to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments of any of the preceding sequences.
  • Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%o, 98%>, 97% > , 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%,or 50% homology to one of the polypeptide sequences of the Group B amino acid sequences. Homology maybe determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may result from the conection of a sequencing error.
  • the polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. It will be appreciated that the polypeptide codes as set forth in Group B amino acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.
  • methods of the invention can be used to generate novel polynucleotides encoding biochemical pathways from one or more operons or gene clusters or portions thereof.
  • bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
  • the genes are clustered, in structures refened to as "gene clusters," on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
  • a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
  • An example of a biochemical pathway encoded by gene clusters are polyketides.
  • Gene cluster DNA can be isolated from different organisms and ligated into vectors, particularly vectors containing expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
  • vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli.
  • This f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
  • cloning vectors referred to as "fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library.”
  • Another type of vector for use in the present invention is a cosmid vector. Cosmid vectors were originally designed to clone and propagate large segments of genomic DNA. Cloning into cosmid vectors is described in detail in Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ⁇ d.. Cold Spring Harbor Laboratory Press (1989).
  • two or more vectors containing different polyketide synthase gene clusters can be introduced into a suitable host cell. Regions of partial sequence homology shared by the gene clusters will promote processes which result in sequence reorganization resulting in a hybrid gene cluster. The novel hybrid gene cluster can then be screened for enhanced activities not found in the original gene clusters.
  • the invention relates to a method for producing a biologically active hybrid polypeptide and screening such a polypeptide for enhanced activity by: [00420] 1 ) introducing at least a first polynucleotide in operable linkage and a second polynucleotide in operable linkage, said at least first polynucleotide and second polynucleotide sharing at least one region of partial sequence homology, into a suitable host cell;
  • the invention provides isolated or recombinant antibodies that specifically bind to a polypeptide of the invention. These antibodies can be used to isolate, identify or quantify the peptides and polypeptides of the invention or related proteins. These antibodies can be used to inhibit the activity of an enzyme of the invention. These antibodies can be used to isolated polypeptides related to those of the invention, e.g., related phosphatase enzymes.
  • polypeptides of the invention e.g., Group B amino acid sequences, and sequences substantially identical thereto or fragments, can comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof, may also be used to generate antibodies which bind specifically to the polypeptides or fragments.
  • the resulting antibodies may be used in immunoaffinity chromatography procedures to isolate or purify the polypeptide or to determine whether the polypeptide is present in a biological sample.
  • a protein preparation such as an extract, or a biological sample is contacted with an antibody capable of specifically binding to one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • an antibody capable of specifically binding to one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • the antibody is attached to a solid support, such as a bead or other column matrix.
  • the protein preparation is placed in contact with the antibody under conditions in which the antibody specifically binds to one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, or fragment thereof. After a wash to remove non-specifically bound proteins, the specifically bound polypeptides are eluted.
  • binding may be determined using any of a variety of procedures familiar to those skilled in the art. For example, binding may be determined by labeling the antibody with a detectable label such as a fluorescent agent, an enzymatic label, or a radioisotope. Alternatively, binding of the antibody to the sample may be detected using a secondary antibody having such a detectable label thereon. Particular assays include ELISA assays, sandwich assays, radioimmunoassays, and Western Blots.
  • Polyclonal antibodies generated against.the polypeptides the invention e.g., of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, for example, a nonhuman.
  • the antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies which may bind to the whole native polypeptide.
  • Such antibodies can then be used to isolate the polypeptide from cells expressing that polypeptide.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, Nature, 256:495-497, 1975), the trioma technique, the human B-cell hybridoma technique (Kozbor et al, Immunology Today 4:72, 1983), and the EBV-hybridoma technique (Cole, et al, 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • Techniques described for the production of single chain antibodies can be adapted to produce single chain antibodies to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
  • transgenic mice may be used to express humanized antibodies to these polypeptides or fragments thereof.
  • Antibodies generated against the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in screening for similar polypeptides from other organisms and samples.
  • polypeptides from the organism are contacted with the antibody and those polypeptides which specifically bind the antibody are detected. Any of the procedures described above may be used to detect antibody binding.
  • One such screening assay is described in "Methods for Measuring Cellulase Activities", Methods in Enzymology, Vol 160, pp. 87-116. Catalytic properties of enzymes
  • the present invention exploits the unique catalytic properties of enzymes.
  • biocatalysts i.e., purified or crude enzymes, non-living or living cells
  • the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds, such as small molecules.
  • Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.
  • the biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original small molecule or compound can be produced with each iteration of biocatalytic derivatization.
  • Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods.
  • This high degree of biocatalytic specificity provides the means to identify a single active compound within the library.
  • the library is characterized by the series of biocatalytic reactions used to produce it, a so called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined.
  • This mode of identification unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.
  • the invention provides a method for modifying small molecules, comprising contacting a polypeptide encoded by a polynucleotide described herein or enzymatically active fragments thereof with a small molecule to produce a modified small molecule.
  • a library of modified small molecules is tested to determine if a modified small molecule is present within the library which exhibits a desired activity.
  • a specific biocatalytic reaction which produces the modified small molecule of desired activity is identified by systematically eliminating each of the biocatalytic reactions used to produce a portion of the library, and then testing the small molecules produced in the portion of the library for the presence or absence of the modified small molecule with the desired activity.
  • the specific biocatalytic reactions which produce the modified small molecule of desired activity is optionally repeated.
  • the biocatalytic reactions are conducted with a group of biocatalysts that react with distinct structural moieties found within the structure of a small molecule, each biocatalyst is specific for one structural moiety or a group of related structural moieties; and each biocatalyst reacts with many different small molecules which contain the distinct structural moiety. Kits
  • kits comprising the compositions, e.g., nucleic acids, expression cassettes, vectors, cells, polypeptides (e.g., phosphatases) and/or antibodies of the invention.
  • the kits also can contain instructional material teaching the methodologies and industrial uses of the invention, as described herein. Measuring Metabolic Parameters
  • the methods of the invention involve whole cell evolution, or whole cell engineering, of a cell to develop a new cell strain having a new phenotype by modifying the genetic composition of the cell, where the genetic composition is modified by addition to the cell of a nucleic acid of the invention.
  • At least one metabolic parameter of a modified cell is monitored in the cell in a "real time” or "on-line” time frame.
  • a plurality of cells such as a cell culture, is monitored in "real time” or "on- line.”
  • a plurality of metabolic parameters is monitored in "real time” or “online.”
  • Metabolic flux analysis is based on a known biochemistry framework.
  • a linearly independent metabolic matrix is constructed based on the law of mass conservation and on the pseudo-steady state hypothesis (PSSH) on the intracellular metabolites.
  • PSSH pseudo-steady state hypothesis
  • pathway components e.g. allosteric interactions, enzyme-enzyme interactions etc.
  • Metabolic phenotype relies on the changes of the whole metabolic network within a cell. Metabolic phenotype relies on the change of pathway utilization with respect to environmental conditions, genetic regulation, developmental state and the genotype, etc.
  • the dynamic behavior of the cells, their phenotype and other properties are analyzed by investigating the pathway utilization. For example, if the glucose supply is increased and the oxygen decreased during the yeast fermentation, the utilization of respiratory pathways will be reduced and/or stopped, and the utilization of the fermentative pathways will dominate. Control of physiological state of cell cultures will become possible after the pathway analysis.
  • the methods of the invention can help determine how to manipulate the fermentation by determining how to change the substrate supply, temperature, use of inducers, etc. to control the physiological state of cells to move along desirable direction.
  • the MFA results can also be compared with transcriptome and proteome data to design experiments and protocols for metabolic engineering or gene shuffling, etc.
  • any modified or new phenotype can be confened and detected, including new or improved characteristics in the cell. Any aspect of metabolism or growth can be monitored. Monitoring expression of an mRNA transcript
  • the engineered phenotype comprises increasing or decreasing the expression of an mRNA transcript or generating new transcripts in a cell.
  • mRNA transcript, or message can be detected and quantified by any method known in the art, including, e.g., Northern blots, quantitative amplification reactions, hybridization to anays, and the like.
  • Quantitative amplification reactions include, e.g., quantitative PCR, including, e.g., quantitative reverse transcription polymerase chain reaction, or RT-PCR; quantitative real time RT-PCR, or "real-time kinetic RT-PCR" (see, e.g., Kreuzer (2001) Br. J. Haematol. 114:313-318; Xia (2001) Transplantation 72:907-914).
  • the engineered phenotype is generated by knocking out expression of a homologous gene.
  • the gene's coding sequence or one or more transcriptional control elements can be knocked out, e.g., promoters enhancers.
  • promoters enhancers e.g., promoters enhancers.
  • the engineered phenotype comprises increasing the expression of a homologous gene. This can be effected by knocking out of a negative control element, including a transcriptional regulatory element acting in cis- or trans- , or, mutagenizing a positive control element.
  • transcripts of a cell can be measured by hybridization of a sample comprising transcripts of the cell, or, nucleic acids representative of or complementary to transcripts of a cell, by hybridization to immobilized nucleic acids on an array.
  • Monitoring expression of a polypeptides, peptides and amino acids [00455]
  • the engineered phenotype comprises increasing or decreasing the expression of a polypeptide or generating new polypeptides in a cell.
  • Polypeptides, peptides and amino acids can be detected and quantified by any method known in the art, including, e.g., nuclear magnetic resonance (NMR), spectrophotometry, radiography (protein radiolabeling), electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, various immunological methods, e.g.
  • 1 ⁇ can be monitored by feeding a mixture of uniformly C-labeled and unlabeled carbon source compounds into a bioreaction network. Analysis of the resulting labeling pattern enables both a comprehensive characterization of the network topology and the determination of metabolic flux ratios of the amino acids; see, e.g., Szyperski (1999) Metab. Eng. 1:189-197.
  • DNA encoding the enzymes of the present invention SEQ ID NOS : 1 through 16 were initially amplified from a pBluescript vector containing the DNA by the PCR technique using the primers noted herein. The amplified sequences were then inserted into the respective pQE vector listed beneath the primer sequences, and the enzyme was expressed according to the protocols set forth herein.
  • the 5' and 3' oligonucleotide primer sequences used for subcloning and vectors for the respective genes are as follows: Ammonifex degensii KC4 - 3A1A [00459] 5 ' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG GGG GCA GGT CCG AAA AGG 3' 5' CGGA GGA TCC CTA CAG TTC TAA AAG TCT TTT A 3'
  • the restriction enzyme sites indicated correspond to the restriction enzyme sites on the bacterial expression vector indicated for the respective gene (Qiagen, Inc. Chatsworth, CA).
  • the pQE vector encodes antibiotic resistance (Amp 1 ), a bacterial origin of replication (ori), an EPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites.
  • the pQE vector was digested with the restriction enzymes indicated.
  • the amplified sequences were ligated into the respective pQE vector and inserted in frame with the sequence encoding for the RBS.
  • the native stop codon was inco ⁇ orated so the genes were not fused to the His tag of the vector.
  • the ligation mixture was then used to transform the E. coli strain M15/pREP4 (Qiagen, Lnc.) by electroporation.
  • M15/pREP4 contains multiple copies of the plasmid pREP4, which expresses the lad repressor and also confers kanamycin resistance (Kan 1 ).
  • Transformants were identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture was used to inoculate a large culture at a ratio of 1 : 100 to 1 :250. The cells were grown to an optical density 600 (O.D. 600 ) of between 0.4 and 0.6. IPTG (“Isopropyl-B-D-thiogalacto pyranoside”) was then added to a final concentration of 1 mM. EPTG induces by inactivating the lad repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation.
  • O/N optical density 600
  • the primer sequences set out above may also be employed to isolate the target gene from the deposited material by hybridization techniques described above.
  • Example 2 Isolation of A Selected-Clone From the Deposited Genomic Clones
  • a clone is isolated directly by screening the deposited material using the oligonucleotide primers set forth in Example 1 for the particular gene desired to be isolated. The specific oligonucleotides are synthesized using an Applied Biosystems DNA synthesizer.
  • the two oligonucleotide primers conesponding to the gene of interest are used to amplify the gene from the deposited material.
  • a polymerase chain reaction is carried out in 25 ⁇ l of reaction mixture with 0.1 ug of the DNA of the gene of interest.
  • the reaction mixture is 1.5-5 mM MgCl 2 , 0.01% (w/v) gelatin, 20 ⁇ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 1.25 Unit of Taq polymerase.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides enzymes having phosphatase activity, e.g., thermostable phosphatase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The phosphatase activity of the enzymes of the invention include the enzymatic removal of phosphate groups from organophosphate ester compounds and hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA.

Description

THERMOSTABLE PHOSPHATASES AND METHODS OF MAKING AND USING THEM
TECHNICAL FIELD
[0001] This invention relates generally to molecular and cellular biology. In particular, the invention is directed to enzymes having phosphatase activity, particularly, thermostable phosphatase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The phosphatase activity of the enzymes of the invention include the enzymatic removal of phosphate groups from organophosphate ester compounds and hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA.
BACKGROUND [0002] Phosphatases are a group of enzymes that remove phosphate groups from organophosphate ester compounds. There are numerous phosphatases, including alkaline phosphatases, phosphodiesterases and phytases. Alkaline phosphatases are widely distributed enzymes and are composed of a group of enzymes that hydrolyze organic phosphate ester bonds at alkaline pH.
[0003] Phosphodiesterases are capable of hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA. The classification of phosphodiesterases depends upon which side of the phosphodiester bridge is attacked. The 3' enzymes specifically hydrolyze the ester linkage between the 3' carbon and the phosphoric group whereas the 5' enzymes hydrolyze the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge. The best known of the class 3' enzymes is a phosphodiesterase from the venom of the rattlesnake or from a rustle's viper, which hydrolyses all the 3' bonds in either RNA or DNA liberating nearly all the nucleotide units as nucleotide 5' phosphates. This enzyme requires a free 3' hydroxyl group on the terminal nucleotide residue and proceeds stepwise from that end of the polynucleotide chain. This enzyme and all other nucleases that attack only at the ends of the polynucleotide chains are called exonucleases. The 5' enzymes are represented by a phosphodiesterase from bovine spleen, also an exonuclease, which hydrolyses all the 5' linkages of both DNA and RNA and thus liberates only nucleoside 3' phosphates. It begins its attack at the end of the chain having a free 3' hydroxyl group.
[0004] Phytases are enzymes that recently have been introduced to commerce. The phytase enzyme removes phosphate from phytic acid (inositol hexaphosphoric acid), a compound found in plants such as corn, wheat and rice. The enzyme has commercial use for the treatment of animal feed, making the inositol of the phytic acid available for animal nutrition. Aspergillus fwuum and wheat are sources of phytase.
[0005] Phytase is used to improve the utilization of natural phosphorus in animal feed. Use of phytase as a feed additive enables the animal to metabolize a larger degree of its cereal feed's natural mineral content thereby reducing or altogether eliminating the need for synthetic phosphorus additives. More important than the reduced need for phosphorus additives is the corresponding reduction of phosphorus in pig and chicken waste. Many European countries severely limit the amount of manure that can be spread per acre due to concerns regarding phosphorus contamination of ground water. This is highly important in northern Europe, and will eventually be regulated throughout the remainder of the European Continent and the United States as well, (see, e.g., Excerpts from Business Trend Analysts, Inc., January 1994, Frost and Sullivan Report 1995 and USDA on-line information.). [0006] Alkaline phosphatase hydro lyzes monophosphate esters, releasing an organic phosphate and the cognate alcohol compound. It is non-specific with respect to the alcohol moiety and it is this feature that accounts for the many uses of this enzyme. The enzyme has a pH optimum between 9 and 10, however, it can also function at neutral pH. Thermostable alkaline phosphatases are not irreversibly inactivated even when heated to 60°C or more for brief periods of time, as, for example, in the practice of hydrolyzing monophosphate esters. Alkaline phosphatases may be obtained from numerous thermophilic organisms, such as Ammonifex degensii, Aquifex pyrophilus, Archaeoglobus lithotrophicus, Methanococcus igneus, Pyrolobus (a Crenarchaeota), Pyrococcus and Thermococcus, which are mostly Eubacteria and Euryarchaeota. Many of these organisms grow at temperatures up to about 103°C and are unable to grow below 70°C. These anaerobes are isolated from extreme environments. For example, the Thermococcus CL-2 was isolated from a worm residing on a "black smoker" sulfite structure. Interest in alkaline phosphatases from thermophilic microbes has increased recently due to their value for commercial applications. [0007] Two sources of alkaline phosphatases dominate and compete commercially:
(i) animal, from bovine and calf intestinal mucosa, and (ii) bacterial, from E. coli. Due to the high turnover number of calf intestinal phosphatase, it is often selected as the label in many enzyme immunoassays. The usefulness of calf alkaline phosphatase, however, is limited by its inherently low thermostability, which is even further compromised during the chemical preparation of the enzyme: antibody conjugates. Bacterial alkaline phosphatase is an alternative to calf alkaline phosphatase due to bacterial alkaline phosphatase's extreme thermotolerance at temperatures as high as 95°C (see, e.g., Tomazic- Allen, S.J.; Recombinant Bacterial Phosphatase as an Immunodiagnostic Enzyme, Annals D Biology Clinique, 49(5):287:90 (1991)), however, the enzyme has a very low turnover number.
[0008] There is a need for novel phosphatase enzymes having enhanced thermostability. This includes a need for thermostable alkaline phosphatases whose enhanced thermostability is beneficial in enzyme labeling processes and certain recombinant DNA techniques, such as in the dephosphorylation of vector DNA prior to insert DNA ligation. Recombinant phosphatase enzymes provide the proteins in a format amenable to efficient production of pure enzyme, which can be utilized in a variety of applications as described herein. Accordingly, there is a need for the characterization, amino acid sequencing, DNA sequencing, and heterologous expression of thermostable phosphatase enzymes.
[0009] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
SUMMARY
[0010] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO: 19 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, e.g., thermostable phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection. [0011] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:20 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0012 ] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:21 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0013 ] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:22 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0014] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:23 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0015] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:24 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0016] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:25 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0017] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:26 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0018] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:27 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0019] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:37 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 4000, 4200, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0020] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:38 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0021] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:39 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 3800, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0022] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:37 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3200, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0023] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:41 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0024] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:43 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0025] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:45 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0026] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:47 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0027] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:49 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0028] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:51 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0029] The invention provides isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to SEQ ID NO:53 over a region of at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or more, residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
[0030] In one aspect, the invention provides isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleic acid having a sequence as set forth in SEQ ED NO: 19, sequence as set forth in SEQ ID NO:20, sequence as set forth in SEQ ID NO:21, sequence as set forth in SEQ ED NO:22, sequence as set forth in SEQ ID NO:23, sequence as set forth in SEQ ED NO:24, sequence as set forth in SEQ ID NO:25, sequence as set forth in SEQ ID NO:26, sequence as set forth in SEQ ED NO:27, sequence as set forth in SEQ ED NO:37, sequence as set forth in SEQ ED NO:38, sequence as set forth in SEQ ED NO:39, sequence as set forth in SEQ ID NO:40, sequence as set forth in SEQ ID NO:41, sequence as set forth in SEQ ED NO:43, sequence as set forth in SEQ ED NO:45, sequence as set forth in SEQ ID NO:47, sequence as set forth in SEQ ID NO:49, sequence as set forth in SEQ ED NO:51, or sequence as set forth in SEQ ID NO:53.
[0031] En one aspect, the invention provides isolated or recombinant nucleic acid, wherein the nucleic acid sequence encodes a polypeptide comprising a sequence as set forth in SEQ ED NO:28, sequence as set forth in SEQ ED NO:29, sequence as set forth in SEQ ID NO:30, sequence as set forth in SEQ ED NO:31, sequence as set forth in SEQ ID NO:32, sequence as set forth in SEQ ID NO:33, sequence as set forth in SEQ ID NO:34, sequence as set forth in SEQ ID NO:35, sequence as set forth in SEQ ID NO:36, sequence as set forth in SEQ ED NO:42, sequence as set forth in SEQ ID NO:44, sequence as set forth in SEQ ID NO:46, sequence as set forth in SEQ ED NO:48, sequence as set forth in SEQ ID NO:50, sequence as set forth in SEQ ID NO:52, or sequence as set forth in SEQ ID NO:54. [0032 ] En one aspect, the sequence comparison algorithm is a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall -p blastp -d "nr pataa" -F F, and all other options are set to default.
[0033 ] En one aspect, the phosphatase activity comprises an alkaline phosphatase activity. En another aspect, the phosphatase activity comprises a phosphodiesterase activity. In one aspect, the phosphatase activity comprises a phytase activity. En one aspect, the phosphatase activity comprises removal of phosphate group. In an alternative aspect, the phosphodiesterase activity comprises hydrolysis of the phosphodiester bridges of nucleic acids. En one aspect, the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the 3' carbon and the phosphoric group. In another aspect, the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge. In one aspect, the phytase activity can comprise removal of phosphate from phytic acid (inositol hexaphosphoric acid). En another aspect, the alkaline phosphatase activity can comprise hydrolysis of monophosphate esters. Additionally, the alkaline phosphatase activity can comprise hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
[0034] En one aspect, the isolated or recombinant nucleic acid encodes a polypeptide having a phosphatase activity that is thermostable. The polypeptide can retain a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C.
[0035] In one aspect, the isolated or recombinant nucleic acid encodes a polypeptide having a phosphatase activity that is thermotolerant. The polypeptide can retain a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C. Alternatively, the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 50°C.
[0036] In one aspect, the isolated or recombinant nucleic acid comprises a sequence that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ED NO:26, a sequence as set forth in SEQ ED NO:27, a sequence as set forth in SEQ ID NO:37, a sequence as set forth in SEQ ED NO:38, a sequence as set forth in SEQ ID NO:39, a sequence as set forth in SEQ ED NO:40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ID NO:43, a sequence as set forth in SEQ ED NO:45, a sequence as set forth in SEQ ED NO:47, a sequence as set forth in SEQ ID NO:49, a sequence as set forth in SEQ ED NO:51, or a sequence as set forth in SEQ ID NO:53, [0037] wherein the nucleic acid encodes a polypeptide having a phosphatase activity.
[0038] The nucleic acid can be at least about 100, 200, 300, 400, 500, 600, 700, 800,
900, 1000 residues in length or the full length of the gene or transcript. [0039] In one aspect, the stringent conditions can include a wash step comprising a wash in 0.2X SSC at a temperature of about 65°C for about 15 minutes. [0040] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 consecutive bases of a sequence comprising a sequence as set forth in SEQ ED NO: 19, a sequence as set forth in SEQ ID NO:20, a sequence as set forth in SEQ ED NO:21, a sequence as set forth in SEQ ID NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ID NO:25, a sequence as set forth in SEQ ID NO:26, a sequence as set forth in SEQ ID NO:27, a sequence as set forth in SEQ ED NO:37, a sequence as set forth in SEQ ID NO:38, a sequence as set forth in SEQ ED NO:39, a sequence as set forth in SEQ ID NO:40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ED NO:43, a sequence as set forth in SEQ ED NO:45, a sequence as set forth in SEQ ID NO:47, a sequence as set forth in SEQ ED NO:49, a sequence as set forth in SEQ ID NO:51, or a sequence as set forth in SEQ ID NO:53, wherein the probe identifies the nucleic acid by binding or hybridization. The probe can comprise at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence as set forth in SEQ ID NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ID NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ID NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ID NO:26, a sequence as set forth in SEQ ID NO:27, a sequence as set forth in SEQ ID NO:37, a sequence as set forth in SEQ ED NO:38, a sequence as set forth in SEQ ID NO:39, a sequence as set forth in SEQ ED NO:40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ID NO:43, a sequence as set forth in SEQ ID NO:45, a sequence as set forth in SEQ ID NO:47, a sequence as set forth in SEQ ID NO:49, a sequence as set forth in SEQ ID NO:51, or a sequence as set forth in SEQ ID NO:53. [0041] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO: 19, or a subsequence thereof, over a region of at least about 100 residues.
[0042 ] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:20, or a subsequence thereof, over a region of at least about 100 residues.
[0043] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:21, or a subsequence thereof, over a region of at least about 100 residues.
[0044] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ED NO:22, or a subsequence thereof, over a region of at least about 100 residues.
[0045] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:23, or a subsequence thereof, over a region of at least about 100 residues.
[0046] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:24, or a subsequence thereof, over a region of at least about 100 residues. [0047] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%>, or more, sequence identity to SEQ ED NO:25, or a subsequence thereof, over a region of at least about 100 residues.
[0048] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:26, or a subsequence thereof, over a region of at least about 100 residues.
[0049] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:27, or a subsequence thereof, over a region of at least about 100 residues.
[0050] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO: 37, or a subsequence thereof, over a region of at least about 100 residues.
[0051] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ED NO:38, or a subsequence thereof, over a region of at least about 100 residues.
[0052] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%>, or more, sequence identity to SEQ ID NO:39, or a subsequence thereof, over a region of at least about 100 residues. [0053] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%>, or more, sequence identity to SEQ ID NO:40, or a subsequence thereof, over a region of at least about 100 residues.
[0054] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:41, or a subsequence thereof, over a region of at least about 100 residues.
[0055] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:43, or a subsequence thereof, over a region of at least about 100 residues.
[0056] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:45, or a subsequence thereof, over a region of at least about 100 residues.
[0057] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:47, or a subsequence thereof, over a region of at least about 100 residues.
[0058] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:49, or a subsequence thereof, over a region of at least about 100 residues. [0059] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:51, or a subsequence thereof, over a region of at least about 100 residues.
[0060] The invention provides a nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:53, or a subsequence thereof, over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection.
[0061] The probe can comprise an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence as set forth in SEQ ED NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ID NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ID NO:23, a sequence as set forth in SEQ ED NO:24, a sequence as set forth in SEQ ID NO:25, a sequence as set forth in SEQ ED NO:26, a sequence as set forth in SEQ ID NO:27, a sequence as set forth in SEQ ED NO:37, a sequence as set forth in SEQ ID NO:38, a sequence as set forth in SEQ ED NO:39, a sequence as set forth in SEQ ID NO:40, a sequence as set forth in SEQ ED NO:41, a sequence as set forth in SEQ ID NO:43, a sequence as set forth in SEQ ED NO:45, a sequence as set forth in SEQ ED NO:47, a sequence as set forth in SEQ ED NO:49, a sequence as set forth in SEQ ID NO:51, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
[0062] The invention provides an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof. One or each member of the amplification primer sequence pair can comprise an oligonucleotide comprising at least about 10 to 50 consecutive bases of the sequence. [0063] The invention provides methods of amplifying a nucleic acid encoding a polypeptide with a phosphatase activity comprising amplification of a template nucleic acid with an amplification primer sequence pair capable of amplifying a nucleic acid sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
[0064] The invention provides expression cassettes comprising a nucleic acid of the invention, e.g., comprising: (i) a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, at least 50%» sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, at least 50% sequence identity to SEQ ED NO: 51 over a region of at least about 100 residues, or at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence
[0065] The invention provides vectors comprising a nucleic acid of the invention, e.g., (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ED NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
[0066] The invention provides cloning vehicles comprising a nucleic acid of the invention or a vector of the invention. The cloning vehicle can be a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome. The viral vector can comprise an adenovirus vector, a retroviral vectors or an adeno-associated viral vector. The cloning vehicle can comprise a bacterial artificial chromosome (B AC), a plasmid, a bacteriophage PI -derived vector (PAC), a yeast artificial chromosome (YAC), a mammalian artificial chromosome (MAC).
[0067] The invention provides transformed cells comprising a nucleic acid of the invention or a vector of the invention or a cloning vehicle of the invention. The vector can comprise a nucleic acid of the invention, for example, a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ED NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
[0068] The invention provides transformed cells comprising a nucleic acid of the invention, e.g., (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ED NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ D NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ED NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof. In one aspect, the cell can be a bacterial cell, a mammalian cell , a fungal cell, a yeast cell, an insect cell or a plant cell.
[0069] The invention provides non-human animals comprising a nucleic acid of the invention or a vector of the invention. In one aspect, the transgenic animal is a mouse. [0070] The invention provides transgenic plants comprising a nucleic acid of the invention or a vector of the invention. The transgenic plant can be an oilseed plant, a rapeseed plant, a soybean plant, a palm, a canola plant, a sunflower plant, a sesame plant, a peanut plant or a tobacco plant.
[0071] The invention provides transgenic seeds comprising a nucleic acid of the invention or a vector of the invention. The transgenic seed can be an oilseed, a rapeseed, a soybean seed, a palm kernel, a canola plant seed, a sunflower seed, a sesame seed, a peanut or a tobacco plant seed.
[00 )7722]] The invention provides an antisense oligonucleotide comprising a nucleic acid s -.e-q^uαeennccee complementary to or capable of hybridizing under stringent conditions to (i) a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO: 22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof. The antisense oligonucleotide can be between about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 bases in length. [0073] The invention provides methods of inhibiting the translation of a phosphatase message in a cell comprising administering to the cell or expressing in the cell an antisense oligonucleotide comprising a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to a nucleic acid comprising (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
[0074] The invention provides an isolated or recombinant polypeptide comprising an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%), 98%, 99%o, or more, sequence identity to SEQ ID NO:28 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%o, or more, sequence identity to SEQ ED NO:29 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:30 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%>, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:31 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%>, 55%, 60%o, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:32 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%>, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:33 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or more, residues; an amino acid sequence having at least 50%>, 55%>, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO: 34 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%>, 70%), 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:35 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%>, 55%, 60%>, 65%, 70%, 75%>, 80%, 85%., 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:30 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%), or more, sequence identity to SEQ ID NO:42 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:44 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:46 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, or more, residues; an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:48 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more, residues; an amino acid sequence having at least 50%, 55%>, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ED NO:50 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, or more, residues; an amino acid sequence having at least 50%>, 55%>, 60%, 65%, 70%, 75%, 80%>, 85%o, 90%, 95%, 98%, 99%, or more, sequence identity to SEQ ID NO:52 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or more, residues; an amino acid sequence having at least 50%>, 55%>, 60%, 65%>, 70%>, 75%, 80%>, 85%o, 90%, 95%o, 98%, 99%, or more, sequence identity to SEQ ED NO:54 over a region of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, or more, residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection; or, a polypeptide encoded by a nucleic acid comprising (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ JD NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
[0075] En one aspect, the polypeptide can have a phosphatase activity. In one aspect, the phosphatase activity comprises an alkaline phosphatase activity. The phosphatase activity can comprise a phytase activity. In one aspect, the phosphatase activity can comprise a phosphodiesterase activity.
[0076] In one aspect, the phosphatase activity can comprise removal of phosphate group. In another aspect, the phosphodiesterase activity can comprise hydrolysis of the phosphodiester bridges of nucleic acids. The phosphodiesterase activity can comprise hydrolysis of the ester linkage between the 3' carbon and the phosphoric group. In one aspect, the phosphodiesterase activity can comprise hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge. In one aspect, the phytase activity comprises removal of phosphate from phytic acid (inositol hexaphosphoric acid). In one aspect, the phosphatase activity comprises hydrolysis of monophosphate esters. The phosphatase activity can comprise hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
[0077] En one aspect, the phosphatase activity is thermostable. The polypeptide can retain a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C. In another aspect, the phosphatase activity is thermotolerant. The polypeptide can retain a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C, or in the range from greater than 37°C to about 50°C. [0078] In one aspect, the invention provides the isolated or recombinant polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:28, an amino acid sequence as set forth in SEQ ID NO:29, an amino acid sequence as set forth in SEQ ED NO:30, an amino acid sequence as set forth in SEQ ID NO:31, an amino acid sequence as set forth in SEQ ID NO:32, an amino acid sequence as set forth in SEQ ED NO:33, an amino acid sequence as set forth in SEQ ID NO:34, an amino acid sequence as set forth in SEQ ED NO:35, an amino acid sequence as set forth in SEQ ID NO:36, an amino acid sequence as set forth in SEQ ID NO:42, an amino acid sequence as set forth in SEQ ID NO:44, an amino acid sequence as set forth in SEQ ID NO:46, an amino acid sequence as set forth in SEQ ID NO:48, an amino acid sequence as set forth in SEQ ED NO:50, an amino acid sequence as set forth in SEQ ED NO:52, or an amino acid sequence as set forth in SEQ ED NO:54. [0079] In one aspect, the isolated or recombinant polypeptide can comprise a polypeptide of the invention that lacks a signal sequence.
[0080] In one aspect, the phosphatase activity can be thermostable when heated to a temperature in the range from about 37°C to about 50°C, about 50°C to about 70°C or about 70°C to about 90°C. The phosphatase activity can comprise a specific activity at about 37°C in the range from about 100 to about 1000 units per milligram of protein. In one aspect, the phosphatase activity comprises a specific activity from about 500 to about 750 units per milligram of protein. In another aspect, the phosphatase activity comprises a specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein. In one aspect, the phosphatase activity comprises a specific activity at 37°C in the range from about 750 to about 1000 units per milligram of protein.
[0081] In one aspect, the phosphatase activity can be thermotolerant after being heated to an elevated temperature in the range from about 37°C to about 90°C. The phosphatase activity can be thermotolerant after being heated to a temperature in the range from about 37°C to about 70°C. The thermotolerance can comprise retention of at least half of the specific activity of the phosphatase at 37°C after being heated to the elevated temperature. In one aspect, the thermotolerance can comprise retention of specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein after being heated to the elevated temperature.
[0082 ] The invention provides the isolated or recombinant polypeptide, wherein the phosphatase comprises at least one glycosylation site. In one aspect, glycosylation can be an N-linked glycosylation. In one aspect, the polypeptide can be glycosylated after being expressed in a P. pastoris or a S. pombe.
[0083] In one aspect, the polypeptide can retain a phosphatase activity under conditions comprising about pH 5. In another aspect, the polypeptide can retain a phosphatase activity under conditions comprising about pH 4.5. Alternatively, the polypeptide of the invention can retain a phosphatase activity under conditions comprising about pH 9.0, pH 9.5, pH 10, 10.5, pH 11, pH 11.5 or pH 12.
[0084] The invention provides protein preparations comprising a polypeptide of the invention, wherein the protein preparation comprises a liquid, a solid or a gel. [0085] The invention provides heterodimers comprising a polypeptide of the invention and a second domain. n one aspect, the second domain can be a polypeptide and the heterodimer is a fusion protein. En one aspect, the second domain can be an epitope or a tag.
[0086] The invention provides immobilized polypeptides having a phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or is a polypeptide encoded by a nucleic acid of the invention, or a polypeptide comprising a polypeptide of the invention and a second domain. The polypeptide can be immobilized on a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, an array or a capillary tube.
[0087] The invention provides arrays comprising an immobilized polypeptide, wherein the polypeptide is a polypeptide of the invention, or is a polypeptide encoded by a nucleic acid of the invention, or a polypeptide comprising a polypeptide of the invention and a second domain. The invention provides arrays comprising an immobilized nucleic acid of the invention. The invention provides arrays comprising an antibody of the invention.
[0088] The invention provides isolated or recombinant antibodies that specifically bind to a polypeptide of the invention or to a polypeptide encoded by a nucleic acid of the invention. The antibody can be a monoclonal or a polyclonal antibody. The invention provides hybridomas comprising an antibody of the invention.
[0089] The invention provides food supplements for an animal comprising a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention. In one aspect, the polypeptide can be glycosylated.
[0090] The invention provides edible enzyme delivery matrices comprising a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention, wherein the polypeptide comprises a phosphatase activity. The delivery matrix can comprise a pellet. In one aspect, the polypeptide can be glycosylated. En one aspect, the phosphatase activity can be thermotolerant or thermostable.
[0091] The invention provides methods of isolating or identifying a polypeptide with phosphatase activity comprising the steps of: (a) providing an antibody of the invention; (b) providing a sample comprising polypeptides; and (c) contacting the sample of step (b) with the antibody of step (a) under conditions wherein the antibody can specifically bind to the polypeptide, thereby isolating or identifying a phosphatase.
[0092 ] The invention provides methods of making an anti -phosphatase antibody comprising administering to a non-human animal a nucleic acid of the invention, or a polypeptide of the invention, in an amount sufficient to generate a humoral immune response, thereby making an anti-phosphatase antibody.
[0093 ] The invention provides methods of producing a recombinant polypeptide comprising the steps of: (a) providing a nucleic acid of the invention operably linked to a promoter; and (b) expressing the nucleic acid of step (a) under conditions that allow expression of the polypeptide, thereby producing a recombinant polypeptide. In one aspect, the method can further comprise transforming a host cell with the nucleic acid of step (a) followed by expressing the nucleic acid of step (a), thereby producing a recombinant polypeptide in a transformed cell. [0094] The invention provides methods for identifying a polypeptide having a phosphatase activity comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention; (b) providing a phosphatase substrate; and (c) contacting the polypeptide or a fragment or variant thereof of step (a) with the substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of a reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product detects a polypeptide having a phosphatase activity. In one aspect, the substrate can be an organophosphate ester compound.
[0095] The invention provides methods for identifying a phosphatase substrate comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic of the invention; (b) providing a test substrate; and (c) contacting the polypeptide of step (a) with the test substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of a reaction product identifies the test substrate as a phosphatase substrate.
[0096] The invention provides methods of determining whether a compound specifically binds to a polypeptide comprising the following steps: (a) expressing a nucleic acid of the invention or a vector comprising the nucleic acid of the invention under conditions permissive for translation of the nucleic acid to a polypeptide, or, providing a polypeptide of the invention; (b) contacting the polypeptide with the test compound; and (c) determining whether the test compound specifically binds to the polypeptide, thereby determining that the compound specifically binds to the polypeptide. [0097] The invention provides methods for identifying a modulator of a phosphatase activity comprising the following steps: (a) providing a polypeptide of the invention or a polypeptide encoded by a nucleic acid of the invention; (b) providing a test compound; (c) contacting the polypeptide of step (a) with the test compound of step (b) and measuring an activity of the phosphatase, wherein a change in the phosphatase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the phosphatase activity. In one aspect, the phosphatase activity can be measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product, or, an increase in the amount of the substrate or a decrease in the amount of a reaction product. In one aspect, a decrease in the amount of the substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity. In another aspect, an increase in the amount of the substrate or a decrease in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an inhibitor of phosphatase activity.
[0098] The invention provides computer systems comprising a processor and a data storage device wherein said data storage device has stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises a polypeptide of the invention, or subsequence thereof, and the nucleic acid comprises a nucleic acid of the invention, or subsequence thereof. En one aspect, the computer system can further comprise a sequence comparison algorithm and a data storage device having at least one reference sequence stored thereon. En another aspect, the sequence comparison algorithm comprises a computer program that indicates polymorphisms. In one aspect, the computer system can further comprise an identifier that identifies one or more features in said sequence. [0099] The invention provides computer readable mediums having stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention, or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention, or subsequence thereof.
[00100] The invention provides methods for identifying a feature in a sequence comprising the steps of: (a) reading the sequence using a computer program which identifies one or more features in a sequence, wherein the sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention or subsequence thereof; and (b) identifying one or more features in the sequence with the computer program.
[00101] The invention provides methods for comparing a first sequence to a second sequence comprising the steps of: (a) reading the first sequence and the second sequence through use of a computer program which compares sequences, wherein the first sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide can be a polypeptide of the invention, or subsequence thereof, and the nucleic acid can be a nucleic acid of the invention or subsequence thereof; and (b) determining differences between the first sequence and the second sequence with the computer program. In one aspect, the step of determining differences between the first sequence and the second sequence can comprise the step of identifying polymorphisms. En another aspect, the step of determining differences between the first sequence and the second sequence further comprises the step of identifying polymoφhisms. En one aspect, the method comprises an identifier that identifies one or more features in a sequence. In one aspect, the method can comprise reading the first sequence using a computer program and identifying one or more features in the sequence. [00102] The invention provides methods for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of: (a) providing an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO:54, or a subsequence thereof; (b) isolating a nucleic acid from the environmental sample or treating the environmental sample such that nucleic acid in the sample is accessible for hybridization to the amplification primer pair; and, (c) combining the nucleic acid of step (b) with the amplification primer pair of step (a) and amplifying nucleic acid from the environmental sample, thereby isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample. En one aspect, each member of the amplification primer sequence pair comprises an oligonucleotide comprising at least about 10 to 50 consecutive bases of a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO: 54, or a subsequence thereof. [00103] The invention provides methods for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of: (a) providing a polynucleotide probe, wherein the polynucleotide probe comprises a nucleic acid of the invention or a subsequence thereof; (b) isolating a nucleic acid from the environmental sample or treating the environmental sample such that nucleic acid in the sample is accessible for hybridization to a polynucleotide probe of step (a); (c) combining the isolated nucleic acid or the treated environmental sample of step (b) with the polynucleotide probe of step (a); and (d) isolating a nucleic acid that specifically hybridizes with the polynucleotide probe of step (a), thereby isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample. The environmental sample can comprise a water sample, a liquid sample, a soil sample, an air sample or a biological sample. The biological sample can be derived from a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell. [00104] The invention provides methods of generating a variant of a nucleic acid encoding a phosphatase comprising the steps of: (a) providing a template nucleic acid of the invention; and (b) modifying, deleting or adding one or more nucleotides in the template sequence, or a combination thereof, to generate a variant of the template nucleic acid. In one aspect, the method can further comprise expressing the variant nucleic acid to generate a variant phosphatase polypeptide. In one aspect, the modifications, additions or deletions can be introduced by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site- specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR) and a combination thereof. In one aspect, the modifications, additions or deletions are introduced by a method comprising recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof. [00105] In one aspect, the method is iteratively repeated until a phosphatase having an altered or different activity or an altered or different stability from that of a polypeptide encoded by the template nucleic acid is produced. In one aspect, the variant phosphatase polypeptide can be thermotolerant, and retains some activity after being exposed to an elevated temperature. In another aspect, the variant phosphatase polypeptide has increased glycosylation as compared to the phosphatase encoded by a template nucleic acid. En one aspect, the variant phosphatase polypeptide has a phosphatase activity under a high temperature, wherein the phosphatase encoded by the template nucleic acid is not active under the high temperature. En one aspect, the method can be iteratively repeated until a phosphatase coding sequence having an altered codon usage from that of the template nucleic acid is produced. In another aspect, the method is iteratively repeated until a phosphatase gene having higher or lower level of message expression or stability from that of the template nucleic acid is produced.
[00106] The invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising: (a) providing a nucleic acid of the invention; and, (b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a preferred or neutrally used codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell.
[00107] The invention provides methods for modifying codons in a nucleic acid encoding a phosphatase polypeptide, the method comprising (a) providing a nucleic acid of the invention; and, (b) identifying a codon in the nucleic acid of step (a) and replacing it with a different codon encoding the same amino acid as the replaced codon, thereby modifying codons in a nucleic acid encoding a phosphatase.
[00108] The invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising (a) providing a nucleic acid of the invention; and, (b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a preferred or neutrally used codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell. [00109] The invention provides methods for modifying a codon in a nucleic acid encoding a phosphatase to decrease its expression in a host cell, the method comprising (a) providing a nucleic acid of the invention; and (b) identifying at least one preferred codon in the nucleic acid of step (a) and replacing it with a non-preferred or less preferred codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in a host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to decrease its expression in a host cell. The host cell can be a bacterial cell, a fungal cell, an insect cell, a yeast cell, a plant cell or a mammalian cell. [00110] The invention provides methods for producing a library of nucleic acids encoding a plurality of modified phosphatase active sites or substrate binding sites, wherein the modified active sites or substrate binding sites are derived from a first nucleic acid comprising a sequence encoding a first active site or a first substrate binding site the method comprising: (a) providing a first nucleic acid encoding a first active site or first substrate binding site, wherein the first nucleic acid sequence comprises a sequence that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having a sequence as set forth in SEQ ID NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ID NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ID NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO:54, or a subsequence thereof, and the nucleic acid encodes a phosphatase active site or a phosphatase substrate binding site; (b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and, (c) using the set of mutagenic oligonucleotides to generate a set of active site-encoding or substrate binding site-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized, thereby producing a library of nucleic acids encoding a plurality of modified phosphatase active sites or substrate binding sites. [00111] In one aspect, the method can comprise mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system, site-saturation mutagenesis (GSSM), synthetic ligation reassembly (SLR). En another aspect, the method can comprise mutagenizing the first nucleic acid of step (a) or variants by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, and a combination thereof. In one aspect, the method can comprise mutagenizing the first nucleic acid of step (a) or variants by a method comprising recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction- purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof.
[00112] The invention provides methods of making a small molecule comprising the steps of: (a) providing a plurality of biosynthetic enzymes capable of synthesizing or modifying a small molecule, wherein one of the enzymes comprises a phosphatase enzyme encoded by a nucleic acid of the invention; (b) providing a substrate for at least one of the enzymes of step (a); and (c) reacting the substrate of step (b) with the enzymes under conditions that facilitate a plurality of biocatalytic reactions to generate a small molecule by a series of biocatalytic reactions.
[00113] The invention provides method for modifying a small molecule comprising the steps: (a) providing a polypeptide of the invention, or, a polypeptide which is encoded by a nucleic acid of the invention; (b) providing a small molecule; and (c) reacting the polypeptide of step (a) with the small molecule of step (b) under conditions that facilitate an enzymatic reaction catalyzed by the phosphatase enzyme, thereby modifying a small molecule by a phosphatase enzymatic reaction. In one aspect, the method comprises a plurality of small molecule substrates for the enzyme of step (a), thereby generating a library of modified small molecules produced by at least one enzymatic reaction catalyzed by the phosphatase enzyme. In one aspect, the method can further comprise a plurality of additional enzymes under conditions that facilitate a plurality of biocatalytic reactions by the enzymes to form a library of modified small molecules produced by the plurality of enzymatic reactions. En another aspect, the method can comprise the step of testing the library to determine if a particular modified small molecule that exhibits a desired activity is present within the library. In one aspect, the step of testing the library further comprises the steps of systematically eliminating all but one of the biocatalytic reactions used to produce a portion of the plurality of the modified small molecules within the library by testing the portion of the modified small molecule for the presence or absence of the particular modified small molecule with a desired activity, and identifying at least one specific biocatalytic reaction that produces the particular modified small molecule of desired activity.
[00114] The invention provides methods for determining a functional fragment of a phosphatase enzyme comprising the steps of: (a) providing a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; and (b) deleting a plurality of amino acid residues from the sequence of step (a) and testing the remaining subsequence for a phosphatase activity, thereby determining a functional fragment of a phosphatase enzyme. In one aspect, the phosphatase activity is measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product. En one aspect, a decrease in the amount of an enzyme substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity.
[00115] The invention provides methods for whole cell engineering of new or modified phenotypes by using real-time metabolic flux analysis, the method comprising the following steps: (a) making a modified cell by modifying the genetic composition of a cell, wherein the genetic composition is modified by addition to the cell of a nucleic acid of the invention; (b) culturing the modified cell to generate a plurality of modified cells; (c) measuring at least one metabolic parameter of the cell by monitoring the cell culture of step (b) in real time; and, (d) analyzing the data of step (c) to determine if the measured parameter differs from a comparable measurement in an unmodified cell under similar conditions, thereby identifying an engineered phenotype in the cell using real-time metabolic flux analysis. In one aspect, the genetic composition of the cell is modified by a method comprising deletion of a sequence or modification of a sequence in the cell, or, knocking out the expression of a gene. En one aspect, the method can further comprise selecting a cell comprising a newly engineered phenotype. In another aspect, the method can comprise culturing the selected cell, thereby generating a new cell strain comprising a newly engineered phenotype.
[00116] The invention provides methods for inhibiting degradation of the cyclic nucleotides comprising the following steps: (a) providing a polypeptide liaving a phosphodiesterase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphodiesterase inhibitor; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the composition inhibits phosphodiesterase activity thereby inhibiting degradation of the cyclic nucleotides. In one aspect, the phosphodiesterase is cyclic AMP or cyclic GMP specific. [00117] The invention provides methods for removing a phosphate group comprising the following steps: (a) providing a polypeptide having a phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphate group; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphatase group.
[00118] The invention provides methods for hydrolysis of the phosphodiester bridges comprising the following steps: (a) providing a polypeptide having a phosphodiesterase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphodiester bridge; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the phosphodiester bridge. In one aspect, the composition comprising a phosphodiester bridge can be a nucleic acid. [00119] The invention provides methods for removal of phosphate comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a phosphate; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphate group. In one aspect, the composition is phytic acid. [00120] The invention provides methods for hydrolysis of monophosphate esters comprising the following steps: (a) providing a polypeptide having an alkaline phosphatase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a composition comprising a monophosphate ester; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the monophosphate esters. [00121] The invention provides methods of increasing thermotolerance or thermostability of a phosphatase polypeptide, the method comprising glycosylating a phosphatase polypeptide, wherein the polypeptide comprises at least thirty contiguous amino acids of a sequence of a polypeptide of the invention, or a polypeptide encoded by a nucleic acid of the invention, thereby increasing the thermotolerance or thermostability of the phosphatase polypeptide. En one aspect, the phosphatase specific activity can be thermostable or thermotolerant at a temperature in the range from greater than about 37°C to about 90°C.
[00122] The invention provides methods for overexpressing a recombinant phosphatase polypeptide in a cell comprising expressing a vector comprising a nucleic acid of the invention, e.g., a nucleic acid comprising a sequence having at least 50%> sequence identity to the nucleic acid of the invention over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection, wherein overexpression is effected by use of a high activity promoter, a dicistronic vector or by gene amplification of the vector. [00123 ] The invention provides methods for improving phosphate consumption in animals comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide is a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) ingesting the polypeptide of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization.
[00124] The invention provides methods for improving phosphate consumption in animals comprising the following steps: (a) providing a genetically engineered seed comprising a nucleic acid of the invention, wherein the nucleic acid encodes a polypeptide comprising a phytase activity; (b) ingesting the seeds of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization. In one aspect, the animals can be swine or poultry.
[00125] The invention provides methods for treating solid or liquid animal waste products comprising the following steps: (a) providing a polypeptide having a phytase activity, wherein the polypeptide comprises a polypeptide of the invention, or, a polypeptide encoded by a nucleic acid of the invention; (b) providing a solid or a liquid animal waste; and (c) contacting the polypeptide of step (a) and the solid or liquid waste of step (b) under conditions wherein the phytase can treat the waste.
[00126] The present invention provides nucleic acids (e.g., DNA) and amino acid sequence information and expression and purification protocols for thermostable phosphatases.
[00127] The invention provides an isolated nucleic acid having a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 and variants thereof having at least 50%> sequence identity to SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 and encoding polypeptides having phosphatase activity. One aspect of the invention is an isolated nucleic acid having a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53 (hereinafter referred to as "Group A nucleic acid sequences"), sequences substantially identical thereto, and sequences complementary thereto. Another aspect of the invention is an isolated nucleic acid including at least 10 consecutive bases of a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, and the sequences complementary thereto. In another aspect, the invention provides an isolated nucleic acid encoding a polypeptide having a sequence as set forth in SEQ ID NOs.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 44, 46, 48, 50, 52, 54, and variants thereof encoding a polypeptide having phosphatase activity and having at least 50% sequence identity to such sequences. Another aspect of the invention is an isolated nucleic acid encoding a polypeptide or a functional fragment thereof having a sequence as set forth in SEQ ID Nos.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 43, 44, 46, 47, 48, 50, 52, 54, (hereinafter referred to as "Group B amino acid sequences"), and sequences substantially identical thereto. Another aspect of the invention is an isolated nucleic acid encoding a polypeptide having at least 10 consecutive amino acids of a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. En another aspect, the invention provides a purified polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
[00128] Another aspect of the invention is an isolated or purified antibody that specifically binds to a polypeptide of the invention, e.g., a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is an isolated or purified antibody or binding fragment thereof, which specifically binds to a polypeptide having at least 10 consecutive amino acids of one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto.
[00129] Another aspect of the invention is a method of making a polypeptide of the invention, e.g., having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid.
[00130] Another aspect of the invention is a method of making a polypeptide having at least 10 amino acids of a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid, thereby producing the polypeptide.
[00131] Another aspect of the invention is a method of generating a variant including obtaining a nucleic acid having a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, sequences complementary to the sequences of Group A nucleic acid sequences, fragments comprising at least 30 consecutive nucleotides of the foregoing sequences, and changing one or more nucleotides in the sequence to another nucleotide, deleting one or more nucleotides in the sequence, or adding one or more nucleotides to the sequence. [00132] Another aspect of the invention is a computer readable medium having stored thereon a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer system including a processor and a data storage device wherein the data storage device has stored thereon a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a method for comparing a first sequence to a reference sequence wherein the first sequence is a nucleic acid having a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide of the invention, e.g., a code of Group B amino acid sequences, and sequences substantially identical thereto. The method includes reading the first sequence and the reference sequence through use of a computer program that compares sequences; and determining differences between the first sequence and the reference sequence with the computer program. Another aspect of the invention is a method for identifying a feature in a sequence of the invention, e.g., as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence of the invention, e.g., as set forth in Group B amino acid sequences, and sequences substantially identical thereto, including reading the sequence through the use of a computer program which identifies features in sequences; and identifying features in the sequence with the computer program. [00133] Another aspect of the invention is an assay for identifying fragments or variants of polypeptides of the invention, e.g., of Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of the polypeptides of the invention, e.g., of Group B amino acid sequences, and sequences substantially identical thereto. The assay includes contacting the polypeptide of the invention, e.g., of Group B amino acid sequences, sequences substantially identical thereto, or polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate thereby identifying a fragment or variant of such sequences.
[00134] The details of one or more aspects of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[00135] All publications, patents, patent applications, GenBank sequences and ATCC deposits, cited herein are hereby expressly incoφorated by reference for all puφoses.
DESCRIPTION OF DRAWINGS
[00136] The following drawings are illustrative of aspects of the invention and are not meant to limit the scope of the invention as encompassed by the claims.
[00137] Figure 1 is a block diagram of a computer system.
[00138] Figure 2 is a flow diagram illustrating one aspect of a process for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.
[00139] Figure 3 is a flow diagram illustrating one aspect of a process in a computer for determining whether two sequences are homologous.
[00140] Figure 4 is a flow diagram illustrating one aspect of an identifier process 300 for detecting the presence of a feature in a sequence.
[00141] Figure 5 is an illustration of an exemplary sequence of the invention, a full- length DNA and corresponding deduced amino acid sequence of isolated Ammonifex degensii KC4 of the present invention. Sequencing was performed using a 378 automated DNA sequence for all sequences of the present invention (Applied Biosystems, Inc. Foster City, California).
[00142] Figure 6 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Methanococcus igneus Kol5.
[00143] Figure 7 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus alcaliphilus AEDII12RA. [00144] Figure 8 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus celer.
[00145] Figures 9A and 9B are an illustration of an exemplary sequence of the invention, the full-length DNA and corresponding deduced amino acid sequence of isolated Thermococcus GU5L5.
[00146] Figures 10A and 10B are an illustration of an exemplary sequence of the invention, the full-length DNA and corresponding deduced amino acid sequence of isolated OC9a.
[00147] Figure 11 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Ml 1TL.
[00148] Figure 12 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Thermococcus CL- 2.
[00149] Figure 13 is an illustration of an exemplary sequence of the invention, the full- length DNA and corresponding deduced amino acid sequence of isolated Aquifex VF-5.
[00150] Like reference symbols in the various drawings indicate like elements.
DETAILED DESCRIPTION
[ 00151 ] The invention provides enzymes having various phosphatase activities, such as thermostable phosphatase activities, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The phosphatase activity of the enzymes of the invention include the enzymatic removal of phosphate groups from organophosphate ester compounds and hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA. Definitions
[ 00152 ] The present invention provides phosphatases, polynucleotides encoding them, antibodies that bind to them and methods for making and using these compositions. As used herein, the term "phosphatase" encompasses all enzymes having any phosphatase activity as described herein, such as the enzymatic removal of phosphate groups from organophosphate ester compounds, or, hydrolyzing nucleic acids by hydrolyzing the phosphodiester bridges of DNA and RNA; including any hydrolase activity, for example, including enzymes capable of hydrolyzing glycosidic linkages present in starch. [00153] The term "antibody" includes a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope, see, e.g. Fundamental Immunology, Third Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994) J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., "antigen binding sites," (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341 : 544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term "antibody."
[00154] The terms "aπay" or "microarray" or "biochip" or "chip" as used herein is a plurality of target elements, each target element comprising a defined amount of one or more polypeptides (including antibodies) or nucleic acids immobilized onto a defined area of a substrate surface.
[00155] As used herein, the terms "computer," "computer program" and "processor" are used in their broadest general contexts and incoφorate all such devices. [00156] The term "expression cassette" as used herein refers to a nucleotide sequence which is capable of affecting expression of a structural gene (i.e., a protein coding sequence, such as a phosphatase of the invention) in a host compatible with such sequences. Expression cassettes include at least a promoter operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used, e.g., enhancers. "Operably linked" as used herein refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence. Thus, expression cassettes also include plasmids, expression vectors, recombinant viruses, any form of recombinant "naked DNA" vector, and the like. A "vector" comprises a nucleic acid that can infect, transfect, and transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid. The vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.). Vectors include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated. Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Patent No. 5,217,879), and includes both the expression and non-expression plasmids. Where a recombinant microorganism or cell culture is described as hosting an "expression vector" this includes both extra-chromosomal circular and linear DNA and DNA that has been incoφorated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incoφorated within the host's genome. [00157] The phrases "nucleic acid" or "nucleic acid sequence" as used herein refer to an oligonucleotide, nucleotide, polynucleotide, or to a fragment of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin, including, e.g., iRNA, ribonucleoproteins (e.g., iRNPs). The term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides. The term also encompasses nucleic- acid-like structures with synthetic backbones, see e.g., Mata (1997) Toxicol. Appl. Pharmacol. 144:189-197; Strauss-Soukup (1997) Biochemistry 36:8692-8698; Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156. The phrases "nucleic acid" or "nucleic acid sequence" as used herein include oligonucleotides, nucleotides, polynucleotides and to fragments of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin. [00158] A "coding sequence of ' or a "nucleotide sequence encoding" a particular polypeptide or protein, is a nucleic acid sequence which is transcribed and translated into a polypeptide or protein when placed under the control of appropriate regulatory sequences. [00159] The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as, where applicable, intervening sequences (introns) between individual coding segments (exons).
[00160] "Amino acid" or "amino acid sequence" as used herein refer to an oligopeptide, peptide, polypeptide, or protein sequence, or to a fragment, portion, or subunit of any of these, and to naturally occurring or synthetic molecules.
[00161] The term "polypeptide" as used herein, refers to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also a given polypeptide may have many types of modifications. Modifications include acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphytidylinositol, cross-linking cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation. (See Creighton, T.E., Proteins - Structure and Molecular Properties 2nd Ed., W.H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B.C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983)).
[00162] As used herein, the term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual nucleic acids obtained from a library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The purified nucleic acids of the invention have been purified from the remainder of the genomic DNA in the organism by at least 104-106 fold. However, the term "purified" also includes nucleic acids that have been purified from the remainder of the genomic DNA or from other sequences in a library or other environment by at least one order of magnitude, typically two or three orders, and more typically four or five orders of magnitude.
[00163 ] As used herein, the term "recombinant" means that the nucleic acid is adjacent to a "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the nucleic acids will represent 5%> or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. In one aspect, the enriched nucleic acids represent 15%> or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. En one aspect, the enriched nucleic acids represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In one aspect, the enriched nucleic acids represent 90%> or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. [00164] "Recombinant" polypeptides or proteins refer to polypeptides or proteins produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide or protein. "Synthetic" polypeptides or protein are those prepared by chemical synthesis. Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art since the early 1960's (Merrifield, R. B., J. Am. Chem. Soc, 85:2149-2154, 1963) (See also Stewart, J. M. and Young, J. D., Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, 111., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research Biochemicals). Such commercially available laboratory kits have generally utilized the teachings of H. M. Geysen et al, Proc. Natl. Acad. Sci., USA, 81:3998 (1984) and provide for synthesizing peptides upon the tips of a multitude of "rods" or "pins" all of which are connected to a single plate. When such a system is utilized, a plate of rods or pins is inverted and inserted into a second plate of corresponding wells or reservoirs, which contain solutions for attaching or anchoring an appropriate amino acid to the pin's or rod's tips. By repeating such a process step, i.e., inverting and inserting the rod's and pin's tips into appropriate solutions, amino acids are built into desired peptides. In addition, a number of available FMOC peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431 A automated peptide synthesizer. Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.
[00165] A promoter sequence is "operably linked to" a coding sequence when RNA polymerase which initiates transcription at the promoter will transcribe the coding sequence into mRNA.
[00166] "Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical puφoses, typically 1 mg of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ml of buffer solution. For the puφose of isolating DNA fragments for plasmid construction, typically 5 to 50 mg of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion, gel electrophoresis may be performed to isolate the desired fragment.
[00167] "Oligonucleotide" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.
[00168] The phrase "substantially identical" in the context of two nucleic acids or polypeptides, refers to two or more sequences that have at least 50%>, 60%, 70%>, 80%, and in some aspects 90-95 %>, or more, nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the known sequence comparison algorithms or by visual inspection. In one aspect, the substantial identity exists over a region of at least about 100 residues, and most commonly the sequences are substantially identical over at least about 150-200 residues. In one aspect, the sequences are substantially identical over the entire length of the coding regions. Additionally a "substantially identical" amino acid sequence is a sequence that differs from a reference sequence by one or more conservative or non-conservative amino acid substitutions, deletions, or insertions, particularly when such a substitution occurs at a site that is not the active site of the molecule, and provided that the polypeptide essentially retains its functional properties. A conservative amino acid substitution, for example, substitutes one amino acid for another of the same class (e.g., substitution of one hydrophobic amino acid, such as isoleucine, valine, leucine, or methionine, for another, or substitution of one polar amino acid for another, such as substitution of arginine for lysine, glutamic acid for aspartic acid or glutamine for asparagine). One or more amino acids can be deleted, for example, from a phosphatase polypeptide, resulting in modification of the structure of the polypeptide, without significantly altering its biological activity. For example, amino- or carboxyl- terminal amino acids that are not required for phosphatase biological activity can be removed. Modified polypeptide sequences of the invention can be assayed for phosphatase biological activity by any number of methods, including contacting the modified polypeptide sequence with a phosphatase substrate and determining whether the modified polypeptide decreases the amount of specific substrate in the assay or increases the bioproducts of the enzymatic reaction of a functional phosphatase polypeptide with the substrate.
[00169] "Fragments" as used herein are a portion of a naturally occurring protein which can exist in at least two different conformations. Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. "Substantially the same" means that an amino acid sequence is largely, but not entirely, the same, but retains at least one functional activity of the sequence to which it is related. In general two amino acid sequences are "substantially the same" or "substantially homologous" if they are at least about 85%> identical. Fragments which have different three dimensional structures as the naturally occurring protein are also included. An example of this, is a "pro-form" molecule, such as a low activity proprotein that can be modified by cleavage to produce a mature enzyme with significantly higher activity.
[00170] "Hybridization" refers to the process by which a nucleic acid strand joins with a complementary strand through base pairing. Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.
[00171] For example, hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C. Hybridization could occur under reduced stringency conditions in about 35%) to 25%) formamide at about 30°C to 35°C. In particular, hybridization could occur under high stringency conditions at 42°C in 50%) formamide, 5X SSPE, 0.3%) SDS, and 200 n/ml sheared and denatured salmon sperm DNA. Hybridization could occur under reduced stringency conditions as described above, but in 35%> formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.
[00172] The term "variant" refers to polynucleotides or polypeptides of the invention modified at one or more base pairs, codons, introns, exons, or amino acid residues (respectively) yet still retain the biological activity of a phosphatase of the invention. Variants can be produced by any number of means included methods such as, for example, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof.
[00173] The term "saturation mutagenesis" or "GSSM" includes a method that uses degenerate oligonucleotide primers to introduce point mutations into a polynucleotide, as described in detail, below.
[00174] The term "optimized directed evolution system" or "optimized directed evolution" includes a method for reassembling fragments of related nucleic acid sequences, e.g., related genes, and explained in detail, below.
[00175] The term "synthetic ligation reassembly" or "SLR" includes a method of ligating oligonucleotide fragments in a non-stochastic fashion, and explained in detail, below.
[00176] The terms "thermostable" and "thermostability" as used herein with reference to an enzyme mean the ability of the enzyme to function at increased temperatures, for example to have comparable specific activity at 70°C and at 85°C at a common pH. A "thermostable" enzyme will maintain much or all of its activity at an increased temperature or may be more active at an increased temperature than at its normal temperature (e.g., room temperature) or its optimum temperature prior to mutagenesis to obtain enhanced thermostability.
[00177] The terms "thermotolerant" and "thermotolerance" as used herein with reference to an enzyme mean the ability of the enzyme to function normally after exposure to high temperature, even though the high temperature may temporarily deactivate the enzyme. Generating and Manipulating Nucleic Acids
[00178] The invention provides nucleic acids, including expression cassettes such as expression vectors, encoding the polypeptides and phosphatases of the invention. The invention also includes methods for discovering new phosphatase sequences using the nucleic acids of the invention. Also provided are methods for modifying the nucleic acids of the invention by, e.g., synthetic ligation reassembly, optimized directed evolution system and/or saturation mutagenesis.
[00179] The nucleic acids of the invention can be made, isolated and/or manipulated by, e.g., cloning and expression of cDNA libraries, amplification of message or genomic DNA by PCR, and the like. In practicing the methods of the invention, homologous genes can be modified by manipulating a template nucleic acid, as described herein. The invention can be practiced in conjunction with any method or protocol or device known in the art, which are well described in the scientific and patent literature.
[00180] As used herein the term "nucleic acid sequence as set forth in SEQ ED Nos. : 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51 and 53 " encompasses the nucleotide sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, as well as sequences homologous to Group A nucleic acid sequences, and fragments thereof and sequences complementary to all of the preceding sequences. The fragments include portions of SEQ ID Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51 and 53 comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto. Homologous sequences and fragments of Group A nucleic acid sequences, and sequences substantially identical thereto, refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%,or 50%) homology to these sequences. Homology may be determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters. Homologous sequences also include RNA sequences in which uridines replace the thymines in the nucleic acid sequences as set forth in the Group A nucleic acid sequences. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error. It will be appreciated that the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format (See, e.g., the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which records the identity of the nucleotides in a sequence.
[00181] In another aspect, the invention provides an isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of the Group B amino acid sequences. The coding sequences of these nucleic acids may be identical to one of the coding sequences of one of the nucleic acids of Group A nucleic acid sequences, or a fragment thereof or may be different coding sequences which encode one of the polypeptides of Group B amino acid sequences, sequences substantially identical thereto, and fragments having at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, as a result of the redundancy or degeneracy of the genetic code. The genetic code is well known to those of skill in the art and can be obtained, for example, on page 214 of B. Lewin, Genes VI, Oxford University Press, 1997.
[00182] The isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, may include, but is not limited to: only the coding sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, and additional coding sequences, such as leader sequences or proprotein sequences and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence. Thus, as used herein, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only the coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
[00183] Alternatively, the nucleic acid sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, may be mutagenized using conventional techniques, such as site directed mutagenesis, or other techniques familiar to those skilled in the art, to introduce silent changes into the polynucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto. As used herein, "silent changes" include, for example, changes which do not alter the amino acid sequence encoded by the polynucleotide. Such changes may be desirable in order to increase the level of the polypeptide produced by host cells containing a vector encoding the polypeptide by introducing codons or codon pairs which occur frequently in the host organism.
[00184] The invention also relates to polynucleotides which have nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. Such nucleotide changes may be introduced using techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion, and other recombinant DNA techniques. Alternatively, such nucleotide changes may be naturally occurring allelic variants which are isolated by identifying nucleic acids which specifically hybridize to probes comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto (or the sequences complementary thereto) under conditions of high, moderate, or low stringency as provided herein.
[00185] One aspect of the invention is an isolated nucleic acid comprising one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of a Group A nucleic acid sequence (or the sequences complementary thereto). The isolated, nucleic acids may comprise DNA, including cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. Alternatively, the isolated nucleic acids may comprise RNA. General Techniques
[00186] The nucleic acids used to practice this invention, whether RNA, iRNA, antisense nucleic acid, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/ generated recombinantly. Recombinant polypeptides generated from these nucleic acids can be individually isolated or cloned and tested for a desired activity. Any recombinant expression system can be used, including bacterial, mammalian, yeast, and insect or plant cell expression systems.
[00187] Alternatively, these nucleic acids can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Patent No. 4,458,066.
[00188] Techniques for the manipulation of nucleic acids, such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).
[00189] Another useful means of obtaining and manipulating nucleic acids used to practice the methods of the invention is to clone from genomic samples, and, if desired, screen and re-clone inserts isolated or amplified from, e.g., genomic clones or cDNA clones. Sources of nucleic acid used in the methods of the invention include genomic or cDNA libraries contained in, e.g., mammalian artificial chromosomes (MACs), see, e.g., U.S. Patent Nos. 5,721,118; 6,025,155; human artificial chromosomes, see, e.g., Rosenfeld (1997) Nat. Genet. 15:333-335; yeast artificial chromosomes (YAC); bacterial artificial chromosomes (BAC); PI artificial chromosomes, see, e.g., Woon (1998) Genomics 50:306-316; Pl-derived vectors (PACs), see, e.g., Kern (1997) Biotechniques 23:120-124; cosmids, recombinant viruses, phages or plasmids.
Transcriptional and translational control sequences
[00190] The nucleic acid sequences of the invention can further comprise transcriptional and translational control elements, e.g., promoters, suitable for expressing the polypeptide or fragment thereof in any cell, e.g., a bacteria, e.g., E. coli. [00191] Promoters suitable for expressing the polypeptide or fragment thereof in bacteria include the E. coli lac or tφ promoters, the lad promoter, the lacZ promoter, the T3 promoter, the T7 promoter, the gpt promoter, the lambda PR promoter, the lambda PL promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter. Fungal promoters include the " factor promoter. Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses may also be used.
Expression vectors and cloning vehicles
[00192] The invention provides expression cassettes and vectors, e.g., expression vectors and cloning vehicles comprising the nucleic acids of the invention. Exemplary expression vectors include viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g., vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), PI -based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, Aspergillus and yeast). Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (lambda-ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXTl, pSG5 (Stratagene), pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or other vector may be used so long as they are replicable and viable in the host. Low copy number or high copy number vectors may be employed with the present invention.
[00193] DNA sequences in the expression vector can be operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis. Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda PR, Pi and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers. In addition, the expression vectors can contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
[00194] Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers. In addition, the expression vectors typically contain one or more selectable marker genes to permit selection of host cells containing the vector. Such selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in E. coli, and the S. cerevisiae TRP1 gene. [00195] The appropriate DNA sequence may be inserted into the vector by a variety of procedures. En general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, blunt ends in both the insert and the vector may be ligated. A variety of cloning techniques are disclosed in Ausubel et al. Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory Press (1989). Such procedures and others are deemed to be within the scope of those skilled in the art.
[00196] The vector may be, for example, in the form of a plasmid, a viral particle, or a phage. Other vectors include chromosomal, nonchromosomal and synthetic DNA sequences, derivatives of SV40; bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. A variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, N.Y., (1989). [00197] Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), GEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pDIO, psiX174 pBluescript II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7. Particular eukaryotic vectors include pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other vector may be used as long as it is replicable and viable in the host cell.
[00198] The vector may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Particular m'ethods include, e.g., calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)). Host cells and transformed cells
[00199] The invention provides cells comprising a polypeptide or a nucleic acid of the invention. The host cell may be any cell, including prokaryotic cells, eukaryotic cells, mammalian cells, insect cells and plant cells. Polynucleotides of the invention can be introduced into a suitable host cell by any means.
[00200] The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, mammalian cells, insect cells, or plant cells. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, fungal cells, such as yeast, insect cells such as Drosophila S2 and Spodoptera Sf9, animal cells such as CHO, COS or Bowes melanoma, and adenoviruses. The selection of an appropriate host is within the abilities of those skilled in the art.
[00201] Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.
[00202] Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification. Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art. The expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.
[00203] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts (described by Gluzman, Cell, 23:175, 1981), and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines.
[00204] The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Depending upon the host employed in a recombinant production procedure, the polypeptides produced by host cells containing the vector may be glycosylated or may be non-glycosylated. Polypeptides of the mvention may or may not also include an initial methionine amino acid residue. [00205] Polynucleotides selected and isolated as hereinabove described are introduced into a suitable host cell. A suitable host cell is any cell which is capable of promoting recombination and/or reductive reassortment. The selected polynucleotides can already be in a vector which includes appropriate control sequences. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or, the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis et al, 1986).
[00206] With particular references to various mammalian cell culture systems that can be employed to express recombinant protein, examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described in "SV40-transformed simian cells support the replication of early SV40 mutants" (Gluzman, 1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.
[00207] Host cells containing the polynucleotides of interest can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The clones which are identified as having the specified enzyme activity may then be sequenced to identify the polynucleotide sequence encoding an enzyme having the enhanced activity. Amplification of Nucleic Acids
[00208] In practicing the invention, nucleic acids encoding the polypeptides of the invention, or modified nucleic acids, can be reproduced by, e.g., amplification. The invention provides amplification primer sequence pairs for amplifying nucleic acids encoding polypeptides with a phosphatase activity, where the primer pairs are capable of amplifying nucleic acid sequences including the exemplary nucleic acids of the invention, or a subsequence thereof. One of skill in the art can design amplification primer sequence pairs for any part of or the full length of these sequences.
[00209] Amplification reactions can also be used to quantify the amount of nucleic acid in a sample (such as the amount of message in a cell sample), label the nucleic acid (e.g., to apply it to an array or a blot), detect the nucleic acid, or quantify the amount of a specific nucleic acid in a sample. In one aspect of the invention, message isolated from a cell or a cDNA library are amplified. The skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (see, e.g., PCR PROTOCOLS, A GUEDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Lnnis, Academic Press, Inc., N.Y., ligase chain reaction (LCR) (see, e.g., Wu (1989) Genomics 4:560; Landegren (1988) Science 241 :1077; Barringer (1990) Gene 89:117); transcription amplification (see, e.g., Kwoh (1989) Proc. Natl. Acad. Sci. USA 86:1173); and, self-sustained sequence replication (see, e.g., Guatelli (1990) Proc. Natl. Acad. Sci. USA 87:1874); Q Beta replicase amplification (see, e.g., Smith (1997) J. Clin. Microbiol. 35:1477-1491), automated Q-beta replicase amplification assay (see, e.g., Burg (1996) Mol. Cell. Probes 10:257-271) and other RNA polymerase mediated techniques (e.g., NASBA, Cangene, Mississauga, Ontario); see also Berger (1987) Methods Enzymol. 152:307-316; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan (1995) Biotechnology 13:563-564.
[00210] PCR protocols are described in Ausubel and Sambrook. Alternatively, the amplification may comprise a ligase chain reaction, 3SR, or strand displacement reaction. (See Barany, F., "The Ligase Chain Reaction in a PCR World", PCR Methods and Applications 1:5- 16, 1991; E. Fahy et al, "Self-sustained Sequence Replication (3SR): An Isothermal Transcription-based Amplification System Alternative to PCR", PCR Methods and Applications 1:25-33, 1991; and Walker G.T. et al, "Strand Displacement Amplification-an Isothermal in vitro DNA Amplification Technique", Nucleic Acid Research 20:1691-1696, 1992). En such procedures, the nucleic acids in the sample are contacted with the probes, the amplification reaction is performed, and any resulting amplification product is detected. The amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide. Alternatively, one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product maybe detected by autoradiography after gel electrophoresis. Determining the degree of sequence identity
[00211] The invention provides an isolated or recombinant nucleic acids comprising a nucleic acid sequence having at least 50%> to about 99%> or more sequence identity to SEQ ID NOs:19 to 27, SEQ ED NOs:37 to 40, SEQ ED NO:41, SEQ ED NO:43, SEQ ED NO:45, SEQ ED NO:47, SEQ ED NO:49, SEQ ED NO:51, and SEQ ED NO:53, over a region of at least about 100 residues to the full length of the coding sequence. The invention provides an isolated or recombinant polypeptides having at least 50%> to about 99% or more sequence identity to SEQ ID NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54, over a region of at least about 100 residues to the full length of the protein.
[00212] Protein and/or nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-2448, 1988; Altschul et al, J. Mol. Biol. 2_15(3):403-410, 1990; Thompson et al, Nucleic Acids Res. 22(2):4673-4680, 1994; Higgins et al, Methods Enzymol. 266:383-402. 1996; Altschul et al, J. Mol. Biol. 215(3):403-410, 1990; Altschul et al, Nature Genetics 3:266-272, 1993).
[00213 ] Homology or identity is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various deletions, substitutions and other modifications. The terms "homology" and "identity" in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or designated region as measured using any number of sequence comparison algorithms or by manual alignment and visual inspection. [00214] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. [00215] A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol 48:443, 1970, by the search for similarity method of person & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection. Other algorithms for determining homology or identity include, for example, in addition to a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLocks EMProved Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith- Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GEBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi- sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-EF. Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences. A number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (Gibbs, 1995). At least twenty-one other genomes have already been sequenced, including, for example, M. genitalium (Fraser et al, 1995), M. jannaschii (Bult et al, 1996), H. influenzae (Fleischmann et al, 1995), E. coli (Blattner et al, 1997), and yeast (S. cerevisiae) (Mewes et al, 1997), and ). melanogaster (Adams et al, 2000). Significant progress has also been made in sequencing the genomes of model organism, such as mouse, C. elegans, and Arabadopsis sp. Several databases containing genomic information annotated with some functional information are maintained by different organization, and are accessible via the internet.
[00216] One example of a useful algorithm is BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402, 1977, and Altschul et al, J. Mol. Biol. 215:403-410, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is refened to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N—4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectations (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, M=5, N= -4, and a comparison of both strands. [00217] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873, 1993). One measure of similarity provided by BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a references sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, or, less than about 0.01, or, less than about 0.001.
[00218] In one aspect, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") In particular, five specific BLAST programs are used to perform the following task: [00219] (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;
[00220] (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;
[00221] (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; [00222] (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and [00223] (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database. [00224] The BLAST programs identify homologous sequences by identifying similar segments, which are refened to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which can be obtained from a protein or nucleic acid sequence database. High-scoring segment pairs can be identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. The scoring matrix used can be the BLOSUM62 matrix (Gonnet et al, Science 256:1443-1445, 1992; Henikoff and Henikoff, Proteins 17:49-61, 1993). The PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation). BLAST programs are accessible through the U.S. National Library of Medicine.
[00225] The parameters used with the above algorithms may be adapted depending on the sequence length and degree of homology studied. In some aspects, the parameters may be the default parameters used by the algorithms in the absence of instructions from the user. Computer systems and computer program products
[00226] To determine and identify sequence identities, structural homologies, motifs and the like in silico the sequences of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. Accordingly, the invention provides computers, computer systems, computer readable mediums, computer programs products and the like recorded or stored thereon the nucleic acid and polypeptide sequences of the invention, e.g., the exemplary sequences of the invention. The sequences of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto. [00227] Another aspect of the invention is a computer readable medium having recorded thereon one or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 of the sequences as set forth above. Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.
[00228] Aspects of the invention include systems (e.g. , internet based systems), particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 1. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze a nucleotide sequence of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in the Group B amino acid sequences. The computer system 100 typically includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as, for example, the Pentium III from Intel Coφoration, or similar processor from Sun, Motorola, Compaq, AMD or International Business Machines.
[00229] Typically the computer system 100 is a general puφose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the cunently available computer systems are suitable.
[00230] In one aspect, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (can be implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some aspects, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.
[00231] The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, or a modem capable of connection to a remote data storage system (e.g. , via the internet) etc. In some aspects, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device. The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.
[00232] Software for accessing and processing the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution. [00233 ] In some aspects, the computer system 100 may further comprise a sequence comparison algorithm for comparing a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, stored on a computer readable medium to a reference nucleotide or polypeptide sequence(s) stored on a computer readable medium. A "sequence comparison algorithm" refers to one or more programs which are implemented (locally or remotely) on the computer system 100 to compare a nucleotide sequence with other nucleotide sequences and/or compounds stored within a data storage means. For example, the sequence comparison algorithm may compare the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies or structural motifs. Various sequence comparison programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.
[00234] Figure 2 is a flow diagram illustrating one aspect of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK that is available through the Internet. The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device. The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system. Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200. If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database. It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.
[00235] Accordingly, one aspect of the invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described nucleic acid code of Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some aspects, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
[00236] Another aspect of the invention is a method for determining the level of homology between a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a reference nucleotide sequence. The method including reading the nucleic acid code or the polypeptide code and the reference nucleotide or polypeptide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code or polypeptide code and the reference nucleotide or polypeptide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, (e.g., BLAST2N with the default parameters or with any modified parameters). The method may be implemented using the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the above described nucleic acid sequences as set forth in the Group A nucleic acid sequences, or the polypeptide sequences as set forth in the Group B amino acid sequences through use of the computer program and determining homology between the nucleic acid codes or polypeptide codes and reference nucleotide sequences or polypeptide sequences.
[00237] Figure 3 is a flow diagram illustrating one aspect of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it can be in the single letter amino acid code so that the first and sequence sequences can be easily compared.
[00238] A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read. If there are not any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%>.
[00239] Alternatively, the computer program may be a computer program which compares the nucleotide sequences of a nucleic acid sequence as set forth in the invention, to one or more reference nucleotide sequences in order to determine whether the nucleic acid code of Group A nucleic acid sequences, and sequences substantially identical thereto, differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto. In one aspect, the computer program may be a program which determines whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, contains a single nucleotide polymoφhism (SNP) with respect to a reference nucleotide sequence. [00240] Another aspect of the invention is a method for determining whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some aspects, the computer program is a program which identifies single nucleotide polymoφhisms. The method may be implemented by the computer systems described above and the method illustrated in Figure 3. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.
[00241] In other aspects the computer based system may further comprise an identifier for identifying features within a nucleic acid sequence as set forth in the Group A nucleic acid sequences or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. An "identifier" refers to one or more programs which identifies certain features within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. In one aspect, the identifier may comprise a program which identifies an open reading frame in a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.
[00242] Figure 5 is a flow diagram illustrating one aspect of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG". Another example would be the feature name "TAATAA Box" and the feature attribute would be "TAATAA". An example of such a database is produced by the University of Wisconsin Genetics Computer Group. Alternatively, the features may be structural polypeptide motifs such as alpha helices, beta sheets, or functional polypeptide motifs such as enzymatic active sites, helix-turn-helix motifs or other motifs known to those skilled in the art. [00243] Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user. The process 300 then moves to a decision state 320 wherein a determination is made whether move features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence. It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.
[00244] Another aspect of the invention is a method of identifying a feature within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, comprising reading the nucleic acid code(s) or polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) with the computer program. In one aspect, computer program comprises a computer program which identifies open reading frames. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 40 of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto, through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.
[00245] A nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparison algorithms, identifiers, or sources of reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.
[00246] The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, J. Mol. Biol. 2L5: 403, 1990), FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444, 1988), FASTDB (Brutlag et al Comp. App. Biosci. 6:237-245, 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius2.DB Access (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Enc), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure. [00247] Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.
Hybridization of nucleic acids
[00248] The invention provides isolated or recombinant nucleic acids that hybridize under stringent conditions to an exemplary sequence of the invention, e.g., a sequence as set forth in SEQ ID NOs:19 to 27, SEQ ED NOs:37 to 40, SEQ ED NO:41, SEQ ED NO:43, SEQ ED NO:45, SEQ ED NO:47, SEQ ED NO:49, SEQ ED NO:51, and SEQ ED NO:53, or a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ED NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54. The stringent conditions can be highly stringent conditions, medium stringent conditions, low stringent conditions, including the high and reduced stringency conditions described herein.
[00249] In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.
[00250] Hybridization may be carried out under conditions of low stringency, moderate stringency or high stringency. As an example of nucleic acid hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45 DC in a solution consisting of 0.9 M NaCl, 50 mM NaH2PO4, pH 7.0, 5.0 mM Na2EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid. Approximately 2 X 107 cpm (specific activity 4-9 X 108 cpm/ug) of 32P end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in IX SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na2EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh IX SET at Tm-10DC for the oligonucleotide probe. The membrane is then exposed to auto-radiographic film for detection of hybridization signals. [00251] By varying the stringency of the hybridization conditions used to identify nucleic acids, such as cDNAs or genomic DNAs, which hybridize to the detectable probe, nucleic acids having different levels of homology to the probe can be identified and isolated. Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes. The melting temperature, Tm, is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly complementary probe. Very stringent conditions are selected to be equal to or about 5°C lower than the Tm for a particular probe. The melting temperature of the probe may be calculated using the following formulas: For probes between 14 and 70 nucleotides in length the melting temperature (Tm) is calculated using the formula: Tm=81.5+16.6(log [Na+])+0.41 (fraction G+C)-(600/N) where N is the length of the probe. [00252] If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation: Tm=81.5+16.6(log [Na+])+0.41 (fraction G+C)-(0.63%> formamide)-(600/N) where N is the length of the probe. [00253] Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5%> SDS, lOODg denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5%) SDS, lOODg denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook. [00254] Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25 DC below the Tm. For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 5-10DC below the Tm. Typically, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68 DC. Usually, for hybridizations in 50%) formamide containing solutions, the hybridization is conducted at approximately 42 DC.
[00255] All of the foregoing hybridizations would be considered to be under conditions of high stringency.
[00256] Following hybridization, the filter is washed to remove any non-specifically bound detectable probe. The stringency used to wash the filters can also be varied depending on the nature of the nucleic acids being hybridized, the length of the nucleic acids being hybridized, the degree of complementarity, the nucleotide sequence composition (e.g., GC v. AT content), and the nucleic acid type (e.g., RNA v. DNA). Examples of progressively higher stringency condition washes are as follows: 2X SSC, 0.1% SDS at room temperature for 15 minutes (low stringency); 0.1X SSC, 0.5%> SDS at room temperature for 30 minutes to 1 hour (moderate stringency); 0.1X SSC, 0.5%> SDS for 15 to 30 minutes at between the hybridization temperature and 68°C (high stringency); and 0.15M NaCl for 15 minutes at 72°C (very high stringency). A final low stringency wash can be conducted in 0. IX SSC at room temperature. The examples above are merely illustrative of one set of conditions that can be used to wash filters. One of skill in the art would know that there are numerous recipes for different stringency washes. Some other examples are given below. [00257] Nucleic acids which have hybridized to the probe are identified by autoradiography or other conventional techniques.
[00258] The above procedure may be modified to identify nucleic acids having decreasing levels of homology to the probe sequence. For example, to obtain nucleic acids of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5DC from 68 DC to 42 DC in a hybridization buffer having a Na+ concentration of approximately 1M. Following hybridization, the filter maybe washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate" conditions above 50DC and "low" conditions below 50DC. A specific example of "moderate" hybridization conditions is when the above hybridization is conducted at 55 DC. A specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 45 DC.
[00259] Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5%> increments from 50%> to 0%> to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide. A specific example of "moderate" hybridization conditions is when the above hybridization is conducted at 30% formamide. A specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 10% formamide. [00260] For example, the preceding methods may be used to isolate nucleic acids having a sequence with at least about 97%>, at least 95%>, at least 90%, at least 85%, at least 80%), at least 75%, at least 70%, at least 65%>, at least 60%, at least 55%, or at least 50% homology to a nucleic acid sequence selected from the group consisting of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. Homology may be measured using the alignment algorithm. For example, the homologous polynucleotides may have a coding sequence which is a naturally occurring allelic variant of one of the coding sequences described herein. Such allelic variants may have a substitution, deletion or addition of one or more nucleotides when compared to the nucleic acids of Group A nucleic acid sequences or the sequences complementary thereto.
[00261] Additionally, the above procedures may be used to isolate nucleic acids which encode polypeptides having at least about 99%, 95%, at least 90%>, at least 85%, at least 80%), at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, or at least 50%> homology to a polypeptide having the sequence of one of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using a sequence alignment algorithm (e.g., such as the FASTA version 3.0t78 algorithm with the default parameters).
[00262] The selection of a hybridization format is not critical, as is known in the art, it is the stringency of the wash conditions that set forth the conditions which determine whether a nucleic acid is within the scope of the invention. Wash conditions used to identify nucleic acids within the scope of the invention include, e.g.: a salt concentration of about 0.02 molar at pH 7 and a temperature of at least about 50°C or about 55°C to about 60°C; or, a salt concentration of about 0.15 M NaCl at 72°C for about 15 minutes; or, a salt concentration of about 0.2X SSC at a temperature of at least about 50°C or about 55°C to about 60°C for about 15 to about 20 minutes; or, the hybridization complex is washed twice with a solution with a salt concentration of about 2X SSC containing 0.1 %> SDS at room temperature for 15 minutes and then washed twice by 0.1X SSC containing 0.1%> SDS at 68oC for 15 minutes; or, equivalent conditions. Stringent conditions for washing can also be 0.2 X SSC/0.1%> SDS at 420C. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("oligos"), stringent conditions can include washing in 6X SSC/0.05% sodium pyrophosphate at 37EC (for 14_base oligos), 48EC (for 17-base oligos), 55EC (for 20-base oligos), and 60EC (for 23-base oligos). See Sambrook, ed., MOLECULAR CLONENG: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS EN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997),or Tijssen (1993) supra, for detailed descriptions of equivalent hybridization and wash conditions and for reagents and buffers, e.g., SSC buffers and equivalent reagents and conditions. Oligonucleotides probes and methods for using them
[00263] The invention also provides nucleic acid probes for identifying and isolating nucleic acids of the invention and nucleic acids encoding a polypeptide of the invention. The nucleic acid sequences of the invention can be used as probes to determine whether a biological sample, such as a soil sample, contains an organism having a nucleic acid sequence of the invention or an organism from which the nucleic acid was obtained. In such procedures, a biological sample potentially harboring the organism from which the nucleic acid was isolated is obtained and nucleic acids are obtained from the sample. The nucleic acids are contacted with the probe under conditions which permit the probe to specifically hybridize to any complementary sequences from which are present therein. [00264] Where necessary, conditions which permit the probe to specifically hybridize to complementary sequences may be determined by placing the probe in contact with complementary sequences from samples known to contain the complementary sequence as well as control sequences which do not contain the complementary sequence. Hybridization conditions, such as the salt concentration of the hybridization buffer, the formamide concentration of the hybridization buffer, or the hybridization temperature, may be varied to identify conditions which allow the probe to hybridize specifically to complementary nucleic acids.
[00265] If the sample contains the organism from which the nucleic acid was isolated, specific hybridization of the probe is then detected. Hybridization may be detected by labeling the probe with a detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product. [00266] Many methods for using the labeled probes to detect the presence of complementary nucleic acids in a sample are familiar to those skilled in the art. These include Southern Blots, Northern Blots, colony hybridization procedures, and dot blots. Protocols for each of these procedures are provided in Ausubel et al. Cunent Protocols in Molecular Biology, John Wiley 503 Sons, Enc. (1997) and Sambrook et al. Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory Press (1989). [00267] Alternatively, more than one probe (at least one of which is capable of specifically hybridizing to any complementary sequences which are present in the nucleic acid sample), may be used in an amplification reaction to determine whether the sample contains an organism containing a nucleic acid sequence of the invention (e.g., an organism from which the nucleic acid was isolated). Typically, the probes comprise oligonucleotides. In one aspect, the amplification reaction may comprise a PCR reaction. PCR protocols are described in Ausubel and Sambrook. Alternatively, the amplification may comprise a ligase chain reaction, 3SR, or strand displacement reaction. (See Barany, F., "The Ligase Chain Reaction in a PCR World", PCR Methods and Applications 1:5-16, 1991; E. Fahy et al, "Self- sustained Sequence Replication (3SR): An Isothermal Transcription-based Amplification System Alternative to PCR", PCR Methods and Applications 1:25-33, 1991; and Walker G.T. et al, "Strand Displacement Amplification-an Isothermal in vitro DNA Amplification Technique", Nucleic Acid Research 20:1691-1696, 1992. In such procedures, the nucleic acids in the sample are contacted with the probes, the amplification reaction is performed, and any resulting amplification product is detected. The amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide. Alternatively, one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product may be detected by autoradiography after gel electrophoresis.
[00268] Probes derived from sequences near the ends of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, may also be used in chromosome walking procedures to identify clones containing genomic sequences located adjacent to the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto. Such methods allow the isolation of genes which encode additional proteins from the host organism.
[00269] The isolated nucleic acids of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or the sequences complementary thereto may be used as probes to identify and isolate related nucleic acids. In some aspects, the related nucleic acids may be cDNAs or genomic DNAs from organisms other than the one from which the nucleic acid was isolated. For example, the other organisms may be related organisms. In such procedures, a nucleic acid sample is contacted with the probe under conditions which permit the probe to specifically hybridize to related sequences. Hybridization of the probe to nucleic acids from the related organism is then detected using any of the methods described above. Antisense Oligonucleotides [00270] The invention provides antisense oligonucleotides capable of binding phosphatase message which can inhibit phosphatase activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such phosphatase oligonucleotides using the novel reagents of the invention. For example, gene walking/ RNA mapping protocols to screen for effective antisense oligonucleotides are well known in the art, see, e.g., Ho (2000) Methods Enzymol. 314:168-183, describing an RNA mapping assay, which is based on standard molecular techniques to provide an easy and reliable method for potent antisense sequence selection. See also Smith (2000) Euro. J. Pharm. Sci. 11:191-198. [00271] Naturally occurring nucleic acids are used as antisense oligonucleotides. The antisense oligonucleotides can be of any length; for example, in alternative aspects, the antisense oligonucleotides are between about 5 to 100, about 10 to 80, about 15 to 60, about 18 to 40. The optimal length can be determined by routine screening. The antisense oligonucleotides can be present at any concentration. The optimal concentration can be determined by routine screening. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2- aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) Toxicol Appl Pharmacol 144:189-197; Antisense Therapeutics, ed. Agarwal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and moφholino carbamate nucleic acids, as described above. [00272] Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense phosphatase sequences of the invention (see, e.g., Gold (1995) J. of Biol. Chem. 270:13581-13584). Inhibitory Ribozymes
[00273] The invention provides for with ribozymes capable of binding phosphatase message which can inhibit phosphatase enzyme activity by targeting mRNA. Strategies for designing ribozymes and selecting the phosphatase-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the conect site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.
[00274] In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non- targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.
[00275] The enzymatic ribozyme RNA molecule can be formed in a hammerhead motif, but may also be formed in the motif of a haiφin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) Aids Research and Human Retroviruses 8:183; haiφin motifs by Hampel (1989) Biochemistry 28:4929, and Hampel (1990) Nuc. Acids Res. 18:299; the hepatitis delta virus motif by Perrotta (1992) Biochemistry 31:16; the RNaseP motif by Guerrier-Takada (1983) Cell 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate binding site which imparts an RNA cleaving activity to the molecule. Modification of Nucleic Acids
[00276] The invention provides methods of generating variants of the nucleic acids of the invention, e.g., those encoding phosphatase enzymes of the invention. These methods can be repeated or used in various combinations to generate phosphatase enzymes having an altered or different activity or an altered or different stability from that of a phosphatase encoded by the template nucleic acid. These methods also can be repeated or used in various combinations, e.g., to generate variations in gene/ message expression, message translation or message stability. In another aspect, the genetic composition of a cell is altered by, e.g., modification of a homologous gene ex vivo, followed by its reinsertion into the cell. [00277] A nucleic acid of the invention can be altered by any means. For example, random or stochastic methods, or, non-stochastic, or "directed evolution," methods. [00278] Methods for random mutation of genes are well known in the art, see, e.g., U.S. Patent No. 5,830,696. For example, mutagens can be used to randomly mutate a gene. Mutagens include, e.g., ultraviolet light or gamma inadiation, or a chemical mutagen, e.g., mitomycin, nitrous acid, photoactivated psoralens, alone or in combination, to induce DNA breaks amenable to repair by recombination. Other chemical mutagens include, for example, sodium bisulfite, nitrous acid, hydroxylamine, hydrazine or formic acid. Other mutagens are analogues of nucleotide precursors, e.g., nitrosoguanidine, 5-bromouracil, 2-aminopurine, or acridine. These agents can be added to a PCR reaction in place of the nucleotide precursor thereby mutating the sequence. Intercalating agents such as proflavine, acriflavine, quinacrine and the like can also be used. Any technique in molecular biology can be used, e.g., random PCR mutagenesis, see, e.g., Rice (1992) Proc. Natl. Acad. Sci. USA 89:5467- 5471; or, combinatorial multiple cassette mutagenesis, see, e.g., Crameri (1995) Biotechniques 18:194-196. Alternatively, nucleic acids, e.g., genes, can be reassembled after random, or "stochastic," fragmentation, see, e.g., U.S. Patent Nos. 6,291,242; 6,287,862; 6,287,861; 5,955,358; 5,830,721; 5,824,514; 5,811,238; 5,605,793. In alternative aspects, modifications, additions or deletions are introduced by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR), recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair- deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation, and/or a combination of these and other methods.
[00279] The following publications describe a variety of recursive recombination procedures and/or methods which can be incoφorated into the methods of the invention: Stemmer (1999) "Molecular breeding of viruses for targeting and other clinical properties" Tumor Targeting 4:1-4; Ness (1999) Nature Biotechnology 17:893-896; Chang (1999) "Evolution of a cytokine using DNA family shuffling" Nature Biotechnology 17:793-797; Minshull (1999) "Protein evolution by molecular breeding" Current Opinion in Chemical Biology 3:284-290; Christians (1999) "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling" Nature Biotechnology 17:259-264; Crameri (1998) "DNA shuffling of a family of genes from diverse species accelerates directed evolution" Nature 391:288-291; Crameri (1997) "Molecular evolution of an arsenate detoxification pathway by DNA shuffling," Nature Biotechnology 15:436-438; Zhang (1997) "Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening" Proc. Natl. Acad. Sci. USA 94:4504-4509; Patten et al. (1997) "Applications of DNA Shuffling to Pharmaceuticals and Vaccines" Current Opinion in Biotechnology 8:724- 733; Crameri et al. (1996) "Construction and evolution of antibody-phage libraries by DNA shuffling" Nature Medicine 2:100-103; Crameri et al. (1996) "improved green fluorescent protein by molecular evolution using DNA shuffling" Nature Biotechnology 14:315-319; Gates et al. (1996) "Affinity selective isolation of ligands from peptide libraries through display on a lac repressor 'headpiece dimer ' Journal of Molecular Biology 255:373-386; Stemmer (1996) "Sexual PCR and Assembly PCR" In: The Encyclopedia of Molecular Biology. VCH Publishers, New York, pp.447-457; Crameri and Stemmer (1995) "Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes" BioTechniques 18:194-195; Stemmer et al. (1995) "Single-step assembly of a gene and entire plasmid form large numbers of oligodeoxyribonucleotides" Gene, 164:49-53; Stemmer (1995) "The Evolution of Molecular Computation" Science 270: 1510; Stemmer (1995) "Searching Sequence Space" Bio/Technology 13:549-553; Stemmer (1994) "Rapid evolution of a protein in vitro by DNA shuffling" Nature 370:389-391; and Stemmer (1994) "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution." Proc. Natl. Acad. Sci. USA 91 :10747-10751.
[00280] Mutational methods of generating diversity include, for example, site-directed mutagenesis (Ling et al. (1997) "Approaches to DNA mutagenesis: an overview" Anal Biochem. 254(2): 157-178; Dale et al. (1996) "Oligonucleotide-directed random mutagenesis using the phosphorothioate method" Methods Mol. Biol. 57:369-374; Smith (1985) "In vitro mutagenesis" Ann. Rev. Genet. 19:423-462; Botstein & Shortle (1985) "Strategies and applications of in vitro mutagenesis" Science 229:1193-1201; Carter (1986) "Site-directed mutagenesis" Biochem. J. 237:1-7; and Kunkel (1987) "The efficiency of oligonucleotide directed mutagenesis" in Nucleic Acids & Molecular Biology (Eckstein, F. and Lilley, D. M. J. eds., Springer Verlag, Berlin)); mutagenesis using uracil containing templates (Kunkel (1985) "Rapid and efficient site-specific mutagenesis without phenotypic selection" Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) "Rapid and efficient site-specific mutagenesis without phenotypic selection" Methods in Enzymol. 154, 367-382; and Bass et al. (1988) "Mutant Tφ repressors with new DNA-binding specificities" Science 242:240- 245); oligonucleotide-directed mutagenesis (Methods in Enzymol. 100: 468-500 (1983); Methods in Enzymol. 154: 329-350 (1987); Zoller & Smith (1982) "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment" Nucleic Acids Res. 10:6487-6500; Zoller & Smith (1983) "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors" Methods in Enzymol. 100:468-500; and Zoller (1987) "Oligonucleotide- directed mutagenesis: a simple method using two oligonucleotide primers and a single- stranded DNA template" Methods in Enzymol. 154:329-350); phosphorothioate-modified DNA mutagenesis (Taylor et al. (1985) "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA" Nucl. Acids Res. 13: 8749-8764; Taylor et al. (1985) "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA" Nucl. Acids Res. 13: 8765-8787 (1985); Nakamaye (1986) "inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis" Nucl. Acids Res. 14: 9679-9698; Sayers (1988) "Y-T Exonucleases in phosphorothioate-based oligonucleotide- directed mutagenesis" Nucl. Acids Res. 16:791-802; and Sayers et al. (1988) "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide" Nucl. Acids Res. 16: 803-814); mutagenesis using gapped duplex DNA (Kramer et al. (1984) "The gapped duplex DNA approach to oligonucleotide- directed mutation construction" Nucl. Acids Res. 12: 9441-9456; Kramer & Fritz (1987) Methods in Enzymol. "Oligonucleotide-directed construction of mutations via gapped duplex DNA" 154:350-367; Kramer et al. (1988) "Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations" Nucl. Acids Res. 16: 7207; and Fritz et al. (1988) "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro" Nucl. Acids Res. 16: 6987-6999).
[00281] Additional protocols used in the methods of the invention include point mismatch repair (Kramer (1984) "Point Mismatch Repair" Cell 38:879-887), mutagenesis using repair-deficient host strains (Carter et al. (1985) "Improved oligonucleotide site- directed mutagenesis using Ml 3 vectors" Nucl. Acids Res. 13: 4431-4443; and Carter (1987) "Improved oligonucleotide-directed mutagenesis using Ml 3 vectors" Methods in Enzymol. 154: 382-403), deletion mutagenesis (Eghtedarzadeh (1986) "Use of oligonucleotides to generate large deletions" Nucl. Acids Res. 14: 5115), restriction-selection and restriction- selection and restriction-purification (Wells et al. (1986) "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" Phil. Trans. R. Soc. Lond. A 317: 415-423), mutagenesis by total gene synthesis (Nambiar et al. (1984) "Total synthesis and cloning of a gene coding for the ribonuclease S protein" Science 223: 1299-1301; Sakamar and Khorana (1988) "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin)" Nucl. Acids Res. 14: 6361- 6372; Wells et al. (1985) "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" Gene 34:315-323; and Grundstrom et al. (1985) "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis" Nucl. Acids Res. 13: 3305-3316), double-strand break repair (Mandecki (1986); Arnold (1993) "Protein engineering for unusual environments" Cunent Opinion in Biotechnology 4:450-455. "Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis" Proc. Natl. Acad. Sci. USA, 83:7177-7181). Additional details on many of the above methods can be found in Methods in Enzymology Volume 154, which also describes useful controls for trouble-shooting problems with various mutagenesis methods. See also U.S. Patent Nos. 5,605,793 to Stemmer (Feb. 25, 1997), "Methods for In Vitro Recombination;" U.S. Pat. No. 5,811,238 to Stemmer et al. (Sep. 22, 1998) "Methods for Generating Polynucleotides having Desired Characteristics by Iterative Selection and Recombination;" U.S. Pat. No. 5,830,721 to Stemmer et al. (Nov. 3, 1998), "DNA Mutagenesis by Random Fragmentation and Reassembly;" U.S. Pat. No. 5,834,252 to Stemmer, et al. (Nov. 10, 1998) "End-Complementary Polymerase Reaction;" U.S. Pat. No. 5,837,458 to Minshull, et al. (Nov. 17, 1998), "Methods and Compositions for Cellular and Metabolic Engineering;" WO 95/22625, Stemmer and Crameri, "Mutagenesis by Random Fragmentation and Reassembly;" WO 96/33207 by Stemmer and Lipschutz "End Complementary Polymerase Chain Reaction;" WO 97/20078 by Stemmer and Crameri "Methods for Generating Polynucleotides having Desired Characteristics by Iterative Selection and Recombination;" WO 97/35966 by Minshull and Stemmer, "Methods and Compositions for Cellular and Metabolic Engineering;" WO 99/41402 by Punnonen et al. "Targeting of Genetic Vaccine Vectors;" WO 99/41383 by Punnonen et al. "Antigen Library ImLmunization;" WO 99/41369 by Punnonen et al. "Genetic Vaccine Vector Engineering;" WO 99/41368 by Punnonen et al. "Optimization of Immunomodulatory Properties of Genetic Vaccines;" EP 752008 by Stemmer and Crameri, "DNA Mutagenesis by Random Fragmentation and Reassembly;" EP 0932670 by Stemmer "Evolving Cellular DNA Uptake by Recursive Sequence Recombination;" WO 99/23107 by Stemmer et al., "Modification of Virus Tropism and Host Range by Viral Genome Shuffling;" WO 99/21979 by Apt et al., "Human Papillomavirus Vectors;" WO 98/31837 by del Cardayre et al. "Evolution of Whole Cells and Organisms by Recursive Sequence Recombination;" WO 98/27230 by Patten and Stemmer, "Methods and Compositions for Polypeptide Engineering;" WO 98/27230 by Stemmer et al., "Methods for Optimization of Gene Therapy by Recursive Sequence Shuffling and Selection," WO 00/00632, "Methods for Generating Highly Diverse Libraries," WO 00/09679, "Methods for Obtaining in Vitro Recombined Polynucleotide Sequence Banks and Resulting Sequences," WO 98/42832 by Arnold et al., "Recombination of Polynucleotide Sequences Using Random or Defined Primers," WO 99/29902 by Arnold et al., "Method for Creating Polynucleotide and Polypeptide Sequences," WO 98/41653 by Vind, "An in Vitro Method for Construction of a DNA Library," WO 98/41622 by Borchert et al., "Method for Constructing a Library Using DNA Shuffling," and WO 98/42727 by Pati and Zarling, "Sequence Alterations using Homologous Recombination." [00282] Certain U. S . applications provide additional details regarding various diversity generating methods, including "SHUFFLING OF CODON ALTERED GENES" by Patten et al. filed Sep. 28, 1999, (U.S. Ser. No. 09/407,800); "EVOLUTION OF WHOLE CELLS AND ORGANISMS BY RECURSIVE SEQUENCE RECOMBINATION" by del Cardayre et al., filed Jul. 15, 1998 (U.S. Ser. No. 09/166,188), and Jul. 15, 1999 (U.S. Ser. No. 09/354,922); "OLIGONUCLEOTIDE MEDIATED NUCLEIC ACED RECOMBINATION" by Crameri et al., filed Sep. 28, 1999 (U.S. Ser. No. 09/408,392), and "OLIGONUCLEOTIDE MEDEATED NUCLEIC ACED RECOMBENATION" by Crameri et al., filed Jan. 18, 2000 (PCT/US00/01203); "USE OF CODON- VAREED OLIGONUCLEOTEDE SYNTHESIS FOR SYNTHETIC SHUFFLENG" by Welch et al., filed Sep. 28, 1999 (U.S. Ser. No. 09/408,393); "METHODS FOR MAKING CHARACTER STRENGS, POLYNUCLEOTEDES & POLYPEPTEDES HAVENG DESERED CHARACTERISTICS" by Selifonov et al., filed Jan. 18, 2000, (PCT/US00/01202) and, e.g. "METHODS FOR MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTEDES HAVENG DESERED CHARACTERISTICS" by Selifonov et al., filed Jul. 18, 2000 (U.S. Ser. No. 09/618,579); "METHODS OF POPULATING DATA STRUCTURES FOR USE EN EVOLUTIONARY SEMULATIONS" by Selifonov and Stemmer, filed Jan. 18, 2000 (PCT/USOO/01138); and "SENGLE-STRANDED NUCLEEC ACED TEMPLATE-MEDEATED RECOMBINATION AND NUCLEIC ACED FRAGMENT ESOLATION" by Affholter, filed Sep. 6, 2000 (U.S. Ser. No. 09/656,549). [00283] Non-stochastic, or "directed evolution," methods include, e.g., saturation mutagenesis (GSSM), synthetic ligation reassembly (SLR), or a combination thereof are used to modify the nucleic acids of the invention to generate phosphatases with new or altered properties (e.g., activity under highly acidic or alkaline conditions, high temperatures, and the like). Polypeptides encoded by the modified nucleic acids can be screened for an activity before testing for a phosphatase or other activity. Any testing modality or protocol can be used, e.g., using a capillary anay platform. See, e.g., U.S. Patent Nos. 6,280,926; 5,939,250. Saturation mutagenesis, or, GSSM
[00284] In one aspect of the invention, non- stochastic gene modification, a "directed evolution process," is used to generate phosphatases with new or altered properties. Variations of this method have been termed "gene site-saturation mutagenesis," "site- saturation mutagenesis," "saturation mutagenesis" or simply "GSSM." It can be used in combination with other mutagenization processes. See, e.g., U.S. Patent Nos. 6,171,820; 6,238,884. In one aspect, GSSM comprises providing a template polynucleotide and a plurality of oligonucleotides, wherein each oligonucleotide comprises a sequence homologous to the template polynucleotide, thereby targeting a specific sequence of the template polynucleotide, and a sequence that is a variant of the homologous gene; generating progeny polynucleotides comprising non-stochastic sequence variations by replicating the template polynucleotide with the oligonucleotides, thereby generating polynucleotides comprising homologous gene sequence variations.
[00285] The invention also provides for the use of proprietary codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)). The oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, but not necessarily a second homologous sequence. The downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
[00286] In one aspect, one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions. In another aspect, at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions. Thus, more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site. This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s). In another aspect, oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
[00287] In one exemplification, it is possible to simultaneously mutagenize two or more contiguous amino acid positions using an oligo that contains contiguous N,N,N triplets, i.e. a degenerate (N,N,N)n sequence. In another aspect, the present invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence. For example, it may be desirable in some instances to use (e.g. in an oligo) a degenerate triplet sequence comprised of only one N, where said N can be in the first second or third position of the triplet. Any other bases including any combinations and permutations thereof can be used in the remaining two positions of the triplet. Alternatively, it may be desirable in some instances to use (e.g., in an oligo) a degenerate N,N,N triplet sequence, N,N,G/T, or an N,N, G/C triplet sequence. It is appreciated, however, that the use of a degenerate triplet (such as N,N,G/T or an N,N, G/C triplet sequence) as disclosed in the instant invention is advantageous for several reasons. In one aspect, this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide. Thus, for a 100 amino acid polypeptide, the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
[00288] This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to conesponding amino acid changes, and point mutations that cause the generation of stop codons and the conesponding expression of polypeptide fragments. Thus, in one aspect of this invention, each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position conesponding to the codon position mutagenized in the parental polynucleotide. The 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g., cloned into a suitable E. coli host using an expression vector) and subjected to expression screening. When an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the correspondingly favorable amino acid substitution contained therein.
[00289] It is appreciated that upon mutagenizing each and every amino acid position in a parental polypeptide using saturation mutagenesis as disclosed herein, favorable amino acid changes may be identified at more than one amino acid position. One'or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position. [00290] In one aspect, site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening. This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. En one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening. Thus, in a non-limiting exemplification, this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
[00291] In addition to performing mutagenesis along the entire sequence of a gene, the instant invention provides that mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000. Thus, instead of mutagenizing every position along a molecule, one can subject every or a discrete number of bases (can be a subset totaling from 15 to 100,000) to mutagenesis. A separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence. A group of 3 positions to be mutagenized may be a codon. The mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette. Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo). [00292] In a general sense, saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length). Thus, a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized. A grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis. Such groupings are exemplified by deletions, additions, groupings of particular codons, and groupings of particular nucleotide cassettes. [00293] Defined sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group. Generally, a "defined sequences" for this puφose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
[00294] In one exemplification a grouping of mutations that can be introduced into a mutagenic cassette, this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby. The invention also provides for the use of proprietary codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)). The oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, and can be a second homologous sequence. The downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
[00295] In one aspect, one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions. In another aspect, at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions. Thus, more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site. This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s). In another aspect, oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
[00296] In one exemplification, it is possible to simultaneously mutagenize two or more contiguous amino acid positions using an oligo that contains contiguous N,N,N triplets, i.e. a degenerate (N,N,N)n sequence. In another aspect, the present invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence. For example, it may be desirable in some instances to use (e.g. in an oligo) a degenerate triplet sequence comprised of only one N, where said N can be in the first second or third position of the triplet. Any other bases including any combinations and permutations thereof can be used in the remaining two positions of the triplet. Alternatively, it may be desirable in some instances to use (e.g., in an oligo) a degenerate N,N,N triplet sequence, N,N,G/T, or an N,N, G/C triplet sequence. It is appreciated, however, that the use of a degenerate triplet (such as N,N,G/T or an N,N, G/C triplet sequence) as disclosed in the instant invention is advantageous for several reasons. In one aspect, this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide. Thus, for a 100 amino acid polypeptide, the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
[00297] This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to conesponding amino acid changes, and point mutations that cause the generation of stop codons and the conesponding expression of polypeptide fragments. Thus, in one aspect of this invention, each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position conesponding to the codon position mutagenized in the parental polynucleotide. The 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g., cloned into a suitable E. coli host using an expression vector) and subjected to expression screening. When an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the conespondingly favorable amino acid substitution contained therein.
[00298] It is appreciated that upon mutagenizing each and every amino acid position in a parental polypeptide using saturation mutagenesis as disclosed herein, favorable amino acid changes may be identified at more than one amino acid position. One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position.
[00299] In yet another aspect, site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening. This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. In one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening. Thus, in a non-limiting exemplification, this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
[00300] In addition to performing mutagenesis along the entire sequence of a gene, the instant invention provides that mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000. Thus, instead of mutagenizing every position along a molecule, one can subject every or a discrete number of bases (can be a subset totaling from 15 to 100,000) to mutagenesis. A separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence. A group of 3 positions to be mutagenized may be a codon. The mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette. Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo). [00301] In a general sense, saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length). Thus, a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized. A grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis. Such groupings are exemplified by deletions, additions, groupings of particular codons, and groupings of particular nucleotide cassettes. [00302] Defined sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group. Generally, a "defined sequences" for this puφose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
[00303] In one exemplification a grouping of mutations that can be introduced into a mutagenic cassette, this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby. The invention also provides for the use of codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)). The oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, and can be a second homologous sequence. The downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.
[00304] In one aspect, one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions. In another aspect, at least two degenerate N,N,N cassettes are used - either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions. Thus, more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site. This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s). In another aspect, oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
[00305] In one exemplification, it is possible to simultaneously mutagenize two or more contiguous amino acid positions using an oligo that contains contiguous N,N,N triplets, i.e. a degenerate (N,N,N)n sequence.
[00306] In another aspect, the invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence. For example, it may be desirable in some instances to use (e.g. in an oligo) a degenerate triplet sequence comprised of only one N, where said N can be in the first second or third position of the triplet. Any other bases including any combinations and permutations thereof can be used in the remaining two positions of the triplet. Alternatively, it may be desirable in some instances to use (e.g., in an oligo) a degenerate N,N,N triplet sequence, N,N,G/T, or an N,N, G/C triplet sequence. It is appreciated, however, that the use of a degenerate triplet (such as N,N,G/T or an N,N, G/C triplet sequence) as disclosed in the instant invention is advantageous for several reasons. In one aspect, this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide. Thus, for a 100 amino acid polypeptide, the invention provides a way to systematically and fairly easily generate 2000 distinct species (i.e., 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.
[00307] This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to corresponding amino acid changes, and point mutations that cause the generation of stop codons and the corresponding expression of polypeptide fragments.
[00308] In one aspect, each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position corresponding to the codon position mutagenized in the parental polynucleotide. The 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g. , cloned into a suitable E. coli host using an expression vector) and subjected to expression screening. When an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the conespondingly favorable amino acid substitution contained therein. [00309] It is appreciated that upon mutagenizing each and every amino acid position in a parental polypeptide using saturation mutagenesis as disclosed herein, favorable amino acid changes may be identified at more than one amino acid position. One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e., 2 at each of three positions) and no change at any position.
[00310] En another aspect, site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening. This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. In one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening.
[00311] Thus, in a non- limiting exemplification, this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
[00312 ] In addition to performing mutagenesis along the entire sequence of a gene, the instant invention provides that mutagenesis can be use to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized can be every integer from 15 to 100,000. Thus, instead of mutagenizing every position along a molecule, one can subject every or a discrete number of bases (can be a subset totaling from 15 to 100,000) to mutagenesis. A separate nucleotide can be used for mutagenizing each position or group of positions along a polynucleotide sequence. A group of 3 positions to be mutagenized may be a codon. The mutations can be introduced using a mutagenic primer, containing a heterologous cassette, also refened to as a mutagenic cassette. Cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A G, A T, C/G, C/T, G/T, C/G/T, A G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be refened to as a designer oligo). [00313] In a general sense, saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette can be about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the sequence to be mutagenized can be from about 15 to 100,000 bases in length). Thus, a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized. A grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis. Such groupings are exemplified by deletions, additions, groupings of particular codons, and groupings of particular nucleotide cassettes. [00314] Defined sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group. Generally, a "defined sequences" for this puφose may be any polynucleotide that a 15 base- polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.
[00315] In one exemplification a grouping of mutations that can be introduced into a mutagenic cassette, this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby. Synthetic Ligation Reassembly (SLR)
[00316] The invention provides a non-stochastic gene modification system termed "synthetic ligation reassembly," or simply "SLR," a "directed evolution process," to generate phosphatases with new or altered properties. SLR is a method of ligating oligonucleotide fragments together non-stochastically. This method differs from stochastic oligonucleotide shuffling in that the nucleic acid building blocks are not shuffled, concatenated or chimerized randomly, but rather are assembled non-stochastically. See, e.g., U.S. Patent Application Serial No. (USSN) 09/332,835 entitled "Synthetic Ligation Reassembly in Directed Evolution" and filed on June 14, 1999 ("USSN 09/332,835"). [00317] In one aspect, SLR comprises the following steps: (a) providing a template polynucleotide, wherein the template polynucleotide comprises sequence encoding a homologous gene; (b) providing a plurality of building block polynucleotides, wherein the building block polynucleotides are designed to cross-over reassemble with the template polynucleotide at a predetermined sequence, and a building block polynucleotide comprises a sequence that is a variant of the homologous gene and a sequence homologous to the template polynucleotide flanking the variant sequence; (c) combining a building block polynucleotide with a template polynucleotide such that the building block polynucleotide cross-over reassembles with the template polynucleotide to generate polynucleotides comprising homologous gene sequence variations.
[00318] En one aspect, the present invention provides a non-stochastic method termed synthetic gene reassembly, that is somewhat related to stochastic shuffling, save that the nucleic acid building blocks are not shuffled or concatenated or chimerized randomly, but rather are assembled non-stochastically.
[00319] The synthetic gene reassembly method does not depend on the presence of a high level of homology between polynucleotides to be shuffled. The invention can be used to non-stochastically generate libraries (or sets) of progeny molecules comprised of over 10100 different chimeras. Conceivably, synthetic gene reassembly can even be used to generate libraries comprised of over 101000 different progeny chimeras. [00320] Thus, in one aspect, the invention provides a non- stochastic method of producing a set of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design, which method is comprised of the steps of generating by design a plurality of specific nucleic acid building blocks having serviceable mutually compatible ligatable ends, and assembling these nucleic acid building blocks, such that a designed overall assembly order is achieved.
[00321] The mutually compatible ligatable ends of the nucleic acid building blocks to be assembled are considered to be "serviceable" for this type of ordered assembly if they enable the building blocks to be coupled in predetermined orders. Thus, in one aspect, the overall assembly order in which the nucleic acid building blocks can be coupled is specified by the design of the ligatable ends and, if more than one assembly step is to be used, then the overall assembly order in which the nucleic acid building blocks can be coupled is also specified by the sequential order of the assembly step(s). In a one aspect of the invention, the annealed building pieces are treated with an enzyme, such as a ligase (e.g., T4 DNA ligase) to achieve covalent bonding of the building pieces.
[00322] In another aspect, the design of nucleic acid building blocks is obtained upon analysis of the sequences of a set of progenitor nucleic acid templates that serve as a basis for producing a progeny set of finalized chimeric nucleic acid molecules. These progenitor nucleic acid templates thus serve as a source of sequence information that aids in the design of the nucleic acid building blocks that are to be mutagenized, i.e. chimerized or shuffled. [00323] In one exemplification, the invention provides for the chimerization of a family of related genes and their encoded family of related products. In a particular exemplification, the encoded products are enzymes. The phosphatases of the present invention can be mutagenized in accordance with the methods described herein. [00324] Thus, according to one aspect of the invention, the sequences of a plurality of progenitor nucleic acid templates (e.g., polynucleotides of Group A nucleic acid sequences) are aligned in order to select one or more demarcation points, which demarcation points can be located at an area of homology. The demarcation points can be used to delineate the boundaries of nucleic acid building blocks to be generated. Thus, the demarcation points identified and selected in the progenitor molecules serve as potential chimerization points in the assembly of the progeny molecules.
[00325] Typically a serviceable demarcation point is an area of homology (comprised of at least one homologous nucleotide base) shared by at least two progenitor templates, but the demarcation point can be an area of homology that is shared by at least half of the progenitor templates, at least two thirds of the progenitor templates, at least three fourths of the progenitor templates, or, at almost all of the progenitor templates. In one aspect, a serviceable demarcation point is an area of homology that is shared by all of the progenitor templates.
[00326] In one aspect, the gene reassembly process is performed exhaustively in order to generate an exhaustive library. In other words, all possible ordered combinations of the nucleic acid building blocks are represented in the set of finalized chimeric nucleic acid molecules. At the same time, the assembly order (i.e. the order of assembly of each building block in the 5' to 3 sequence of each finalized chimeric nucleic acid) in each combination is by design (or non-stochastic). Because of the non-stochastic nature of the method, the possibility of unwanted side products is greatly reduced.
[00327] In another aspect, the method provides that the gene reassembly process is performed systematically, for example to generate a systematically compartmentalized library, with compartments that can be screened systematically, e.g., one by one. In other words the invention provides that, through the selective and judicious use of specific nucleic acid building blocks, coupled with the selective and judicious use of sequentially stepped assembly reactions, an experimental design can be achieved where specific sets of progeny products are made in each of several reaction vessels. This allows a systematic examination and screening procedure to be performed. Thus, it allows a potentially very large number of progeny molecules to be examined systematically in smaller groups. [00328] Because of its ability to perform chimerizations in a manner that is highly flexible yet exhaustive and systematic as well, particularly when there is a low level of homology among the progenitor molecules, the instant invention provides for the generation of a library (or set) comprised of a large number of progeny molecules. Because of the non- stochastic nature of the instant gene reassembly invention, the progeny molecules generated can comprise a library of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design. In one aspect, such a generated library is comprised of greater than 103 to greater than lθ1000 different progeny molecular species. [00329] En one aspect, a set of finalized chimeric nucleic acid molecules, produced as described is comprised of a polynucleotide encoding a polypeptide. According to one aspect, this polynucleotide is a gene, which may be a man-made gene. According to another aspect, this polynucleotide is a gene pathway, which may be a man-made gene pathway. The invention provides that one or more man-made genes generated by the invention may be incoφorated into a man-made gene pathway, such as pathway operable in a eukaryotic organism (including a plant).
[00330] In another exemplification, the synthetic nature of the step in which the building blocks are generated allows the design and introduction of nucleotides (e.g., one or more nucleotides, which may be, for example, codons or introns or regulatory sequences) that can later be optionally removed in an in vitro process (e.g., by mutagenesis) or in an in vivo process (e.g., by utilizing the gene splicing ability of a host organism). It is appreciated that in many instances the introduction of these nucleotides may also be desirable for many other reasons in addition to the potential benefit of creating a serviceable demarcation point.
[00331] Thus, according to another aspect, the invention provides that a nucleic acid building block can be used to introduce an intron. Thus, the invention provides that functional introns may be introduced into a man-made gene of the invention. The invention also provides that functional introns may be introduced into a man-made gene pathway of the invention. Accordingly, the invention provides for the generation of a chimeric polynucleotide that is a man-made gene containing one (or more) artificially introduced intron(s).
[00332] The invention also provides for the generation of a chimeric polynucleotide that is a man-made gene pathway containing one (or more) artificially introduced intron(s). The artificially introduced intron(s) can be functional in one or more host cells for gene splicing much in the way that naturally-occurring introns serve functionally in gene splicing. The invention provides a process of producing man-made intron-containing polynucleotides to be introduced into host organisms for recombination and/or splicing.
[00333] A man-made gene produced using the invention can also serve as a substrate for recombination with another nucleic acid. Likewise, a man-made gene pathway produced using the invention can also serve as a substrate for recombination with another nucleic acid. The recombination can be facilitated by, or occurs at, areas of homology between the man- made, intron-containing gene and a nucleic acid, which serves as a recombination partner. The recombination partner may also be a nucleic acid generated by the invention, including a man-made gene or a man-made gene pathway. Recombination may be facilitated by or may occur at areas of homology that exist at the one (or more) artificially introduced intron(s) in the man-made gene.
[00334] The synthetic gene reassembly method of the invention utilizes a plurality of nucleic acid building blocks, each of which can have two ligatable ends. The two ligatable ends on each nucleic acid building block may be two blunt ends (i.e. each having an overhang of zero nucleotides), or, one blunt end and one overhang, or, two overhangs.
[00335] A useful overhang for this puφose may be a 3 ' overhang or a 5 ' overhang. Thus, a nucleic acid building block may have a 3 ' overhang or alternatively a 5 ' overhang or alternatively two 3' overhangs or alternatively two 5' overhangs. The overall order in which the nucleic acid building blocks are assembled to form a finalized chimeric nucleic acid molecule is determined by puφoseful experimental design and is not random. [00336] In one aspect, a nucleic acid building block is generated by chemical synthesis of two single-stranded nucleic acids (also referred to as single-stranded oligos) and contacting them so as to allow them to anneal to form a double-stranded nucleic acid building block. A double-stranded nucleic acid building block can be of variable size. The sizes of these building blocks can be small or large. Sizes for building blocks can range from 1 base pair (not including any overhangs) to 100,000 base pairs (not including any overhangs). Other size ranges are also provided, which have lower limits of from 1 bp to 10,000 bp (including every integer value in between), and upper limits of from 2 bp to 100, 000 bp (including every integer value in between). Many methods exist by which a double- stranded nucleic acid building block can be generated that is serviceable for the invention; and these are known in the art and can be readily performed by the skilled artisan. [00337] According to one aspect, a double-stranded nucleic acid building block is generated by first generating two single stranded nucleic acids and allowing them to anneal to form a double-stranded nucleic acid building block. The two strands of a double-stranded nucleic acid building block may be complementary at every nucleotide apart from any that form an overhang; thus containing no mismatches, apart from any overhang(s). According to another aspect, the two strands of a double-stranded nucleic acid building block are complementary at fewer than every nucleotide apart from any that form an overhang. Thus, according to this aspect, a double-stranded nucleic acid building block can be used to introduce codon degeneracy. The codon degeneracy can be introduced using the site- saturation mutagenesis described herein, using one or more N,N,G/T cassettes or alternatively using one or more N,N,N cassettes. In vivo recombination methods
[00338] The in vivo recombination method of the invention can be performed blindly on a pool of unknown hybrids or alleles of a specific polynucleotide or sequence. However, it is not necessary to know the actual DNA or RNA sequence of the specific polynucleotide. The approach of using recombination within a mixed population of genes can be useful for the generation of any useful proteins, for example, interleukin I, antibodies, tPA and growth hormone. This approach may be used to generate proteins having altered specificity or activity. The approach may also be useful for the generation of hybrid nucleic acid sequences, for example, promoter regions, introns, exons, enhancer sequences, 31 untranslated regions or 51 untranslated regions of genes. Thus this approach may be used to generate genes having increased rates of expression. This approach may also be useful in the study of repetitive DNA sequences. Finally, this approach may be useful to mutate ribozymes or aptamers.
[00339] In one aspect the invention described herein is directed to the use of repeated cycles of reductive reassortment, recombination and selection which allow for the directed molecular evolution of highly complex linear sequences, such as DNA, RNA or proteins thorough recombination.
[00340] In vivo shuffling of molecules is useful in providing variants and can be performed utilizing the natural property of cells to recombine multimers. While recombination in vivo has provided the major natural route to molecular diversity, genetic recombination remains a relatively complex process that involves 1) the recognition of homologies; 2) strand cleavage, strand invasion, and metabolic steps leading to the production of recombinant chiasma; and finally 3) the resolution of chiasma into discrete recombined molecules. The formation of the chiasma requires the recognition of homologous sequences.
[00341] In another aspect, the invention includes a method for producing a hybrid polynucleotide from at least a first polynucleotide and a second polynucleotide. The invention can be used to produce a hybrid polynucleotide by introducing at least a first polynucleotide and a second polynucleotide which share at least one region of partial sequence homology into a suitable host cell. The regions of partial sequence homology promote processes which result in sequence reorganization producing a hybrid polynucleotide. The term "hybrid polynucleotide", as used herein, is any nucleotide sequence which results from the method of the present invention and contains sequence from at least two original polynucleotide sequences. Such hybrid polynucleotides can result from intermolecular recombination events which promote sequence integration between DNA molecules. In addition, such hybrid polynucleotides can result from intramolecular reductive reassortment processes which utilize repeated sequences to alter a nucleotide sequence within a DNA molecule. [00342] The invention provides a means for generating hybrid polynucleotides which may encode biologically active hybrid polypeptides (e.g., hybrid phosphatases). In one aspect, the original polynucleotides encode biologically active polypeptides. The method of the invention produces new hybrid polypeptides by utilizing cellular processes which integrate the sequence of the original polynucleotides such that the resulting hybrid polynucleotide encodes a polypeptide demonstrating activities derived from the original biologically active polypeptides. For example, the original polynucleotides may encode a particular enzyme from different microorganisms. An enzyme encoded by a first polynucleotide from one organism or variant may, for example, function effectively under a particular environmental condition, e.g. high salinity. An enzyme encoded by a second polynucleotide from a different organism or variant may function effectively under a different environmental condition, such as extremely high temperatures. A hybrid polynucleotide containing sequences from the first and second original polynucleotides may encode an enzyme which exhibits characteristics of both enzymes encoded by the original polynucleotides. Thus, the enzyme encoded by the hybrid polynucleotide may function effectively under environmental conditions shared by each of the enzymes encoded by the first and second polynucleotides, e.g., high salinity and extreme temperatures. In vivo reassortment
[00343] In vivo reassortment is focused on "inter-molecular" processes collectively refened to as "recombination" which in bacteria, is generally viewed as a "RecA-dependent" phenomenon. The invention can rely on recombination processes of a host cell to recombine and re-assort sequences, or the cells' ability to mediate reductive processes to decrease the complexity of quasi -repeated sequences in the cell by deletion. This process of "reductive reassortment" occurs by an "intra-molecular", RecA-independent process.
[00344] Therefore, in another aspect of the invention, novel polynucleotides can be generated by the process of reductive reassortment. The method involves the generation of constructs containing consecutive sequences (original encoding sequences), their insertion into an appropriate vector, and their subsequent introduction into an appropriate host cell. The reassortment of the individual molecular identities occurs by combinatorial processes between the consecutive sequences in the construct possessing regions of homology, or between quasi-repeated units. The reassortment process recombines and/or reduces the complexity and extent of the repeated sequences, and results in the production of novel molecular species. Various treatments may be applied to enhance the rate of reassortment. These could include treatment with ultra-violet light, or DNA damaging chemicals, and/or the use of host cell lines displaying enhanced levels of "genetic instability". Thus the reassortment process may involve homologous recombination or the natural property of quasi-repeated sequences to direct their own evolution.
[00345] Repeated or "quasi-repeated" sequences play a role in genetic instability. In the present invention, "quasi-repeats" are repeats that are not restricted to their original unit structure. Quasi-repeated units can be presented as an array of sequences in a construct; consecutive units of similar sequences. Once ligated, the junctions between the consecutive sequences become essentially invisible and the quasi-repetitive nature of the resulting construct is now continuous at the molecular level. The deletion process the cell performs to reduce the complexity of the resulting construct operates between the quasi-repeated sequences. The quasi-repeated units provide a practically limitless repertoire of templates upon which slippage events can occur. The constructs containing the quasi-repeats thus effectively provide sufficient molecular elasticity that deletion (and potentially insertion) events can occur virtually anywhere within the quasi-repetitive units. [00346] When the quasi-repeated sequences are all ligated in the same orientation, for instance head to tail or vice versa, the cell cannot distinguish individual units. Consequently, the reductive process can occur throughout the sequences. In contrast, when for example, the units are presented head to head, rather than head to tail, the inversion delineates the endpoints of the adjacent unit so that deletion formation will favor the loss of discrete units. The sequences can be in the same orientation. Random orientation of quasi-repeated sequences will result in the loss of reassortment efficiency, while consistent orientation of the sequences will offer the highest efficiency. However, while having fewer of the contiguous sequences in the same orientation decreases the efficiency, it may still provide sufficient elasticity for the effective recovery of novel molecules. Constructs can be made with the quasi-repeated sequences in the same orientation to allow higher efficiency. [00347] Sequences can be assembled in a head to tail orientation using any of a variety of methods, including the following: [00348] a) Primers that include a poly-A head and poly-T tail which when made single-stranded would provide orientation can be utilized. This is accomplished by having the first few bases of the primers made from RNA and hence easily removed RNAseH.
[00349] b) Primers that include unique restriction cleavage sites can be utilized. Multiple sites, a battery of unique sequences, and repeated synthesis and ligation steps would be required.
[00350] c) The inner few bases of the primer could be thiolated and an exonuclease used to produce properly tailed molecules.
[00351] The recovery of the re-assorted sequences relies on the identification of cloning vectors with a reduced repetitive index (RI). The re-assorted encoding sequences can then be recovered by amplification. The products are re-cloned and expressed. The recovery of cloning vectors with reduced RI can be affected by:
[00352] 1 ) The use of vectors only stably maintained when the construct is reduced in complexity.
[00353] 2) The physical recovery of shortened vectors by physical procedures. In this case, the cloning vector would be recovered using standard plasmid isolation procedures and size fractionated on either an agarose gel, or column with a low molecular weight cut off utilizing standard procedures.
[00354] 3) The recovery of vectors containing interrupted genes which can be selected when insert size decreases.
[00355] 4) The use of direct selection techniques with an expression vector and the appropriate selection.
[00356] Encoding sequences (for example, genes) from related organisms may demonstrate a high degree of homology and encode quite diverse protein products. These types of sequences are particularly useful in the present invention as quasi-repeats. However, while the examples illustrated below demonstrate the reassortment of nearly identical original encoding sequences (quasi-repeats), this process is not limited to such nearly identical repeats.
[00357] The following example demonstrates a method of the invention. Encoding nucleic acid sequences (quasi-repeats) derived from three (3) unique species are described. Each sequence encodes a protein with a distinct set of properties. Each of the sequences differs by a single or a few base pairs at a unique position in the sequence. The quasi- repeated sequences are separately or collectively amplified and ligated into random assemblies such that all possible permutations and combinations are available in the population of ligated molecules. The number of quasi-repeat units can be controlled by the assembly conditions. The average number of quasi-repeated units in a construct is defined as the repetitive index (RI).
[00358] Once formed, the constructs may, or may not be size fractionated on an agarose gel according to published protocols, inserted into a cloning vector, and transfected into an appropriate host cell. The cells are then propagated and "reductive reassortment" is effected. The rate of the reductive reassortment process may be stimulated by the introduction of DNA damage if desired. Whether the reduction in RI is mediated by deletion formation between repeated sequences by an "intra-molecular" mechanism, or mediated by recombination-like events through "inter-molecular" mechanisms is immaterial. The end result is a reassortment of the molecules into all possible combinations. [00359] Optionally, the method comprises the additional step of screening the library members of the shuffled pool to identify individual shuffled library members having the ability to bind or otherwise interact, or catalyze a particular reaction (e.g., such as catalytic domain of an enzyme) with a predetermined macromolecule, such as for example a proteinaceous receptor, an oligosaccharide, virion, or other predetermined compound or structure.
[00360] The polypeptides that are identified from such libraries can be used for therapeutic, diagnostic, research and related puφoses (e.g. , catalysts, solutes for increasing osmolarity of an aqueous solution, and the like), and/or can be subjected to one or more additional cycles of shuffling and/or selection.
[00361] In another aspect, it is envisioned that prior to or during recombination or reassortment, polynucleotides generated by the method of the invention can be subjected to agents or processes which promote the introduction of mutations into the original polynucleotides. The introduction of such mutations would increase the diversity of resulting hybrid polynucleotides and polypeptides encoded therefrom. The agents or processes which promote mutagenesis can include, but are not limited to: (+)-CC-1065, or a synthetic analog such as (+)-CC-1065-(N3-Adenine (See Sun and Hurley, (1992); an N-acetylated or deacetylated 4'-fluro-4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See , for example, van de Poll et al. (1992)); or a N-acetylated or deacetylated 4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See also, van de Poll et al. (1992), pp. 751-758); trivalent chromium, a trivalent chromium salt, a polycyclic aromatic hydrocarbon (PAH) DNA adduct capable of inhibiting DNA replication, such as 7-bromomethyl- benz[α]anthracene ("BMA"), tris(2,3-dibromopropyl)phosphate ("Tris-BP"), l,2-dibromo-3- chloropropane ("DBCP"), 2-bromoacrolein (2BA), benzo[α]pyrene-7,8-dihydrodiol-9-10- epoxide ("BPDE"), a platinum(II) halogen salt, N-hydroxy-2-amino-3-methylimidazo[4,5- |- quinoline ("N-hydroxy-IQ"), and N-hydroxy-2-amino-l-methyl-6-phenylimidazo[4,5- j- pyridine ("N-hydroxy-PhIP"). One means for slowing or halting PCR amplification consist of UV light (+)-CC-1065 and (+)-CC-1065-(N3-Adenine). Particularly encompassed means are DNA adducts or polynucleotides comprising the DNA adducts from the polynucleotides or polynucleotides pool, which can be released or removed by a process including heating the solution comprising the polynucleotides prior to further processing. [00362] In another aspect the invention is directed to a method of producing recombinant proteins having biological activity by treating a sample comprising double- stranded template polynucleotides encoding a wild-type protein under conditions according to the invention which provide for the production of hybrid or re-assorted polynucleotides. Optimizing codons to achieve high levels of protein expression in host cells [00363] The invention provides methods for modifying phosphatase-encoding nucleic acids to modify codon usage. In one aspect, the invention provides methods for modifying codons in a nucleic acid encoding a phosphatase to increase or decrease its expression in a host cell. The invention also provides nucleic acids encoding a phosphatase modified to increase its expression in a host cell, phosphatase enzymes so modified, and methods of making the modified phosphatase enzymes. The method comprises identifying a "non- prefened" or a "less prefened" codon in phosphatase-encoding nucleic acid and replacing one or more of these non-prefened or less prefened codons with a "prefened codon" encoding the same amino acid as the replaced codon and at least one non-prefened or less preferred codon in the nucleic acid has been replaced by a preferred codon encoding the same amino acid. A prefened codon is a codon over-represented in coding sequences in genes in the host cell and a non-prefened or less preferred codon is a codon under- represented in coding sequences in genes in the host cell.
[00364] Host cells for expressing the nucleic acids, expression cassettes and vectors of the invention include bacteria, yeast, fungi, plant cells, insect cells and mammalian cells. Thus, the invention provides methods for optimizing codon usage in all of these cells, codon- altered nucleic acids and polypeptides made by the codon-altered nucleic acids. Exemplary host cells include gram negative bacteria, such as Escherichia coli and Pseudomonas fluorescens; gram positive bacteria, such as Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris, Bacillus subtilis. Exemplary host cells also include eukaryotic organisms, e.g., various yeast, such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger, and mammalian cells and cell lines and insect cells and cell lines. Thus, the invention also includes nucleic acids and polypeptides optimized for expression in these organisms and species.
[00365] For example, the codons of a nucleic acid encoding a phosphatase isolated from a bacterial cell are modified such that the nucleic acid is optimally expressed in a bacterial cell different from the bacteria from which the phosphatase was derived, a yeast, a fungi, a plant cell, an insect cell or a mammalian cell. Methods for optimizing codons are well known in the art, see, e.g., U.S. Patent No. 5,795,737; Baca (2000) Int. J. Parasitol. 30:113-118; Hale (1998) Protein Expr. Purif. 12:185-188; Narum (2001) Infect. Immun. 69:7250-7253. See also Narum (2001) Infect. Immun. 69:7250-7253, describing optimizing codons in mouse systems; Outchkourov (2002) Protein Expr. Purif. 24:18-24, describing optimizing codons in yeast; Feng (2000) Biochemistry 39:15399-15409, describing optimizing codons in E. coli; Humphreys (2000) Protein Expr. Purif. 20:252-264, describing optimizing codon usage that affects secretion in E. coli. Transgenic non-human animals
[00366] The invention provides transgenic non-human animals comprising a nucleic acid, a polypeptide, an expression cassette or vector or a transfected or transformed cell of the invention. The transgenic non-human animals can be, e.g., goats, rabbits, sheep, pigs, cows, rats and mice, comprising the nucleic acids of the invention. These animals can be used, e.g., as in vivo models to study phosphatase activity, or, as models to screen for modulators of phosphatase activity in vivo. The coding sequences for the polypeptides to be expressed in the transgenic non-human animals can be designed to be constitutive, or, under the control of tissue-specific, developmental-specific or inducible transcriptional regulatory factors. Transgenic non-human animals can be designed and generated using any method known in the art; see, e.g., U.S. Patent Nos. 6,211,428; 6,187,992; 6,156,952; 6,118,044; 6,111,166; 6,107,541; 5,959,171; 5,922,854; 5,892,070; 5,880,327; 5,891,698; 5,639,940; 5,573,933; 5,387,742; 5,087,571, describing making and using transformed cells and eggs and transgenic mice, rats, rabbits, sheep, pigs and cows. See also, e.g., Pollock (1999) J. Immunol. Methods 231 :147-157, describing the production of recombinant proteins in the milk of transgenic dairy animals; Baguisi (1999) Nat. Biotechnol. 17:456-461, demonstrating the production of transgenic goats. U.S. Patent No. 6,211,428, describes making and using transgenic non-human mammals which express in their brains a nucleic acid construct comprising a DNA sequence. U.S. Patent No. 5,387,742, describes injecting cloned recombinant or synthetic DNA sequences into fertilized mouse eggs, implanting the injected eggs in pseudo-pregnant females, and growing to term transgenic mice whose cells express proteins related to the pathology of Alzheimer's disease. U.S. Patent No. 6,187,992, describes making and using a transgenic mouse whose genome comprises a disruption of the gene encoding amyloid precursor protein (APP).
[00367] Knockout animals" can also be used to practice the methods of the invention. For example, in one aspect, the transgenic or modified animals of the invention comprise a "knockout animal," e.g., a "knockout mouse," engineered not to express or to be unable to express a phosphatase.
Screening Methodologies and "On-line" Monitoring Devices [00368] In practicing the methods of the invention, a variety of apparatus and methodologies can be used to in conjunction with the polypeptides and nucleic acids of the invention, e.g., to screen polypeptides for phosphatase reactivity, to screen compounds as potential modulators of activity (e.g., potentiation or inhibition of enzyme activity), for antibodies that bind to a polypeptide of the invention, for nucleic acids that hybridize to a nucleic acid of the invention, and the like. Immobilized Enzyme Solid Supports
[00369] The phosphatase enzymes, fragments thereof and nucleic acids that encode the enzymes and fragments can be affixed to a solid support. This is often economical and efficient in the use of the phosphatases in industrial processes. For example, a consortium or cocktail of phosphatase enzymes (or active fragments thereof), which are used in a specific chemical reaction, can be attached to a solid support and dunked into a process vat. The enzymatic reaction can occur. Then, the solid support can be taken out of the vat, along with the enzymes affixed thereto, for repeated use. En one embodiment of the invention, an isolated nucleic acid of the invention is affixed to a solid support. In another embodiment of the invention, the solid support is selected from the group of a gel, a resin, a polymer, a ceramic, a glass, a microelectrode and any combination thereof.
[00370] For example, solid supports useful in this invention include gels. Some examples of gels include Sepharose, gelatin, glutaraldehyde, chitosan-treated glutaraldehyde, albumin-glutaraldehyde, chitosan-Xanthan, toyopearl gel (polymer gel), alginate, alginate- polylysine, canageenan, agarose, glyoxyl agarose, magnetic agarose, dextran-agarose, poly(Carbamoyl Sulfonate) hydrogel, BSA-PEG hydrogel, phosphorylated polyvinyl alcohol (PVA), monoaminoethyl-N-÷aminoethyl (MANA), amino, or any combination thereof.
[00371] Another solid support useful in the present invention are resins or polymers. Some examples of resins or polymers include cellulose, acrylamide, nylon, rayon, polyester, anion-exchange resin, AMBERLITE™ XAD-7, AMBERLITE™ XAD-8, AMBERLITE™ ERA-94, AMBERLITE™ IRC-50, polyvinyl, polyacrylic, polymethacrylate, or any combination thereof, another type of solid support useful in the present invention is ceramic. Some examples include non-porous ceramic, porous ceramic, SiO2, A1203. Another type of solid support useful in the present invention is glass. Some examples include non-porous glass, porous glass, aminopropyl glass or any combination thereof. Another type of solid support that can be used is a microelectrode. An example is a polyethyleneimine-coated magnetite. Graphitic particles can be used as a solid support. Another example of a solid support is a cell, such as a red blood cell. Methods of immobilization
[00372] There are many methods that would be known to one of skill in the art for immobilizing enzymes or fragments thereof, or nucleic acids, onto a solid support. Some examples of such methods include, e.g., electrostatic droplet generation, electrochemical means, via adsoφtion, via covalent binding, via cross-linking, via a chemical reaction or process, via encapsulation, via entrapment, via calcium alginate, or via poly (2-hydroxyethyl methacrylate). Like methods are described in Methods in Enzymology, Immobilized Enzymes and Cells, Part C. 1987. Academic Press. Edited by S. P. Colowick and N. O. Kaplan. Volume 136; and Immobilization of Enzymes and Cells. 1997. Humana Press. Edited by G. F. Bickerstaff. Series: Methods in Biotechnology, Edited by J. M. Walker. Capillary Arrays
[00373] Capillary arrays, such as the GIGAMATRIX™, Diversa Coφoration, San Diego, CA, can be used to in the methods of the invention. Nucleic acids or polypeptides of the invention can be immobilized to or applied to an anay, including capillary arrays. Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention. Capillary anays provide another system for holding and screening samples. For example, a sample screening apparatus can include a plurality of capillaries formed into an anay of adjacent capillaries, wherein each capillary comprises at least one wall defining a lumen for retaining a sample. The apparatus can further include interstitial material disposed between adjacent capillaries in the anay, and one or more reference indicia formed within of the interstitial material. A capillary for screening a sample, wherein the capillary is adapted for being bound in an array of capillaries, can include a first wall defining a lumen for retaining the sample, and a second wall formed of a filtering material, for filtering excitation energy provided to the lumen to excite the sample. [00374] A polypeptide or nucleic acid, e.g., a ligand, can be introduced into a first component into at least a portion of a capillary of a capillary array. Each capillary of the capillary anay can comprise at least one wall defining a lumen for retaining the first component. An air bubble can be introduced into the capillary behind the first component. A second component can be introduced into the capillary, wherein the second component is separated from the first component by the air bubble. A sample of interest can be introduced as a first liquid labeled with a detectable particle into a capillary of a capillary anay, wherein each capillary of the capillary anay comprises at least one wall defining a lumen for retaining the first liquid and the detectable particle, and wherein the at least one wall is coated with a binding material for binding the detectable particle to the at least one wall. The method can further include removing the first liquid from the capillary tube, wherein the bound detectable particle is maintained within the capillary, and introducing a second liquid into the capillary tube.
[00375] The capillary array can include a plurality of individual capillaries comprising at least one outer wall defining a lumen. The outer wall of the capillary can be one or more walls fused together. Similarly, the wall can define a lumen that is cylindrical, square, hexagonal or any other geometric shape so long as the walls form a lumen for retention of a liquid or sample. The capillaries of the capillary array can be held together in close proximity to form a planar structure. The capillaries can be bound together, by being fused (e.g., where the capillaries are made of glass), glued, bonded, or clamped side-by-side. The capillary anay can be formed of any number of individual capillaries, for example, a range from 100 to 4,000,000 capillaries. A capillary array can form a microtiter plate having about 100,000 or more individual capillaries bound together. Arrays, or "BioChips"
[00376] Nucleic acids or polypeptides of the invention can be immobilized to or applied to an array. Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention. For example, in one aspect of the invention, a monitored parameter is transcript expression of a phosphatase gene. One or more, or, all the transcripts of a cell can be measured by hybridization of a sample comprising transcripts of the cell, or, nucleic acids representative of or complementary to transcripts of a cell, by hybridization to immobilized nucleic acids on an anay, or "biochip." By using an "array" of nucleic acids on a microchip, some or all of the transcripts of a cell can be simultaneously quantified. Alternatively, arrays comprising genomic nucleic acid can also be used to determine the genotype of a newly engineered strain made by the methods of the invention. "Polypeptide anays" can also be used to simultaneously quantify a plurality of proteins.
[00377] The present invention can be practiced with any known "anay," also refened to as a "microaπay" or "nucleic acid anay" or "polypeptide anay" or "antibody anay" or "biochip," or variation thereof. Arrays are generically a plurality of "spots" or "target elements," each target element comprising a defined amount of one or more biological molecules, e.g., oligonucleotides, immobilized onto a defined area of a substrate surface for specific binding to a sample molecule, e.g., mRNA transcripts.
[00378] In practicing the methods of the invention, any known array and/or method of making and using anays can be incoφorated in whole or in part, or variations thereof, as described, for example, in U.S. Patent Nos. 6,277,628; 6,277,489; 6,261,776; 6,258,606; 6,054,270; 6,048,695; 6,045,996; 6,022,963; 6,013,440; 5,965,452; 5,959,098; 5,856,174; 5,830,645; 5,770,456; 5,632,957; 5,556,752; 5,143,854; 5,807,522; 5,800,992; 5,744,305; 5,700,637; 5,556,752; 5,434,049; see also, e.g., WO 99/51773; WO 99/09217; WO 97/46313; WO 96/17958; see also, e.g., Johnston (1998) Cun. Biol. 8:R171-R174; Schummer (1997) Biotechniques 23:1087-1092; Kern (1997) Biotechniques 23:120-124; Solinas-Toldo (1997) Genes, Chromosomes & Cancer 20:399-407; Bowtell (1999) Nature Genetics Supp. 21:25-32. See also published U.S. patent applications Nos. 20010018642; 20010019827; 20010016322; 20010014449; 20010014448; 20010012537; 20010008765. Polypeptides and peptides
[00379] The invention provides an isolated or recombinant polypeptides having at least 50%o to about 99%> or more sequence identity to SEQ ED NOs:28 to 36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, and SEQ ED NO:54, over a region of at least about 100 residues to the full length of the protein. [00380] The isolated nucleic acids of one of the Group A nucleic acid sequences, and sequences substantially identical thereto, may be used to prepare one of the polypeptides of a Group B amino acid sequence, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, .75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is an isolated or purified polypeptide comprising the sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. As discussed above, such polypeptides may be obtained by inserting a nucleic acid encoding the polypeptide into a vector such that the coding sequence is operably linked to a sequence capable of driving the expression of the encoded polypeptide in a suitable host cell. For example, the expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.
[00381] In some aspects, the nucleic acid encoding one of the polypeptides of Group B' amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof. Optionally, the nucleic acid can encode a fusion polypeptide in which one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is fused to heterologous peptides or polypeptides, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification.
[00382] Alternatively, the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be synthetically produced by conventional peptide synthesizers. In other aspects, fragments or portions of the polypeptides may be employed for producing the conesponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides.
[00383 ] Cell-free translation systems can also be employed to produce one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof using mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof. In some aspects, the DNA construct may be linearized prior to conducting an in vitro transcription reaction. The transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.
[00384] The invention also relates to variants of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. The term "variant" includes derivatives or analogs of these polypeptides. In particular, the variants may differ in amino acid sequence from the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination. [00385] The variants may be naturally occurring or created in vitro. En particular, such variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, Exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures. [00386] Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids which encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the sequence obtained from the natural isolate are generated and characterized. Typically, these nucleotide differences result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates.
[00387] For example, variants may be created using enor prone PCR. En error prone PCR, PCR is performed under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Enor prone PCR is described in Leung, D.W., et al, Technique, 1:11-15, 1989) and Caldwell, R. C. & Joyce G.F., PCR Methods Applic, 2:28-33, 1992. Briefly, in such procedures, nucleic acids to be mutagenized are mixed with PCR primers, reaction buffer, MgCl2, MnCl2, Taq polymerase and an appropriate concentration of dNTPs for achieving a high rate of point mutation along the entire length of the PCR product. For example, the reaction may be performed using 20 fmoles of nucleic acid to be mutagenized, 30pmole of each PCR primer, a reaction buffer comprising 50mM KC1, lOmM Tris HCl (pH 8.3) and 0.01% gelatin, 7mM MgCl2, 0.5mM MnCl2, 5 units of Taq polymerase, 0.2mM dGTP, 0.2mM dATP, ImM dCTP, and ImM dTTP. PCR may be performed for 30 cycles of 94° C for 1 min, 45° C for 1 min, and 72° C for 1 min. However, it will be appreciated that these parameters may be varied as appropriate. The mutagenized nucleic acids are cloned into an appropriate vector and the activities of the polypeptides encoded by the mutagenized nucleic acids is evaluated.
[00388] Variants may also be created using oligonucleotide directed mutagenesis to generate site-specific mutations in any cloned DNA of interest. Oligonucleotide mutagenesis is described in Reidhaar-Olson, J.F. & Sauer, R.T., et al, Science, 241:53-57, 1988. Briefly, in such procedures a plurality of double stranded oligonucleotides bearing one or more mutations to be introduced into the cloned DNA are synthesized and inserted into the cloned DNA to be mutagenized. Clones containing the mutagenized DNA are recovered and the activities of the polypeptides they encode are assessed.
[00389] Another method for generating variants is assembly PCR. Assembly PCR involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction. Assembly PCR is described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, "Method of DNA Reassembly by Interrupting Synthesis".
[00390] Still another method of generating variants is sexual PCR mutagenesis. In sexual PCR mutagenesis, forced homologous recombination occurs between DNA molecules of different but highly related DNA sequence in vitro, as a result of random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Sexual PCR mutagenesis is described in Stemmer, W.P., PNAS, USA, 91:10747-10751, 1994. Briefly, in such procedures a plurality of nucleic acids to be recombined are digested with DNase to generate fragments having an average size of 50-200 nucleotides. Fragments of the desired average size are purified and resuspended in a PCR mixture. PCR is conducted under conditions which facilitate recombination between the nucleic acid fragments. For example, PCR may be performed by resuspending the purified fragments at a concentration of 10-30ng/μl in a solution of 0.2mM of each dNTP, 2.2mM MgC12, 50mM KCL, lOmM Tris HCl, pH 9.0, and 0.1% Triton X- 100. 2.5 units of Taq polymerase per lOOμl of reaction mixture is added and PCR is performed using the following regime: 94° C for 60 seconds, 94° C for 30 seconds, 50-55° C for 30 seconds, 72° C for 30 seconds (30-45 times) and 72° C for 5 minutes. However, it will be appreciated that these parameters may be varied as appropriate. In some aspects, oligonucleotides may be included in the PCR reactions. In other aspects, the Klenow fragment of DNA polymerase I may be used in a first set of PCR reactions and Taq polymerase may be used in a subsequent set of PCR reactions. Recombinant sequences are isolated and the activities of the polypeptides they encode are assessed. [00391] Variants may also be created by in vivo mutagenesis. In some aspects, random mutations in a sequence of interest are generated by propagating the sequence of interest in a bacterial strain, such as an E. coli strain, which carries mutations in one or more of the DNA repair pathways. Such "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA. Mutator strains suitable for use for in vivo mutagenesis are described in PCT Publication No. WO 91/16427, published October 31, 1991, entitled "Methods for Phenotype Creation from Multiple Gene Populations". [00392 ] Variants may also be generated using cassette mutagenesis. In cassette mutagenesis a small region of a double stranded DNA molecule is replaced with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence. [00393] Recursive ensemble mutagenesis may also be used to generate variants. Recursive ensemble mutagenesis is an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Recursive ensemble mutagenesis is described, e.g., in Arid (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815. [00394] In some aspects, variants are created using exponential ensemble mutagenesis. Exponential ensemble mutagenesis is a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. Exponential ensemble mutagenesis is described in Delegrave (1993) Biotechnology Research 11 :1548-1552. Random and site-directed mutagenesis are described in Arnold (1993) Cunent Opinion in Biotechnology 4:450-455. [00395] In some aspects, the variants are created using shuffling procedures wherein portions of a plurality of nucleic acids which encode distinct polypeptides are fused together to create chimeric nucleic acid sequences which encode chimeric polypeptides as described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, "Method of DNA Reassembly by Interrupting Synthesis", and U.S. Patent No. 5,939,250, filed May 22, 1996, entitled, "Production of Enzymes Having Desired Activities by Mutagenesis". [00396] The variants of the polypeptides of Group B amino acid sequences may be variants in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences are substituted with a conserved or non-conserved amino acid residue (can be a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.
[00397] Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Alanine, Valine, Leucine and Isoleucine with another aliphatic amino acid; replacement of a Serine with a Threonine or vice versa; replacement of an acidic residue such as Aspartic acid and Glutamic acid with another acidic residue; replacement of a residue bearing an amide group, such as Asparagine and Glutamine, with another residue bearing an amide group; exchange of a basic residue such as Lysine and Arginine with another basic residue; and replacement of an aromatic residue such as Phenylalanine, Tyrosine with another aromatic residue. Other variants are those in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences includes a substituent group. Still other variants are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol). Additional variants are those in which additional amino acids are fused to the polypeptide, such as a leader sequence, a secretory sequence, a proprotein sequence or a sequence which facilitates purification, enrichment, or stabilization of the polypeptide. [00398] In some aspects, the fragments, derivatives and analogs retain the same biological function or activity as a polypeptide of the invention, e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. In other aspects, the fragment, derivative, or analog includes a proprotein, such that the fragment, derivative, or analog can be activated by cleavage of the proprotein portion to produce an active polypeptide.
[00399] Another aspect of the invention is polypeptides or fragments thereof which have at least about 50%, at least about 55%, at least about 60%, at least about 65%>, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more than about 95%> homology to a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. Homology may be determined using any of the programs described above which aligns the polypeptides or fragments being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid "homology" includes conservative amino acid substitutions such as those described above. [00400] The polypeptides or fragments having homology to a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be obtained by isolating the nucleic acids encoding them using the techniques described above. [00401] Alternatively, the homologous polypeptides or fragments may be obtained through biochemical enrichment or purification procedures. The sequence of potentially homologous polypeptides or fragments may be determined by proteolytic digestion, gel electrophoresis and/or microsequencing. The sequence of the prospective homologous polypeptide or fragment can be compared to a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof using any of the programs described above. [00402] Another aspect of the invention is an assay for identifying fragments or variants of a polypeptide of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of a polypeptide of the invention, e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. For example the fragments or variants of said polypeptides, may be used to catalyze biochemical reactions, which indicate that the fragment or variant retains the enzymatic activity of a polypeptide of the invention, e.g., the polypeptides in the Group B amino acid sequences.
[00403 ] The assay for determining if fragments of variants retain the enzymatic activity of the polypeptides of a polypeptide of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto includes the steps of: contacting the polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate.
[00404] The polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in a variety of applications. For example, the polypeptides or fragments thereof may be used to catalyze biochemical reactions. In accordance with one aspect of the invention, there is provided a process for utilizing a polypeptide of the invention, e.g., the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto or polynucleotides encoding such polypeptides for hydrolyzing glycosidic linkages. In such procedures, a substance containing a glycosidic linkage (e.g., a starch) is contacted with a polypeptide of the invention, e.g., one of the polypeptides of Group B amino acid sequences, or sequences substantially identical thereto under conditions which facilitate the hydrolysis of the glycosidic linkage.
[00405] Enzymes are highly selective catalysts. Their hallmark is the ability to catalyze reactions with exquisite stereo-, regio-, and chemo- selectivities that are unparalleled in conventional synthetic chemistry. Moreover, enzymes are remarkably versatile. They can be tailored to function in organic solvents, operate at extreme pHs (for example, high pHs and low pHs) extreme temperatures (for example, high temperatures and low temperatures), extreme salinity levels (for example, high salinity and low salinity), and catalyze reactions with compounds that are structurally unrelated to their natural, physiological substrates. [00406] Enzymes are reactive toward a wide range of natural and unnatural substrates, thus enabling the modification of virtually any organic lead compound. Moreover, unlike traditional chemical catalysts, enzymes are highly enantio- and regio-selective. The high degree of functional group specificity exhibited by enzymes enables one to keep track of each reaction in a synthetic sequence leading to a new active compound. Enzymes are also capable of catalyzing many diverse reactions unrelated to their physiological function in nature.
[00407] The present invention exploits the unique catalytic properties of enzymes. Whereas the use of biocatalysts (i.e., purified or crude enzymes, non-living or living cells) in chemical transformations normally requires the identification of a particular biocatalyst that reacts with a specific starting compound, the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds. Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group. The biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original compound can be produced with each iteration of biocatalytic derivatization. [00408] Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods. This high degree of biocatalytic specificity provides the means to identify a single active compound within the library. The library is characterized by the series of biocatalytic reactions used to produce it, a so-called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined. This mode of identification, unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.
[00409] Many of the procedural steps are performed using robotic automation enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility. As a result, a library of derivative compounds can be produced in a matter of weeks which would take years to produce using current chemical methods. (For further teachings on modification of molecules, including small molecules, see PCT/US94/09174, herein incoφorated by reference in its entirety).
[00410] Enzymes encoded by the polynucleotides of the invention include, but are not limited to, hydrolases, such as phosphatases. A hybrid polypeptide resulting from the method of the invention may exhibit specialized enzyme activity not displayed in the original enzymes. For example, following recombination and/or reductive reassortment of polynucleotides encoding hydrolase activities, the resulting hybrid polypeptide encoded by a hybrid polynucleotide can be screened for specialized hydrolase activities obtained from each of the original enzymes, i.e. the type of bond on which the hydrolase acts and the temperature at which the hydrolase functions. Thus, for example, the hydrolase may be screened to ascertain those chemical functionalities which distinguish the hybrid hydrolase from the original hydrolases, such as: (a) amide (peptide bonds), i.e., proteases; (b) ester bonds, i.e., esterases and Upases; (c) acetals, i.e., glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.
[00411] Sources of the original polynucleotides may be isolated from individual organisms ("isolates"), collections of organisms that have been grown in defined media ("enrichment cultures"), or, uncultivated organisms ("environmental samples"). The use of a culture-independent approach to derive polynucleotides encoding novel bioactivities from environmental samples can be used since it allows one to access untapped resources of biodiversity.
[00412] "Environmental libraries" are generated from environmental samples and represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. Because the cloned DNA is initially extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species.
[00413] For example, gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest. Potential pathways encoding bioactive molecules of interest are first captured in prokaryotic cells in the form of gene expression libraries. Polynucleotides encoding activities of interest are isolated from such libraries and introduced into a host cell. The host cell is grown under conditions which promote recombination and/or reductive reassortment creating potentially active biomolecules with novel or enhanced activities.
[00414] The microorganisms from which the polynucleotide may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. Polynucleotides may be isolated from environmental samples in which case the nucleic acid may be recovered without culturing of an organism or recovered from one or more cultured organisms. In one aspect, such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, barophiles and acidophiles. Polynucleotides encoding enzymes isolated from extremophilic microorganisms can be used. Such enzymes may function at temperatures above 100°C in tenestrial hot springs and deep sea thermal vents, at temperatures below 0°C in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge. For example, several esterases and lipases cloned and expressed from extremophilic organisms show high activity throughout a wide range of temperatures and pHs.
[00415] As used herein the term "a polypeptide sequence as set forth in SEQ ID Nos.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 43, 44, 46, 47, 48, 50, 52, and 54" encompasses the polypeptide sequence of Group B amino acid sequences, and sequences substantially identical thereto, which are encoded by a sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, 53, polypeptide sequences homologous to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments of any of the preceding sequences. Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%o, 98%>, 97%>, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%,or 50% homology to one of the polypeptide sequences of the Group B amino acid sequences. Homology maybe determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may result from the conection of a sequencing error. The polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. It will be appreciated that the polypeptide codes as set forth in Group B amino acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.
[00416] It will be appreciated by those skilled in the art that a nucleic acid sequence as set forth in SEQ ED Nos.: 19, 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 41, 43, 45, 47, 49, 51, and 53 and a polypeptide sequence as set forth in SEQ ED Nos.:28, 29, 30, 31, 32, 33, 34, 35, 36, 42, 44, 46, 48, 50, 52, and 54. Biochemical pathways
[00417] En another aspect, methods of the invention can be used to generate novel polynucleotides encoding biochemical pathways from one or more operons or gene clusters or portions thereof. For example, bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures refened to as "gene clusters," on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function. An example of a biochemical pathway encoded by gene clusters are polyketides.
[00418] Gene cluster DNA can be isolated from different organisms and ligated into vectors, particularly vectors containing expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli. This f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples. One aspect is to use cloning vectors, referred to as "fosmids" or bacterial artificial chromosome (BAC) vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library." Another type of vector for use in the present invention is a cosmid vector. Cosmid vectors were originally designed to clone and propagate large segments of genomic DNA. Cloning into cosmid vectors is described in detail in Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd Εd.. Cold Spring Harbor Laboratory Press (1989). Once ligated into an appropriate vector, two or more vectors containing different polyketide synthase gene clusters can be introduced into a suitable host cell. Regions of partial sequence homology shared by the gene clusters will promote processes which result in sequence reorganization resulting in a hybrid gene cluster. The novel hybrid gene cluster can then be screened for enhanced activities not found in the original gene clusters.
[00419] In a one aspect, the invention relates to a method for producing a biologically active hybrid polypeptide and screening such a polypeptide for enhanced activity by: [00420] 1 ) introducing at least a first polynucleotide in operable linkage and a second polynucleotide in operable linkage, said at least first polynucleotide and second polynucleotide sharing at least one region of partial sequence homology, into a suitable host cell;
[00421] 2) growing the host cell under conditions which promote sequence reorganization resulting in a hybrid polynucleotide in operable linkage; [00422] 3) expressing a hybrid polypeptide encoded by the hybrid polynucleotide;
[00423] 4) screening the hybrid polypeptide under conditions which promote identification of enhanced biological activity; and [00424] 5) isolating the a polynucleotide encoding the hybrid polypeptide. [00425] Methods for screening for various enzyme activities are known to those of skill in the art and are discussed throughout the present specification. Such methods may be employed when isolating the polypeptides and polynucleotides of the invention. Antibodies and Antibody-based screening methods
[00426] The invention provides isolated or recombinant antibodies that specifically bind to a polypeptide of the invention. These antibodies can be used to isolate, identify or quantify the peptides and polypeptides of the invention or related proteins. These antibodies can be used to inhibit the activity of an enzyme of the invention. These antibodies can be used to isolated polypeptides related to those of the invention, e.g., related phosphatase enzymes.
[00427] The polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto or fragments, can comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof, may also be used to generate antibodies which bind specifically to the polypeptides or fragments. The resulting antibodies may be used in immunoaffinity chromatography procedures to isolate or purify the polypeptide or to determine whether the polypeptide is present in a biological sample. En such procedures, a protein preparation, such as an extract, or a biological sample is contacted with an antibody capable of specifically binding to one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.
[00428] En immunoaffinity procedures, the antibody is attached to a solid support, such as a bead or other column matrix. The protein preparation is placed in contact with the antibody under conditions in which the antibody specifically binds to one of the polypeptides of the invention, e.g., Group B amino acid sequences, and sequences substantially identical thereto, or fragment thereof. After a wash to remove non-specifically bound proteins, the specifically bound polypeptides are eluted.
[00429] The ability of proteins in a biological sample to bind to the antibody may be determined using any of a variety of procedures familiar to those skilled in the art. For example, binding may be determined by labeling the antibody with a detectable label such as a fluorescent agent, an enzymatic label, or a radioisotope. Alternatively, binding of the antibody to the sample may be detected using a secondary antibody having such a detectable label thereon. Particular assays include ELISA assays, sandwich assays, radioimmunoassays, and Western Blots.
[00430] Polyclonal antibodies generated against.the polypeptides the invention, e.g., of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, for example, a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies which may bind to the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from cells expressing that polypeptide.
[00431] For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, Nature, 256:495-497, 1975), the trioma technique, the human B-cell hybridoma technique (Kozbor et al, Immunology Today 4:72, 1983), and the EBV-hybridoma technique (Cole, et al, 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
[00432 ] Techniques described for the production of single chain antibodies (e.g., U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. Alternatively, transgenic mice may be used to express humanized antibodies to these polypeptides or fragments thereof.
[00433] Antibodies generated against the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in screening for similar polypeptides from other organisms and samples. In such techniques, polypeptides from the organism are contacted with the antibody and those polypeptides which specifically bind the antibody are detected. Any of the procedures described above may be used to detect antibody binding. One such screening assay is described in "Methods for Measuring Cellulase Activities", Methods in Enzymology, Vol 160, pp. 87-116. Catalytic properties of enzymes
[00434] The present invention exploits the unique catalytic properties of enzymes. Whereas the use of biocatalysts (i.e., purified or crude enzymes, non-living or living cells) in chemical transformations normally requires the identification of a particular biocatalyst that reacts with a specific starting compound, the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds, such as small molecules. Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.
[00435] The biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original small molecule or compound can be produced with each iteration of biocatalytic derivatization.
[00436] Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods. This high degree of biocatalytic specificity provides the means to identify a single active compound within the library. The library is characterized by the series of biocatalytic reactions used to produce it, a so called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined. This mode of identification, unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.
[00437] Many of the procedural steps are performed using robotic automation enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility. As a result, a library of derivative compounds can be produced in a matter of weeks which would take years to produce using cunent chemical methods.
[00438] In a particular aspect, the invention provides a method for modifying small molecules, comprising contacting a polypeptide encoded by a polynucleotide described herein or enzymatically active fragments thereof with a small molecule to produce a modified small molecule. A library of modified small molecules is tested to determine if a modified small molecule is present within the library which exhibits a desired activity. A specific biocatalytic reaction which produces the modified small molecule of desired activity is identified by systematically eliminating each of the biocatalytic reactions used to produce a portion of the library, and then testing the small molecules produced in the portion of the library for the presence or absence of the modified small molecule with the desired activity. The specific biocatalytic reactions which produce the modified small molecule of desired activity is optionally repeated. The biocatalytic reactions are conducted with a group of biocatalysts that react with distinct structural moieties found within the structure of a small molecule, each biocatalyst is specific for one structural moiety or a group of related structural moieties; and each biocatalyst reacts with many different small molecules which contain the distinct structural moiety. Kits
[00439] The invention provides kits comprising the compositions, e.g., nucleic acids, expression cassettes, vectors, cells, polypeptides (e.g., phosphatases) and/or antibodies of the invention. The kits also can contain instructional material teaching the methodologies and industrial uses of the invention, as described herein. Measuring Metabolic Parameters
[00440] The methods of the invention involve whole cell evolution, or whole cell engineering, of a cell to develop a new cell strain having a new phenotype by modifying the genetic composition of the cell, where the genetic composition is modified by addition to the cell of a nucleic acid of the invention. To detect the new phenotype, at least one metabolic parameter of a modified cell is monitored in the cell in a "real time" or "on-line" time frame. In one aspect, a plurality of cells, such as a cell culture, is monitored in "real time" or "on- line." In one aspect, a plurality of metabolic parameters is monitored in "real time" or "online."
[00441] Metabolic flux analysis (MFA) is based on a known biochemistry framework. A linearly independent metabolic matrix is constructed based on the law of mass conservation and on the pseudo-steady state hypothesis (PSSH) on the intracellular metabolites. In practicing the methods of the invention, metabolic networks are established, including the:
[00442] • identity of all pathway substrates, products and intermediary metabolites
[00443] • identity of all the chemical reactions interconverting the pathway metabolites, the stoichiometry of the pathway reactions,
[00444] • identity of all the enzymes catalyzing the reactions, the enzyme reaction kinetics,
[00445] - the regulatory interactions between pathway components, e.g. allosteric interactions, enzyme-enzyme interactions etc,
[00446] • intracellular compartmentalization of enzymes or any other supramolecular organization of the enzymes, and,
[00447] - the presence of any concentration gradients of metabolites, enzymes or effector molecules or diffusion barriers to their movement.
[00448] Once the metabolic network for a given strain is built, mathematic presentation by matrix notion can be introduced to estimate the intracellular metabolic fluxes if the on-line metabolome data is available.
[00449] Metabolic phenotype relies on the changes of the whole metabolic network within a cell. Metabolic phenotype relies on the change of pathway utilization with respect to environmental conditions, genetic regulation, developmental state and the genotype, etc. In one aspect of the methods of the invention, after the on-line MFA calculation, the dynamic behavior of the cells, their phenotype and other properties are analyzed by investigating the pathway utilization. For example, if the glucose supply is increased and the oxygen decreased during the yeast fermentation, the utilization of respiratory pathways will be reduced and/or stopped, and the utilization of the fermentative pathways will dominate. Control of physiological state of cell cultures will become possible after the pathway analysis. The methods of the invention can help determine how to manipulate the fermentation by determining how to change the substrate supply, temperature, use of inducers, etc. to control the physiological state of cells to move along desirable direction. In practicing the methods of the invention, the MFA results can also be compared with transcriptome and proteome data to design experiments and protocols for metabolic engineering or gene shuffling, etc.
[00450] In practicing the methods of the invention, any modified or new phenotype can be confened and detected, including new or improved characteristics in the cell. Any aspect of metabolism or growth can be monitored. Monitoring expression of an mRNA transcript
[00451] In one aspect of the invention, the engineered phenotype comprises increasing or decreasing the expression of an mRNA transcript or generating new transcripts in a cell. mRNA transcript, or message can be detected and quantified by any method known in the art, including, e.g., Northern blots, quantitative amplification reactions, hybridization to anays, and the like. Quantitative amplification reactions include, e.g., quantitative PCR, including, e.g., quantitative reverse transcription polymerase chain reaction, or RT-PCR; quantitative real time RT-PCR, or "real-time kinetic RT-PCR" (see, e.g., Kreuzer (2001) Br. J. Haematol. 114:313-318; Xia (2001) Transplantation 72:907-914).
[00452] In one aspect of the invention, the engineered phenotype is generated by knocking out expression of a homologous gene. The gene's coding sequence or one or more transcriptional control elements can be knocked out, e.g., promoters enhancers. Thus, the expression of a transcript can be completely ablated or only decreased.
[00453 ] En one aspect of the invention, the engineered phenotype comprises increasing the expression of a homologous gene. This can be effected by knocking out of a negative control element, including a transcriptional regulatory element acting in cis- or trans- , or, mutagenizing a positive control element.
[00454] As discussed below in detail, one or more, or, all the transcripts of a cell can be measured by hybridization of a sample comprising transcripts of the cell, or, nucleic acids representative of or complementary to transcripts of a cell, by hybridization to immobilized nucleic acids on an array. Monitoring expression of a polypeptides, peptides and amino acids [00455] In one aspect of the invention, the engineered phenotype comprises increasing or decreasing the expression of a polypeptide or generating new polypeptides in a cell. Polypeptides, peptides and amino acids can be detected and quantified by any method known in the art, including, e.g., nuclear magnetic resonance (NMR), spectrophotometry, radiography (protein radiolabeling), electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, various immunological methods, e.g. immunoprecipitation, immunodiffusion, immuno-electrophoresis, radioimmunoassays (REAs), enzyme-linked immunosorbent assays (ELISAs), immuno-fluorescent assays, gel electrophoresis (e.g., SDS- PAGE), staining with antibodies, fluorescent activated cell sorter (FACS), pyrolysis mass spectrometry, Fourier-Transform Infrared Spectrometry, Raman spectrometry, GC-MS, and LC-Electrospray and cap-LC-tandem-electrospray mass spectrometries, and the like. Novel bioactivities can also be screened using methods, or variations thereof, described in U.S. Patent No. 6,057,103. Furthermore, as discussed below in detail, one or more, or, all the polypeptides of a cell can be measured using a protein anay.
[00456] Biosynthetically directed fractional C labeling of proteinogenic amino acids
1 ^ can be monitored by feeding a mixture of uniformly C-labeled and unlabeled carbon source compounds into a bioreaction network. Analysis of the resulting labeling pattern enables both a comprehensive characterization of the network topology and the determination of metabolic flux ratios of the amino acids; see, e.g., Szyperski (1999) Metab. Eng. 1:189-197.
[00457] The invention will be further described with reference to the following examples; however, it is to be understood that the invention is not limited to such examples.
EXAMPLES Example 1 : Bacterial Expression and-Purification of Alkaline Phosphatase Enzymes
[00458] DNA encoding the enzymes of the present invention, SEQ ID NOS : 1 through 16, were initially amplified from a pBluescript vector containing the DNA by the PCR technique using the primers noted herein. The amplified sequences were then inserted into the respective pQE vector listed beneath the primer sequences, and the enzyme was expressed according to the protocols set forth herein. The 5' and 3' oligonucleotide primer sequences used for subcloning and vectors for the respective genes are as follows: Ammonifex degensii KC4 - 3A1A [00459] 5 ' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG GGG GCA GGT CCG AAA AGG 3' 5' CGGA GGA TCC CTA CAG TTC TAA AAG TCT TTT A 3'
[00460] Vector: pQET3
[00461] Methanococcus igneus Kol5 - 9A1A
[00462 ] 5' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG TTG GAT ATA CTG GIT 3' 5' CCGA CGA TCC TTA TTT TTT AAC CAA ATGT TCC 3'
[00463] Vector: pQET3
[00464] Thermococcus Alcaliphilus AEDII12RA -18A
[00465] 5 ' CCGA CAA TTG ATT AAA GAG GAG AAA TTA ACT ATG ATG ATG GAA TTC ACT CGC 3' 5' CGGA GGA TCC CTA CAG TTC TAA AAG TCT TIT A 3'
[00466] Vector: pQET3
[00467] Thermococcus Celer 25 A IA (incorporating Mfel restriction site)
[00468] 5 ' CCGA CAA TTG ATT AAA GAG GAG AAA TTA ACT ATG AGA ACC CTG AC A ATA AAC 3' 5' CCGA GGA TCC TTA CAC CCA CAG AAC CCT TAC 3'
[00469] Vector pQET3
[00470] Thermococcus GU5L5 - 26AIA
[00471] 5' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG AAA GGA AAG TCT CIT GIT 3' 5' CCGA GGA TCC TCA AGC TTC CTG GAG AAT CAA 3'
[00472 ] Vector pQET3
[00473 ] OC9a - 27A3A
[00474] 5' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG CCA AGA AAT ATC GCC GCT 3' 5' CCGA GGA TCC TTA AGG CIT CTC GAG GTG GGG GIT 3'
[00475] Vector pQET3
[00476] Ml 1 TL - 29 A IA (incorporating Mfel restriction site)
[00477] 5 ' CCGA CAA TTG ATT AAA GAG GAG AAA TTA ACT ATG TAT AAA TGG ATT ATT GAG GG 3' 5' CCGA GGA CTA AAC ATA GTC TAA, GTA ATT AGC 3' [00478] Vector pQET3
[00479] Thermococcus CL-2 30 A IA
[00480] 5' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG AGA ATC CTC CTC ACC AAC 3' 5' CCGA GGA TCC TCA CAG GCT CAG AAG CCT TTG 3'
[00481] Vector pQET3
[00482] Aquifex VF-5 - 34 A IA
[00483] 5' CCGA GAA TTC ATT AAA GAG GAG AAA TTA ACT ATG GAA AAC TTA AAA AAG TAC CT 3' 5' CCGA GGA TCC TCA CCG CCC CCT GCG GGT GCG 3'
[00484] Vector pQET3
[00485] The restriction enzyme sites indicated correspond to the restriction enzyme sites on the bacterial expression vector indicated for the respective gene (Qiagen, Inc. Chatsworth, CA). The pQE vector encodes antibiotic resistance (Amp1), a bacterial origin of replication (ori), an EPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites.
[00486] The pQE vector was digested with the restriction enzymes indicated. The amplified sequences were ligated into the respective pQE vector and inserted in frame with the sequence encoding for the RBS. The native stop codon was incoφorated so the genes were not fused to the His tag of the vector. The ligation mixture was then used to transform the E. coli strain M15/pREP4 (Qiagen, Lnc.) by electroporation. M15/pREP4 contains multiple copies of the plasmid pREP4, which expresses the lad repressor and also confers kanamycin resistance (Kan1). Transformants were identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture was used to inoculate a large culture at a ratio of 1 : 100 to 1 :250. The cells were grown to an optical density 600 (O.D.600) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") was then added to a final concentration of 1 mM. EPTG induces by inactivating the lad repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation.
[00487] The primer sequences set out above may also be employed to isolate the target gene from the deposited material by hybridization techniques described above. Example 2: Isolation of A Selected-Clone From the Deposited Genomic Clones [00488] A clone is isolated directly by screening the deposited material using the oligonucleotide primers set forth in Example 1 for the particular gene desired to be isolated. The specific oligonucleotides are synthesized using an Applied Biosystems DNA synthesizer.
[00489] The two oligonucleotide primers conesponding to the gene of interest are used to amplify the gene from the deposited material. A polymerase chain reaction is carried out in 25 μl of reaction mixture with 0.1 ug of the DNA of the gene of interest. The reaction mixture is 1.5-5 mM MgCl2, 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 1.25 Unit of Taq polymerase. Thirty cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with the Perkin-Elmer Cetus 9600 thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the gene of interest by subcloning and sequencing the DNA product. The ends of the newly purified genes are nucleotide sequenced to identify full length sequences. Complete sequencing of full length genes is then performed by Exonuclease III digestion or primer walking. [00490] While the invention has been described in detail with reference to certain prefened aspects thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.
[00491] A number of aspects of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other aspects are within the scope of the following claims.

Claims

WHAT ES CLAIMED IS:
1. An isolated or recombinant nucleic acid comprising a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity, e.g., a thermostable phosphatase activity, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.
2. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:26 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ID NO:27 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%ι sequence identity to SEQ ED NO:37 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 200 residues, i nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ID NO:41 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:43 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 200 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 200 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:51 over a region of at least about 200 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 200 residues.
3. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 19 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:20 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:22 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:23 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:26 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:39 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:41 over a region of at least about 300 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:43 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ED NO:45 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:49 over a region of at least about 300 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 300 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 53 over a region of at least about 300 residues.
4. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO: 19 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:20 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:22 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:24 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:26 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:37 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:39 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:40 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 400 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 400 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:51 over a region of at least about 400 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 400 residues.
5. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 500 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:22 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:26 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:37 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 500 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:40 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 500 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 500 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:51 over a region of at least about 500 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 500 residues.
6. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:20 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:37 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 600 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 600 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:43 over a region of at least about 600 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 600 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:47 over a region of at least about 600 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:51 over a region of at least about 600 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 53 over a region of at least about 600 residues.
7. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 700 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:27 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 700 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 700 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:41 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 700 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 700 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 700 residues.
8. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:24 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 800 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 800 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 800 residues.
9. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:37 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID
NO:38 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO:39 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 900 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 900 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 53 over a region of at least about 900 residues.
10. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 1000 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 1000 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:37 over a region of at least about 1000 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 1000 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 1000 residues, nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO:40 over a reg giioonn of at least about 1000 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 1000 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 1000 residues.
11. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:19 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 60% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 60% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 60% sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 60% sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 60% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 60%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues.
12. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 10% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 70%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 70% sequence identity to SEQ ED NO: 51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues.
13. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid sequence comprises a nucleic acid sequence having at least 80%> sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ID NO: 24 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 80% sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 80%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues.
14. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 90%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 53 over a region of at least about 100 residues.
15. The isolated or recombinant nucleic acid of claim 1 , wherein the nucleic acid sequence comprises a nucleic acid sequence having at least 95%0 sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 95% sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 95 %> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 95 %> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 95 %> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 95% sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 95 %> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 95%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 95% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 95 %> sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 95% sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues.
16. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid comprises a nucleic acid sequence having at least 98 > sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%o sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 98% sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 98% sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ID NO: 24 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 98% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%o sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, nucleic acid sequence having at least 98%> sequence identity to SEQ ID
NO:39 over a reg giioonn of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%) sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 98% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 98%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 98%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues.
17. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid sequence comprises a nucleic acid having a sequence as set forth in SEQ ID NO: 19, a nucleic acid having a sequence as set forth in SEQ ID NO:20, a nucleic acid having a sequence as set forth in SEQ ID NO:21, a nucleic acid having a sequence as set forth in SEQ ID NO:22, a nucleic acid having a sequence as set forth in SEQ ID NO:23, a nucleic acid having a sequence as set forth in SEQ ED NO:24, a nucleic acid having a sequence as set forth in SEQ ID NO:25, a nucleic acid having a sequence as set forth in SEQ ED NO:26, a nucleic acid having a sequence as set forth in SEQ ED NO:27, a nucleic acid having a sequence as set forth in SEQ ID NO:37, a nucleic acid having a sequence as set forth in SEQ ED NO:38, a nucleic acid having a sequence as set forth in SEQ ED NO:39, a nucleic acid having a sequence as set forth in SEQ ED NO:40, a nucleic acid having a sequence as set forth in SEQ ED NO:41, a nucleic acid having a sequence as set forth in SEQ ED NO:43, a nucleic acid having a sequence as set forth in SEQ ED NO:45, a nucleic acid having a sequence as set forth in SEQ ED NO:47, a nucleic acid having a sequence as set forth in SEQ ED NO:49, a nucleic acid having a sequence as set forth in SEQ ED NO:51, or a nucleic acid having a sequence as set forth in SEQ ED NO:53.
18. The isolated or recombinant nucleic acid of claim 1, wherein the nucleic acid sequence encodes a polypeptide comprising a polypeptide having a sequence as set forth in SEQ ID NO:28, a polypeptide having a sequence as set forth in SEQ ED NO:29, a polypeptide having a sequence as set forth in SEQ ED NO:30, a polypeptide having a sequence as set forth in SEQ ID NO:31, a polypeptide having a sequence as set forth in SEQ ED NO:32, a polypeptide having a sequence as set forth in SEQ ED NO:33, a polypeptide having a sequence as set forth in SEQ ID NO:34, a polypeptide having a sequence as set forth in SEQ ID NO:35, a polypeptide having a sequence as set forth in SEQ ED NO:36, a polypeptide having a sequence as set forth in SEQ ID NO:42, a polypeptide having a sequence as set forth in SEQ ED NO:44, a polypeptide having a sequence as set forth in SEQ ID NO:46, a polypeptide having a sequence as set forth in SEQ ID NO:48, a polypeptide having a sequence as set forth in SEQ ED NO:50, a polypeptide having a sequence as set forth in SEQ ID NO:52, or a polypeptide having a sequence as set forth in SEQ ID NO:54.
19. The isolated or recombinant nucleic acid of claim 1, wherein the sequence comparison algorithm is a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall -p blastp -d "nr pataa" -F F, and all other options are set to default.
20. The isolated or recombinant nucleic acid of claim 1 , wherein the phosphatase activity comprises an alkaline phosphatase activity.
21. The isolated or recombinant nucleic acid of claim 1 , wherein the phosphatase activity comprises a phosphodiesterase activity.
22. The isolated or recombinant nucleic acid of claim 1, wherein the phosphatase activity comprises a phytase activity.
23. The isolated or recombinant nucleic acid of claim 1, wherein the phosphatase activity comprises removal of phosphate group.
24. The isolated or recombinant nucleic acid of claim 21 , wherein the phosphodiesterase activity comprises hydrolysis of the phosphodiester bridges of nucleic acids.
25. The isolated or recombinant nucleic acid of claim 24, wherein the phosphodiesterase activity comprises hydrolysis of the ester linkage between the 3' carbon and the phosphoric group.
26. The isolated or recombinant nucleic acid of claim 24, wherein the phosphodiesterase activity comprises hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge.
27. The isolated or recombinant nucleic acid of claim 22, wherein the phytase activity comprises removal of phosphate from phytic acid (inositol hexaphosphoric acid).
28. The isolated or recombinant nucleic acid of claim 20, wherein the phosphatase activity comprises hydrolysis of monophosphate esters.
29. The isolated or recombinant nucleic acid of claim 28, wherein the phosphatase activity comprises hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
30. The isolated or recombinant nucleic acid of claim 1, wherein the phosphatase activity is thermostable.
31. The isolated or recombinant nucleic acid of claim 30, wherein the polypeptide retains a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C.
32. The isolated or recombinant nucleic acid of claim 1 , wherein the phosphatase activity is thermotolerant.
33. The isolated or recombinant nucleic acid of claim 32, wherein the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C.
34. The isolated or recombinant nucleic acid of claim 32, wherein the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 50°C.
35. An isolated or recombinant nucleic acid, wherein the nucleic acid comprises a sequence that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ED NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ED NO:23, a sequence as set forth in SEQ ED NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ID NO:26, a sequence as set forth in SEQ ED NO:27, a sequence as set forth in SEQ ID NO: 37, a sequence as set forth in SEQ ID NO:38, a sequence as set forth in SEQ ID NO:39, a sequence as set forth in SEQ ED NO: 40, a sequence as set forth in SEQ ID NO:41, a sequence as set forth in SEQ ID NO: 43, a sequence as set forth in SEQ ID NO:45, a sequence as set forth in SEQ ED NO:47, a sequence as set forth in SEQ ED NO:49, a sequence as set forth in SEQ ID NO:51, or a sequence as set forth in SEQ ID NO:53, wherein the nucleic acid encodes a polypeptide having a phosphatase activity.
36. The isolated or recombinant nucleic acid of claim 35, wherein the nucleic acid is at least about 100 residues in length.
37. The isolated or recombinant nucleic acid of claim 35, wherein the nucleic acid is at least about 200 residues in length.
38. The isolated or recombinant nucleic acid of claim 35, wherein the nucleic acid is at least about 300 residues in length.
39. The isolated or recombinant nucleic acid of claim 35, wherein the nucleic acid is at least about 400 residues in length.
40. The isolated or recombinant nucleic acid of claim 35, wherein the nucleic acid is at least about 500, 600, 700, 800, 900, 1000 residues in length or the full length of the gene or transcript.
41. The isolated or recombinant nucleic acid of claim 35, wherein the stringent conditions include a wash step comprising a wash in 0.2X SSC at a temperature of about 65oC for about 15 minutes.
42. A nucleic acid probe for identifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the probe comprises at least 10 consecutive bases of a sequence comprising a sequence as set forth iin SEQ ED NO: 19, a sequence as set forth in SEQ ED NO:20, a sequence as set forth in SEQ ED NO:21, a sequence as set forth in SEQ ED NO:22, a sequence as set forth in SEQ ED NO:23, a sequence as set forth in SEQ ED NO:24, a sequence as set forth in SEQ ED NO:25, a sequence as set forth in SEQ ED NO:26, a sequence as set forth in SEQ ED NO:27, a sequence as set forth in SEQ ED NO:37, a sequence as set forth in SEQ ED NO:38, a sequence as set forth in SEQ ED NO:39, a sequence as set forth in SEQ ED NO:40, a sequence as set forth in SEQ ED NO:41, a sequence as set forth in SEQ ED NO:43, a sequence as set forth in SEQ ED NO:45, a sequence as set forth in SEQ ED NO:47, a sequence as set forth in SEQ ED NO:49, a sequence as set forth in SEQ ED NO:51, or a sequence as set forth in SEQ ED NO:53, wherein the probe identifies the nucleic acid by binding or hybridization.
43. The nucleic acid probe of claim 42, wherein the probe comprises an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence comprising a sequence as set forth in SEQ ED NO: 19, a sequence as set forth n SEQ ED NO:20, a sequence as set forth n SEQ ED NO:21, a sequence as set forth n SEQ ED NO:22, a sequence as set forth n SEQ ED NO:23, a sequence as set forth n SEQ ED NO:24, a sequence as set forth n SEQ ED NO:25, a sequence as set forth n SEQ ED NO:26, a sequence as set forth n SEQ ED NO:27, a sequence as set forth n SEQ ED NO:37, a sequence as set forth n SEQ ED NO:38, a sequence as set forth n SEQ ED NO:39, a sequence as set forth n SEQ ED NO:40, a sequence as set forth n SEQ ED NO:41, a sequence as set forth n SEQ ED NO:43, a sequence as set forth n SEQ ED NO:45, a sequence as set forth n SEQ ED NO:47, a sequence as set forth n SEQ ED NO:49, a sequence as set forth n SEQ D NO:51, or a sequence as set forth in SEQ ID NO:53.
44. A nucleic acid probe for identifying a nucleic acid encoding a polypeptide having a phosphatase activity, wherein the probe comprises a nucleic acid comprising a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection.
45. The nucleic acid probe of claim 44, wherein the probe comprises an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a nucleic acid sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
46. The nucleic acid probe of claim 44, wherein the probe comprises a nucleic acid sequence having at least 90%) sequence identity to a region of at least about 100 residues of a nucleic acid comprising a sequence as set forth in SEQ ID NO:19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
47. The nucleic acid probe of claim 46, wherein the probe comprises a nucleic acid sequence having at least 95%> sequence identity to a region of at least about 100 residues of a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ED NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
48. The nucleic acid probe of claim 47, wherein the probe comprises a nucleic acid sequence having at least 98% sequence identity to a region of at least about 100 residues of a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
49. An amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide having a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
50. The nucleic acid probe of claim 44, wherein each member of the amplification primer sequence pair comprises an oligonucleotide comprising at least about 10 to 50 consecutive bases of the sequence.
51. A method of amplifying a nucleic acid encoding a polypeptide having a phosphatase activity comprising amplification of a template nucleic acid with an amplification primer sequence pair capable of amplifying a nucleic acid sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
52. An expression cassette comprising a nucleic acid comprising:
(i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO: 51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
53. A vector comprising a nucleic acid comprising
(i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID
NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED
NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ED NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
54. A cloning vehicle comprising a vector as set forth in claim 53, wherein the cloning vehicle comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome.
55. The cloning vehicle of claim 54, wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector.
56. The cloning vehicle of claim 54, comprising a bacterial artificial chromosome (BAC), a plasmid, a bacteriophage Pl-derived vector (PAC), a yeast artificial chromosome (YAC), or a mammalian artificial chromosome (MAC).
57. A transformed cell comprising a vector, wherein the vector comprises (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ED NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
58. A transformed cell comprising
(i) a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the nucleic acid encodes at least one polypeptide having a phosphatase activity and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ED NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
59. The transformed cell of claim 57 or claim 58, wherein the cell is a bacterial cell, a mammalian cell , a fungal cell, a yeast cell, an insect cell or a plant cell.
60. A transgenic non-human animal comprising
(i) a nucleic acid sequence having at least 50%» sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ED NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
61. The transgenic non-human animal of claim 60, wherein the animal is a mouse.
62. A transgenic plant comprising
(i) a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID
NO:39 over a r •eeggiioonn of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO:39, or a subsequence thereof, a sequence as set forth in SEQ ED NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ED NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
63. The transgenic plant of claim 62, wherein the plant is a corn plant, a potato plant, a tomato plant, a wheat plant, an oilseed plant, a rapeseed plant, a soybean plant or a tobacco plant.
64. A transgenic seed comprising (i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID
NO:19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%0 sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%» sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO: 37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence compaπson algorithm or by a visual inspection; or, (ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ED NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
65. The transgenic seed of claim 64, wherein the seed is a corn seed, a wheat kernel, an oilseed, a rapeseed, a soybean seed, a palm kernel, a sunflower seed, a sesame seed, a peanut or a tobacco plant seed.
66. An antisense oligonucleotide comprising a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to
(i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%) sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO:20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ED NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ID NO:25, or a subsequence thereof, a sequence as set forth in SEQ ID NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ED NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ED NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
67. The antisense oligonucleotide of claim 66, wherein the antisense oligonucleotide is between about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 bases in length.
68. A method of inhibiting the translation of a phosphatase message in a cell comprising administering to the cell or expressing in the cell an antisense oligonucleotide comprising a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to a nucleic acid comprising
(i) a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED
NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO: 39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ED NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:43 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:45 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ID NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 20, or a subsequence thereof, a sequence as set forth in SEQ ED NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ID NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ED NO:27, or a subsequence thereof, a sequence as set forth in SEQ ID NO:37, or a subsequence thereof, a sequence as set forth in SEQ ID NO:38, or a subsequence thereof, a sequence as set forth in SEQ ID NO:39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ID NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ID NO:51, or a subsequence thereof, a sequence as set forth in SEQ ID NO:53, or a subsequence thereof.
69. An isolated or recombinant polypeptide comprising (a) a polypeptide comprising an amino acid sequence having at least 50%> identity to SEQ ED NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 50%o identity to SEQ ED NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 50%o identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:52 over a region of at least about 100 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:54 over a region of at least about 100 residues, or
(b) a polypeptide encoded by a nucleic acid comprising
(i) a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO: 19 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:20 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:21 over a region of at least about 100 residues, a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:22 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:23 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:24 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:25 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%o sequence identity to SEQ ED NO:26 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:27 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:37 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:38 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:39 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:40 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:41 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID
NO:43 over a re iggiioonn of at least about 100 residues, nucleic acid sequence having at least 50% sequence identity to SEQ ID
NO:45 over a i : region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:47 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ID NO:49 over a region of at least about 100 residues, a nucleic acid sequence having at least 50%> sequence identity to SEQ ED NO:51 over a region of at least about 100 residues, or a nucleic acid sequence having at least 50% sequence identity to SEQ ID NO:53 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; or,
(ii) a nucleic acid that hybridizes under stringent conditions to a nucleic acid comprising a sequence as set forth in SEQ ED NO: 19, or a subsequence thereof, a sequence as set forth in SEQ ID NO:20, or a subsequence thereof, a sequence as set forth in SEQ ID NO:21, or a subsequence thereof, a sequence as set forth in SEQ ID NO:22, or a subsequence thereof, a sequence as set forth in SEQ ID NO:23, or a subsequence thereof, a sequence as set forth in SEQ ED NO:24, or a subsequence thereof, a sequence as set forth in SEQ ED NO:25, or a subsequence thereof, a sequence as set forth in SEQ ED NO:26, or a subsequence thereof, a sequence as set forth in SEQ ID NO:27, or a subsequence thereof, a sequence as set forth in SEQ ED NO:37, or a subsequence thereof, a sequence as set forth in SEQ ED NO:38, or a subsequence thereof, a sequence as set forth in SEQ ED NO: 39, or a subsequence thereof, a sequence as set forth in SEQ ID NO:40, or a subsequence thereof, a sequence as set forth in SEQ ID NO:41, or a subsequence thereof, a sequence as set forth in SEQ ID NO:43, or a subsequence thereof, a sequence as set forth in SEQ ED NO:45, or a subsequence thereof, a sequence as set forth in SEQ ID NO:47, or a subsequence thereof, a sequence as set forth in SEQ ID NO:49, or a subsequence thereof, a sequence as set forth in SEQ ED NO:51, or a subsequence thereof, a sequence as set forth in SEQ ED NO:53, or a subsequence thereof.
70. The isolated or recombinant polypeptide of claim 69, wherein the polypeptide has a phosphatase activity.
71. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises an alkaline phosphatase activity.
72. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises a phytase activity.
73. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises a phosphodiesterase activity.
74. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises removal of phosphate group.
75. The isolated or recombinant polypeptide of claim 73, wherein the phosphodiesterase activity comprises hydrolysis of the phosphodiester bridges of nucleic acids.
76. The isolated or recombinant polypeptide of claim 75, wherein the phosphodiesterase activity comprises hydrolysis of the ester linkage between the 3' carbon and the phosphoric group.
77. The isolated or recombinant polypeptide of claim 75, wherein the phosphodiesterase activity comprises hydrolysis of the ester linkage between the phosphoric group and the 5' carbon of the phosphodiester bridge.
78. The isolated or recombinant polypeptide of claim 72, wherein the phytase activity comprises removal of phosphate from phytic acid (inositol hexaphosphoric acid).
79. The isolated or recombinant polypeptide of claim 71 , wherein the phosphatase activity comprises hydrolysis of monophosphate esters.
80. The isolated or recombinant polypeptide of claim 79, wherein the phosphatase activity comprises hydrolysis of monophosphate esters to an organic phosphate and the cognate alcohol compound.
81. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity is thermostable.
82. The isolated or recombinant nucleic acid of claim 81 , wherein the polypeptide retains a phosphatase activity under conditions comprising a temperature range of between about 37°C to about 70°C.
83. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity is thermotolerant.
84. The isolated or recombinant nucleic acid of claim 83, wherein the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 90°C.
85. The isolated or recombinant nucleic acid of claim 83, wherein the polypeptide retains a phosphatase activity after exposure to a temperature in the range from greater than 37°C to about 50°C.
86. The isolated or recombinant polypeptide of claim 69, wherein the polypeptide comprises an amino acid sequence having at least 50% identity to SEQ ED NO:28 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:29 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:30 over a region of at least about 200 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:31 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:32 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:33 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO: 34 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:35 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:36 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:42 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:44 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:46 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:48 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:50 over a region of at least about 200 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:52 over a region of at least about 200 residues, or an amino acid sequence having at least 50%> identity to SEQ ID NO:54 over a region of at least about 200 residues.
87. The isolated or recombinant polypeptide of claim 86, wherein the polypeptide comprises an amino acid sequence having at least 50%> identity to SEQ ID NO:28 over a region of at least about 260 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO: 29 over a region of at least about 265 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:30 over a region of at least about 254 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:31 over a region of at least about 271 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:32 over a region of at least about 497 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:33 over a region of at least about 584 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:34 over a region of at least about 301 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:35 over a region of at least about 257 residues, an amino acid sequence having at least 50%> identity to SEQ ED NO:36 over a region of at least about 264 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:42 over a region of at least about 293 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:44 over a region of at least about 317 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:46 over a region of at least about 440 residues, an amino acid sequence having at least 50%> identity to SEQ ID NO:48 over a region of at least about 265 residues, an amino acid sequence having at least 50%o identity to SEQ ID NO:50 over a region of at least about 197 residues, an amino acid sequence having at least 50% identity to SEQ ID NO:52 over a region of at least about 494 residues, or an amino acid sequence having at least 50%0 identity to SEQ ID NO: 54 over a region of at least about 318 residues.
88. The isolated or recombinant polypeptide of claim 69, wherein the polypeptide comprises an amino acid sequence having at least 60% identity to SEQ ID NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ID NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ID NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ID NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ED NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 60%» identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ED NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 60% identity to SEQ ED NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ED NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 60%> identity to SEQ ID NO: 52 over a region of at least about 100 residues, or an amino acid sequence having at least 60% identity to SEQ ID NO: 54 over a region of at least about 100 residues.
89. The isolated or recombinant polypeptide of claim 88, wherein the polypeptide comprises an amino acid sequence having at least 70%> identity to SEQ ID NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 70% identity to SEQ ED NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ID NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ID NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 10% identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ID NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 70%o identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 70% identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 10% identity to SEQ ED NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 70% identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ED NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 70%> identity to SEQ ED NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 70%o identity to SEQ ED NO:52 over a region of at least about 100 residues, or an amino acid sequence having at least 70%> identity to SEQ ID NO:54 over a region of at least about 100 residues.
90. The isolated or recombinant polypeptide of claim 89, wherein the polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 80% identity to SEQ ID NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 80%o identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 80% identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 80%> identity to SEQ ID NO: 50 over a region of at least about 100 residues, an amino acid sequence having at least 80% identity to SEQ ID NO: 52 over a region of at least about 100 residues, or an amino acid sequence having at least 80% identity to SEQ ID NO: 54 over a region of at least about 100 residues.
91. The isolated or recombinant polypeptide of claim 90, wherein the polypeptide comprises an amino acid sequence having at least 90%> identity to SEQ ED NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ED NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ED NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ED NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ED NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 90% identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 90% identity to SEQ ID NO: 35 over a region of at least about 100 residues, an amino acid sequence having at least 90%o identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 90%> identity to SEQ ID NO:52 over a region of at least about 100 residues, or an amino acid sequence having at least 90%> identity to SEQ ID NO: 54 over a region of at least about 100 residues.
92. The isolated or recombinant polypeptide of claim 91, wherein the polypeptide comprises an amino acid sequence having at least 95%o identity to SEQ ID NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 95%o identity to SEQ ED NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ED NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ED NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ED NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ED NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 95% identity to SEQ ED NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 95%> identity to SEQ ID NO:52 over a region of at least about 100 residues, or an amino acid sequence having at least 95%> identity to SEQ ID NO:54 over a region of at least about 100 residues.
93. The isolated or recombinant polypeptide of claim 92, wherein the polypeptide comprises an amino acid sequence having at least 98%> identity to SEQ ID NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 98% identity to SEQ ED NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ED NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ED NO:31 over a region of at least about 100 residues, an amino acid sequence having at least 98% identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 98%> identity to SEQ ID NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 98% identity to SEQ ID NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 98% identity to SEQ ID NO:52 over a region of at least about 100 residues, or an amino acid sequence having at least 98%> identity to SEQ ID NO:54 over a region of at least about 100 residues.
94. The isolated or recombinant polypeptide of claim 93, wherein the polypeptide comprises an amino acid sequence having at least 99%> identity to SEQ ED NO:28 over a region of at least about 100 residues, an amino acid sequence having at least 99% identity to SEQ ID NO:29 over a region of at least about 100 residues, an amino acid sequence having at least 99% identity to SEQ ID NO:30 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO: 31 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:32 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:33 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:34 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:35 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:36 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:42 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:44 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:46 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ED NO:48 over a region of at least about 100 residues, an amino acid sequence having at least 99%> identity to SEQ ID NO:50 over a region of at least about 100 residues, an amino acid sequence having at least 99% identity to SEQ ID NO: 52 over a region of at least about 100 residues, or an amino acid sequence having at least 99% identity to SEQ ID NO:54 over a region of at least about 100 residues.
95. The isolated or recombinant polypeptide of claim 94, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ED NO:28, an amino acid sequence as set forth in SEQ ID NO:29, an amino acid sequence as set forth in SEQ ED
NO: 30, an amino acid sequence as set forth in SEQ ID NO:31, an amino acid sequence as set forth in SEQ ED NO:32, an amino acid sequence as set forth in SEQ ID NO:33, an amino acid sequence as set forth in SEQ ED NO:34, an amino acid sequence as set forth in SEQ ID NO:35, an amino acid sequence as set forth in SEQ ED NO:36, an amino acid sequence as set forth in SEQ ID NO:42, an amino acid sequence as set forth in SEQ ID NO:44, an amino acid sequence as set forth in SEQ ID NO:46, an amino acid sequence as set forth in SEQ ED NO:48, an amino acid sequence as set forth in SEQ ID NO:50, an amino acid sequence as set forth in SEQ ID NO:52, or an amino acid sequence as set forth in SEQ ID NO:54.
96. An isolated or recombinant polypeptide comprising the polypeptide as set forth in claim 69 and lacking a signal sequence.
97. The isolated or recombinant polypeptide of claim 81 , wherein the phosphatase activity is thermostable when heated to a temperature in the range from about 37°C to about 50°C, about 50°C to about 70°C or about 70°C to about 90°C.
98. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises a specific activity at about 37°C in the range from about 100 to about 1000 units per milligram of protein.
99. The isolated or recombinant polypeptide of claim 98, wherein the phosphatase activity comprises a specific activity from about 500 to about 750 units per milligram of protein.
100. The isolated or recombinant polypeptide of claim 70, wherein the phosphatase activity comprises a specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein.
101. The isolated or recombinant polypeptide of claim 100, wherein the phosphatase activity comprises a specific activity at 37°C in the range from about 750 to about 1000 units per milligram of protein.
102. The isolated or recombinant polypeptide of claim 83, wherein the phosphatase activity is thermotolerant after being heated to an elevated temperature in the range from about 37°C to about 90°C.
103. The isolated or recombinant polypeptide of claim 83, wherein the phosphatase activity is thermotolerant after being heated to a temperature in the range from about 37°C to about 70°C.
104. The isolated or recombinant polypeptide of claim 83, wherein the thermotolerance comprises retention of at least half of the specific activity of the phosphatase at 37°C after being heated to the elevated temperature.
105. The isolated or recombinant polypeptide of claim 83, wherein the thermotolerance comprises retention of specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein after being heated to the elevated temperature.
106. The isolated or recombinant polypeptide of claim 69, wherein the phosphatase comprises at least one glycosylation site.
107. The isolated or recombinant polypeptide of claim 106, wherein glycosylation is an N-linked glycosylation.
108. The isolated or recombinant polypeptide of claim 106, wherein phosphatase is glycosylated after being expressed in a P. pastoris or a S. pombe.
109. The isolated or recombinant polypeptide of claim 70, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 5.
110. The isolated or recombinant polypeptide of claim 70, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 4.5.
111. The isolated or recombinant polypeptide of claim 110, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 9.0.
112. The isolated or recombinant polypeptide of claim 111, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 9.5.
113. The isolated or recombinant polypeptide of claim 112, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 10.
114. The isolated or recombinant polypeptide of claim 113, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 10.5.
115. The isolated or recombinant polypeptide of claim 114, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 11.
116. The isolated or recombinant polypeptide of claim 115, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 11.5.
117. The isolated or recombinant polypeptide of claim 116, wherein the polypeptide retains a phosphatase activity under conditions comprising about pH 12.
118. A protein preparation comprising a polypeptide as set forth in claim 69, wherein the protein preparation comprises a liquid, a solid or a gel.
119. A heterodimer comprising a polypeptide as set forth in claim 69 and a second domain.
120. The heterodimer of claim 119, wherein the second domain is a polypeptide and the heterodimer is a fusion protein.
121. The heterodimer of claim 119, wherein the second domain is an epitope.
122. The heterodimer of claim 119, wherein the second domain is a tag.
123. An immobilized polypeptide having a phosphatase activity, wherein the polypeptide comprises a sequence as set forth in claim 62 or claim 119.
124. The immobilized polypeptide of claim 123, wherein the polypeptide is immobilized on a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, an array or a capillary tube.
125. An array comprising an immobilized polypeptide as set forth in claim 69 or claim 119.
126. An anay comprising an immobilized nucleic acid as set forth in claim 1 or claim 35.
127. An isolated or recombinant antibody that specifically binds to a polypeptide as set forth in claim 69 or to a polypeptide encoded by a nucleic acid as set forth in claim 1 or claim 35.
128. The isolated or recombinant antibody of claim 127, wherein the antibody is a monoclonal or a polyclonal antibody.
129. A hybridoma comprising an antibody that specifically binds to a polypeptide as set forth in claim 69 or to a polypeptide encoded by a nucleic acid as set forth in claim 1 or claim 35.
130. A food supplement for an animal comprising a polypeptide as set forth in claim 69 or a polypeptide encoded by a nucleic acid as set forth in claim 1 or claim 35.
131. The food supplement of claim 130, wherein the polypeptide is glycosylated.
132. An edible enzyme delivery matrix comprising a polypeptide as set forth in claim 69 or a polypeptide encoded by a nucleic acid as set forth in claim 1 or claim 35, wherein the polypeptide comprises a phosphatase activity.
133. The edible enzyme delivery matrix of claim 132, wherein the delivery matrix comprises a pellet.
134. The edible enzyme delivery matrix of claim 132, wherein the polypeptide is glycosylated.
135. The edible enzyme delivery matrix of claim 132, wherein the phosphatase activity is thermotolerant.
136. The edible enzyme delivery matrix of claim 132, wherein the phosphatase activity is thermostable.
137. A method of isolating or identifying a polypeptide with phosphatase activity comprising the steps of: (a) providing an antibody as set forth in claim 127;
(b) providing a sample comprising polypeptides; and
(c) contacting the sample of step (b) with the antibody of step (a) under conditions wherein the antibody can specifically bind to the polypeptide, thereby isolating or identifying a phosphatase.
138. A method of making an anti-phosphatase antibody comprising administering to a non-human animal a nucleic acid as set forth in claim 1 or claim 35, or a polypeptide as set forth in claim 69, in an amount sufficient to generate a humoral immune response, thereby making an anti-phosphatase antibody.
139. A method of producing a recombinant polypeptide comprising the steps of:
(a) providing a nucleic acid operably linked to a promoter; wherein the nucleic acid comprises a sequence as set forth in claim 1 or claim 35; and
(b) expressing the nucleic acid of step (a) under conditions that allow expression of the polypeptide, thereby producing a recombinant polypeptide.
140. The method of claim 139, further comprising transforming a host cell with the nucleic acid of step (a) followed by expressing the nucleic acid of step (a), thereby producing a recombinant polypeptide in a transformed cell.
141. A method for identifying a polypeptide having a phosphatase activity comprising the following steps:
(a) providing a polypeptide as set forth in claim 69 or a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a phosphatase substrate; and
(c) contacting the polypeptide or a fragment or variant thereof of step (a) with the substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of a reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product detects a polypeptide having a phosphatase activity.
142. The method of claim 141 , wherein the substrate is an organophosphate ester compound.
143. A method for identifying a phosphatase substrate comprising the following steps:
(a) providing a polypeptide as set forth in claim 69 or a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a test substrate; and
(c) contacting the polypeptide of step (a) with the test substrate of step (b) and detecting an decrease in the amount of substrate or an increase in the amount of reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of a reaction product identifies the test substrate as a phosphatase substrate.
144. A method of determining whether a compound specifically binds to a polypeptide comprising the following steps:
(a) expressing a nucleic acid or a vector comprising the nucleic acid under conditions permissive for translation of the nucleic acid to a polypeptide, wherein the nucleic acid has a sequence as set forth in claim 1 or claim 35, or, providing a polypeptide as set forth in claim 69;
(b) contacting the polypeptide with the test compound; and
(c) determining whether the test compound specifically binds to the polypeptide, thereby determining that the compound specifically binds to the polypeptide.
145. A method for identifying a modulator of a phosphatase activity comprising the following steps:
(a) providing a polypeptide as set forth in claim 69 or a polypeptide encoded by a nucleic acid as set forth in claim 1 or claim 35;
(b) providing a test compound; (c) contacting the polypeptide of step (a) with the test compound of step (b) and measuring an activity of the phosphatase, wherein a change in the phosphatase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the phosphatase activity.
146. The method of claim 145, wherein the phosphatase activity is measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product, or, an increase in the amount of the substrate or a decrease in the amount of a reaction product.
147. The method of claim 146, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity.
148. The method of claim 146, wherein an increase in the amount of the substrate or a decrease in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an inhibitor of phosphatase activity.
149. A computer system comprising a processor and a data storage device wherein said data storage device has stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises sequence as set forth in claim 69, or subsequence thereof, and the nucleic acid comprises a sequence as set forth in claim 1 or claim 35, or subsequence thereof.
150. The computer system of claim 149, further comprising a sequence comparison algorithm and a data storage device having at least one reference sequence stored thereon.
151. The computer system of claim 150, wherein the sequence comparison algorithm comprises a computer program that indicates polymoφhisms.
152. The computer system of claim 149, further comprising an identifier that identifies one or more features in said sequence.
153. A computer readable medium having stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises sequence as set forth in claim 69, or subsequence thereof, and the nucleic acid comprises a sequence as set forth in claim 1 or claim 35, or subsequence thereof.
154. A method for identifying a feature in a sequence comprising the steps of:
(a) reading the sequence using a computer program which identifies one or more features in a sequence, wherein the sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises sequence as set forth in claim 69 or subsequence thereof, and the nucleic acid comprises a sequence as set forth in claim 1 or claim 35 or subsequence thereof; and
(b) identifying one or more features in the sequence with the computer program.
155. A method for comparing a first sequence to a second sequence comprising the steps of:
(a) reading the first sequence and the second sequence through use of a computer program which compares sequences, wherein the first sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises sequence as set forth in claim 69, or subsequence thereof, and the nucleic acid comprises a sequence as set forth in claim 1 or claim 35 or subsequence thereof; and
(b) determining differences between the first sequence and the second sequence with the computer program.
156. The method of claim 155, wherein the step of determining differences between the first sequence and the second sequence further comprises the step of identifying polymoφhisms.
157. The method of claim 155, further comprising an identifier that identifies one or more features in a sequence.
158. The method of claim 155, comprising reading the first sequence using a computer program and identifying one or more features in the sequence.
159. A method for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of:
(a) providing an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide with a phosphatase activity, wherein the primer pair is capable of amplifying a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ED NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ED NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ID NO:54, or a subsequence thereof;
(b) isolating a nucleic acid from the environmental sample or treating the environmental sample such that nucleic acid in the sample is accessible for hybridization to the amplification primer pair; and,
(c) combining the nucleic acid of step (b) with the amplification primer pair of step (a) and amplifying nucleic acid from the environmental sample, thereby isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample.
160. The method of claim 159, wherein each member of the amplification primer sequence pair comprises an oligonucleotide comprising at least about 10 to 50 consecutive bases of the nucleic acid sequence or subsequence thereof.
161. A method for isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample comprising the steps of:
(a) providing a polynucleotide probe comprising a sequence as set forth in claim 1 or claim 35, or a subsequence thereof;
(b) isolating a nucleic acid from the environmental sample or treating the environmental sample such that nucleic acid in the sample is accessible for hybridization to a polynucleotide probe of step (a);
(c) combining the isolated nucleic acid or the treated environmental sample of step (b) with the polynucleotide probe of step (a); and
(d) isolating a nucleic acid that specifically hybridizes with the polynucleotide probe of step (a), thereby isolating or recovering a nucleic acid encoding a polypeptide with a phosphatase activity from an environmental sample.
162. The method of claim 159 or claim 161, wherein the environmental sample comprises a water sample, a liquid sample, a soil sample, an air sample or a biological sample.
163. The method of claim 162, wherein the biological sample is derived from a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell.
164. A method of generating a variant of a nucleic acid encoding a phosphatase comprising the steps of:
(a) providing a template nucleic acid comprising a sequence as set forth in claim 1 or claim 35; and
(b) modifying, deleting or adding one or more nucleotides in the template sequence, or a combination thereof, to generate a variant of the template nucleic acid.
165. The method of claim 164, further comprising expressing the variant nucleic acid to generate a variant phosphatase polypeptide.
166. The method of claim 164, wherein the modifications, additions or deletions are introduced by a method comprising enor-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR) and a combination thereof.
167. The method of claim 164, wherein the modifications, additions or deletions are introduced by a method selected from the group consisting of recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil- containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof.
168. The method of claim 164, wherein the modifications, additions or deletions are introduced by enor-prone PCR.
169. The method of claim 164, wherein the modifications, additions or deletions are introduced by shuffling.
170. The method of claim 164, wherein the modifications, additions or deletions are introduced by oligonucleotide-directed mutagenesis.
171. The method of claim 164, wherein the modifications, additions or deletions are introduced by assembly PCR.
172. The method of claim 164, wherein the modifications, additions or deletions are introduced by sexual PCR mutagenesis.
173. The method of claim 164, wherein the modifications, additions or deletions are introduced by in vivo mutagenesis.
174. The method of claim 164, wherein the modifications, additions or deletions are introduced by cassette mutagenesis.
175. The method of claim 164, wherein the modifications, additions or deletions are introduced by recursive ensemble mutagenesis.
176. The method of claim 164, wherein the modifications, additions or deletions are introduced by exponential ensemble mutagenesis.
177. The method of claim 164, wherein the modifications, additions or deletions are introduced by site-specific mutagenesis.
178. The method of claim 164, wherein the modifications, additions or deletions are introduced by gene reassembly.
179. The method of claim 164, wherein the modifications, additions or deletions are introduced by synthetic ligation reassembly (SLR).
180. The method of claim 164, wherein the modifications, additions or deletions are introduced by gene site saturated mutagenesis (GSSM).
181. The method of claim 164, wherein method is iteratively repeated until a phosphatase having an altered or different activity or an altered or different stability from that of a polypeptide encoded by the template nucleic acid is produced.
182. The method of claim 181, wherein the variant phosphatase polypeptide is thermotolerant, and retains some activity after being exposed to an elevated temperature.
183. The method of claim 181, wherein the variant phosphatase polypeptide has increased glycosylation as compared to the phosphatase encoded by a template nucleic acid.
184. The method of claim 181, wherein the variant phosphatase polypeptide has a phosphatase activity under a high temperature, wherein the phosphatase encoded by the template nucleic acid is not active under the high temperature.
185. The method of claim 164, wherein method is iteratively repeated until a phosphatase coding sequence having an altered codon usage from that of the template nucleic acid is produced.
186. The method of claim 164, wherein method is iteratively repeated until a phosphatase gene having higher or lower level of message expression or stability from that of the template nucleic acid is produced.
187. A method for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising
(a) providing a nucleic acid encoding a phosphatase comprising a sequence as set forth in claim 1 or claim 35; and,
(b) identifying a non-preferred or a less prefened codon in the nucleic acid of step (a) and replacing it with a prefened or neutrally used codon encoding the same amino acid as the replaced codon, wherein a prefened codon is a codon over-represented in coding sequences in genes in the host cell and a non-prefened or less prefened codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell.
188. A method for modifying codons in a nucleic acid encoding a phosphatase polypeptide, the method comprising
(a) providing a nucleic acid encoding a phosphatase comprising a sequence as set forth in claim 1 or claim 35; and,
(b) identifying a codon in the nucleic acid of step (a) and replacing it with a different codon encoding the same amino acid as the replaced codon, thereby modifying codons in a nucleic acid encoding a phosphatase.
189. A method for modifying codons in a nucleic acid encoding a phosphatase to increase its expression in a host cell, the method comprising
(a) providing a nucleic acid encoding a phosphatase comprising a sequence as set forth in claim 1 or claim 35; and,
(b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a prefened or neutrally used codon encoding the same amino acid as the replaced codon, wherein a prefened codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less prefened codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell.
190. A method for modifying a codon in a nucleic acid encoding a phosphatase to decrease its expression in a host cell, the method comprising
(a) providing a nucleic acid encoding a phosphatase comprising a sequence as set forth in claim 1 or claim 35; and
(b) identifying at least one preferred codon in the nucleic acid of step (a) and replacing it with a non-prefened or less prefened codon encoding the same amino acid as the replaced codon, wherein a prefened codon is a codon over-represented in coding sequences in genes in a host cell and a non-preferred or less prefened codon is a codon under- represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to decrease its expression in a host cell.
191. The method of claim 189 or 190, wherein the host cell is a bacterial cell, a fungal cell, an insect cell, a yeast cell, a plant cell or a mammalian cell.
192. A method for producing a library of nucleic acids encoding a plurality of modified phosphatase active sites or substrate binding sites, wherein the modified active sites or substrate binding sites are derived from a first nucleic acid comprising a sequence encoding a first active site or a first substrate binding site the method comprising:
(a) providing a first nucleic acid encoding a first active site or first substrate binding site, wherein the first nucleic acid sequence comprises a sequence that hybridizes under stringent conditions to a sequence as set forth in SEQ ED NO:28, SEQ ED NO:29, SEQ ED NO:30, SEQ ED NO:31, SEQ ED NO:32, SEQ ID NO:33, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ ED NO:42, SEQ ID NO:44, SEQ ED NO:46, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ ED NO:54, or a subsequence thereof, and the nucleic acid encodes a phosphatase active site or a phosphatase substrate binding site;
(b) providing a set of mutagenic oligonucleotides that encode naturally- occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and,
(c) using the set of mutagenic oligonucleotides to generate a set of active site- encoding or substrate binding site-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized, thereby producing a library of nucleic acids encoding a plurality of modified phosphatase active sites or substrate binding sites.
193. The method of claim 192, comprising mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system.
194. The method of claim 192, comprising mutagenizing the first nucleic acid of step (a) by a method comprising gene site-saturation mutagenesis (GSSM).
195. The method of claim 192, comprising mutagenizing the first nucleic acid of step (a) by a method comprising a synthetic ligation reassembly (SLR).
196. The method of claim 192, further comprising mutagenizing the first nucleic acid of step (a) or variants by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis (GSSM), synthetic ligation reassembly (SLR) and a combination thereof.
197. The method of claim 192, further comprising mutagenizing the first nucleic acid of step (a) or variants by a method comprising recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation and a combination thereof.
198. A method making a small molecule comprising the steps of:
(a) providing a plurality of biosynthetic enzymes capable of synthesizing or modifying a small molecule, wherein one of the enzymes comprises a phosphatase enzyme encoded by a nucleic acid comprising a sequence as set forth in claim 1 or claim 35;
(b) providing a substrate for at least one of the enzymes of step (a); and
(c) reacting the substrate of step (b) with the enzymes under conditions that facilitate a plurality of biocatalytic reactions to generate a small molecule by a series of biocatalytic reactions.
199. A method for modifying a small molecule comprising the steps:
(a) providing a phosphatase enzyme, wherein the enzyme comprises an amino acid sequence as set forth in claim 69, or, is encoded by a nucleic acid comprising a sequence as set forth in claim 1 or claim 35;
(b) providing a small molecule; and (c) reacting the enzyme of step (a) with the small molecule of step (b) under conditions that facilitate an enzymatic reaction catalyzed by the phosphatase enzyme, thereby modifying a small molecule by a phosphatase enzymatic reaction.
200. The method of claim 199, comprising a plurality of small molecule substrates for the enzyme of step (a), thereby generating a library of modified small molecules produced by at least one enzymatic reaction catalyzed by the phosphatase enzyme.
201. The method of claim 199, further comprising a plurality of additional enzymes under conditions that facilitate a plurality of biocatalytic reactions by the enzymes to form a library of modified small molecules produced by the plurality of enzymatic reactions.
202. The method of claim 199, further comprising the step of testing the library to determine if a particular modified small molecule which exhibits a desired activity is present within the library.
203. The method of claim 202, wherein the step of testing the library further comprises the steps of systematically eliminating all but one of the biocatalytic reactions used to produce a portion of the plurality of the modified small molecules within the library by testing the portion of the modified small molecule for the presence or absence of the particular modified small molecule with a desired activity, and identifying at least one specific biocatalytic reaction that produces the particular modified small molecule of desired activity.
204. A method for determining a functional fragment of a phosphatase enzyme comprising the steps of:
(a) providing a phosphatase enzyme, wherein the enzyme comprises an amino acid sequence as set forth in claim 69, or, is encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35; and (b) deleting a plurality of amino acid residues from the sequence of step (a) and testing the remaining subsequence for a phosphatase activity, thereby determining a functional fragment of a phosphatase enzyme.
205. The method of claim 204, wherein the phosphatase activity is measured by providing a phosphatase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product.
206. The method of claim 205, wherein a decrease in the amount of an enzyme substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phosphatase activity.
207. A method for whole cell engineering of new or modified phenotypes by using real-time metabolic flux analysis, the method comprising the following steps:
(a) making a modified cell by modifying the genetic composition of a cell, wherein the genetic composition is modified by addition to the cell of a nucleic acid comprising a sequence as set forth in claim 1 or claim 35;
(b) culturing the modified cell to generate a plurality of modified cells;
(c) measuring at least one metabolic parameter of the cell by monitoring the cell culture of step (b) in real time; and,
(d) analyzing the data of step (c) to determine if the measured parameter differs from a comparable measurement in an unmodified cell under similar conditions, thereby identifying an engineered phenotype in the cell using real-time metabolic flux analysis.
208. The method of claim 207, wherein the genetic composition of the cell is modified by a method comprising deletion of a sequence or modification of a sequence in the cell, or, knocking out the expression of a gene.
209. The method of claim 207, further comprising selecting a cell comprising a newly engineered phenotype.
210. The method of claim 209, further comprising culturing the selected cell, thereby generating a new cell strain comprising a newly engineered phenotype.
211. A method for inhibiting degradation of the cyclic nucleotides comprising the following steps:
(a) providing a polypeptide having a phosphodiesterase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a composition comprising a phosphodiesterase inhibitor; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the composition inhibits phosphodiesterase activity thereby inhibiting degradation of the cyclic nucleotides.
212. The method of claim 211, wherein the phosphodiesterase is cyclic AMP or cyclic GMP specific.
213. A method for removing a phosphate group comprising the following steps:
(a) providing a polypeptide having a phosphatase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a composition comprising a phosphate group; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphatase group.
214. A method for hydrolysis of the phosphodiester bridges comprising the following steps: (a) providing a polypeptide having a phosphodiesterase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a composition comprising a phosphodiester bridge; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the phosphodiester bridge.
215. The method as set forth in claim 214, wherein the composition comprising a phosphodiester bridge comprises a nucleic acid.
216. A method for removal of phosphate comprising the following steps:
(a) providing a polypeptide having a phytase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a composition comprising a phosphate; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide removes the phosphate group.
217. The method as set forth in claim 216, wherein the composition is phytic acid.
218. A method for hydrolysis of monophosphate esters comprising the following steps:
(a) providing a polypeptide having an alkaline phosphatase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a composition comprising a monophosphate ester; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide hydrolyzes the monophosphate esters.
219. A method of increasing thermotolerance or thermostability of a phosphatase polypeptide, the method comprising glycosylating a phosphatase polypeptide, wherein the polypeptide comprises at least thirty contiguous amino acids of a sequence as set forth in claim 69, or a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35, thereby increasing the thermotolerance or thermostability of the phosphatase polypeptide.
220. The method of claim 219, wherein the phosphatase specific activity is thermostable or thermotolerant at a temperature in the range from greater than about 37°C to about 90°C.
221. A method for overexpressing a recombinant phosphatase polypeptide in a cell comprising expressing a vector comprising a nucleic acid comprising a nucleic acid sequence at least 50%> sequence identity to the nucleic acid of claim 1 or claim 35 over a region of at least about 100 residues, wherein the sequence identities are determined by analysis with a sequence comparison algorithm or by visual inspection, wherein overexpression is effected by use of a high activity promoter, a dicistronic vector or by gene amplification of the vector.
222. A method for improving phosphate consumption in animals comprising the following steps:
(a) providing a polypeptide having a phytase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) ingesting the polypeptide of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization.
223. A method for improving phosphate consumption in animals comprising the following steps: (a) providing a genetically engineered seed comprising a nucleic acid having a sequence as set forth in claim 1 or claim 35, wherein the nucleic acid encodes a polypeptide comprising a phytase activity
(b) ingesting the seeds of step (a) with a feed or a food comprising phytates capable of being hydrolyzed by a phytase, thereby improving phosphate utilization.
224. The method of claim 222 or claim 223, wherein the animal comprises swine or poultry.
225. A method for treating solid or liquid animal waste products comprising the following steps:
(a) providing a polypeptide having a phytase activity, wherein the polypeptide comprises an amino acid sequence as set forth in claim 69, or, a polypeptide encoded by a nucleic acid having a sequence as set forth in claim 1 or claim 35;
(b) providing a solid or a liquid animal waste; and
(c) contacting the polypeptide of step (a) and the solid or liquid waste of step (b) under conditions wherein the phytase can treat the waste.
PCT/US2002/021693 2001-07-09 2002-07-09 Thermostable phosphatases and methods of making and using them WO2003006610A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324477A AU2002324477A1 (en) 2001-07-09 2002-07-09 Thermostable phosphatases and methods of making and using them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/902,525 2001-07-09
US90252502A 2002-07-09 2002-07-09

Publications (2)

Publication Number Publication Date
WO2003006610A2 true WO2003006610A2 (en) 2003-01-23
WO2003006610A3 WO2003006610A3 (en) 2003-10-16

Family

ID=25415978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021693 WO2003006610A2 (en) 2001-07-09 2002-07-09 Thermostable phosphatases and methods of making and using them

Country Status (1)

Country Link
WO (1) WO2003006610A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
EP2527456A1 (en) 2004-10-22 2012-11-28 Revivicor Inc. Transgenic porcines lacking endogenous immunoglobulin light chain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030756A1 (en) * 1994-04-18 1995-11-16 United States Biochemical Corporation Thermostable alkaline phosphatase of thermus thermophilus
US5629177A (en) * 1992-12-23 1997-05-13 Hyman; Edward D. Method for the enzymatic synthesis of oligonucleotides using thermostable 3'-phosphatase
US5792903A (en) * 1993-10-25 1998-08-11 Yissum Research Development Company Of Hebrew University Of Jerusalem Lycopene cyclase gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629177A (en) * 1992-12-23 1997-05-13 Hyman; Edward D. Method for the enzymatic synthesis of oligonucleotides using thermostable 3'-phosphatase
US5792903A (en) * 1993-10-25 1998-08-11 Yissum Research Development Company Of Hebrew University Of Jerusalem Lycopene cyclase gene
WO1995030756A1 (en) * 1994-04-18 1995-11-16 United States Biochemical Corporation Thermostable alkaline phosphatase of thermus thermophilus
US5633138A (en) * 1994-04-18 1997-05-27 Amersham Life Science, Inc. Thermostable alkaline phosphatase of thermus thermophilus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527456A1 (en) 2004-10-22 2012-11-28 Revivicor Inc. Transgenic porcines lacking endogenous immunoglobulin light chain
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates

Also Published As

Publication number Publication date
WO2003006610A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2002101078A2 (en) Cellulases, nucleic acids encoding them and methods for making and using them
US8148324B2 (en) Chemoenzymatic methods for the synthesis of statins and statin intermediates
US20080227132A1 (en) Hydrolase Enzymes and Their Use in Kinetic Resolution
WO2003068910A2 (en) Glycosidases, nucleic acids encoding them and methods of making and using them
US20040023257A1 (en) Enzymes having secondary amidases activity and methods of use thereof
WO2004085624A2 (en) Transaminases, deaminases and aminomutases and compositions and methods for enzymatic detoxification
WO2003068909A2 (en) Transaminases, nucleic acids encoding them and methods of making and using them
US20050186605A1 (en) Phosphatase -encoding nucleic acids and methods of making and using them
US20050202494A1 (en) Catalases
WO2004035729A2 (en) Esterases, nucleic acids encoding them and methods of making and using them
WO2003023029A1 (en) Polymerases, nucleic acids encoding them and methods for making and using them
WO2003006610A2 (en) Thermostable phosphatases and methods of making and using them
WO2003027315A2 (en) Amidases, nucleic acids encoding them and methods for making and using them
WO2003000921A2 (en) Alpha galactosides, nucleic acids encoding them and methods for making and using them
WO2004069848A2 (en) Amidases, nucleic acids encoding them and methods for making and using them
WO2003000924A2 (en) Endoglucanases, nucleic acids encoding them and methods for making and using them
AU2003216125A1 (en) Amidases, nucleic acids encoding them and methods for making and using them
AU2002246553A1 (en) Hydrolase enzymes and their use in kinetic resolution

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP